US20220096590A1 - Novel-anti-infective strategy against influenza virus and s. aureus coinfections - Google Patents
Novel-anti-infective strategy against influenza virus and s. aureus coinfections Download PDFInfo
- Publication number
- US20220096590A1 US20220096590A1 US17/492,088 US202117492088A US2022096590A1 US 20220096590 A1 US20220096590 A1 US 20220096590A1 US 202117492088 A US202117492088 A US 202117492088A US 2022096590 A1 US2022096590 A1 US 2022096590A1
- Authority
- US
- United States
- Prior art keywords
- inhibitor
- infection
- influenza virus
- virus
- bacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 127
- 208000003322 Coinfection Diseases 0.000 title claims abstract description 80
- 239000003112 inhibitor Substances 0.000 claims abstract description 114
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims abstract description 112
- 241000894006 Bacteria Species 0.000 claims abstract description 105
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 100
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 100
- 229940124647 MEK inhibitor Drugs 0.000 claims abstract description 95
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 claims abstract description 91
- 239000012826 P38 inhibitor Substances 0.000 claims abstract description 88
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 claims abstract description 87
- 238000000034 method Methods 0.000 claims abstract description 70
- 230000009385 viral infection Effects 0.000 claims abstract description 41
- 150000001875 compounds Chemical class 0.000 claims description 54
- 230000008685 targeting Effects 0.000 claims description 45
- 230000003612 virological effect Effects 0.000 claims description 35
- 241000282414 Homo sapiens Species 0.000 claims description 34
- 241000700605 Viruses Species 0.000 claims description 32
- 241000712431 Influenza A virus Species 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 28
- 239000003242 anti bacterial agent Substances 0.000 claims description 25
- 229930182555 Penicillin Natural products 0.000 claims description 18
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 18
- 229940049954 penicillin Drugs 0.000 claims description 18
- QHKYPYXTTXKZST-UHFFFAOYSA-N SB-202190 Chemical group C1=CC(O)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 QHKYPYXTTXKZST-UHFFFAOYSA-N 0.000 claims description 15
- -1 Lysosthaphin Chemical compound 0.000 claims description 14
- 230000003115 biocidal effect Effects 0.000 claims description 14
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical group CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 13
- 239000002911 sialidase inhibitor Substances 0.000 claims description 13
- KKYABQBFGDZVNQ-UHFFFAOYSA-N 6-[5-[(cyclopropylamino)-oxomethyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide Chemical compound CC1=C(F)C=C(C(=O)NC2CC2)C=C1C1=CC=C(C(=O)NCC(C)(C)C)C=N1 KKYABQBFGDZVNQ-UHFFFAOYSA-N 0.000 claims description 12
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims description 10
- MVCOAUNKQVWQHZ-UHFFFAOYSA-N doramapimod Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MVCOAUNKQVWQHZ-UHFFFAOYSA-N 0.000 claims description 9
- ZMELOYOKMZBMRB-DLBZAZTESA-N talmapimod Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)C=2C(=CC=3N(C)C=C(C=3C=2)C(=O)C(=O)N(C)C)Cl)N1CC1=CC=C(F)C=C1 ZMELOYOKMZBMRB-DLBZAZTESA-N 0.000 claims description 8
- FYSRKRZDBHOFAY-UHFFFAOYSA-N 6-(N-carbamoyl-2,6-difluoroanilino)-2-(2,4-difluorophenyl)-3-pyridinecarboxamide Chemical compound FC=1C=CC=C(F)C=1N(C(=O)N)C(N=1)=CC=C(C(N)=O)C=1C1=CC=C(F)C=C1F FYSRKRZDBHOFAY-UHFFFAOYSA-N 0.000 claims description 7
- ORVNHOYNEHYKJG-UHFFFAOYSA-N 8-(2,6-difluorophenyl)-2-(1,3-dihydroxypropan-2-ylamino)-4-(4-fluoro-2-methylphenyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound CC1=CC(F)=CC=C1C1=NC(NC(CO)CO)=NC2=C1C=CC(=O)N2C1=C(F)C=CC=C1F ORVNHOYNEHYKJG-UHFFFAOYSA-N 0.000 claims description 7
- KCAJXIDMCNPGHZ-UHFFFAOYSA-N PH 797804 Chemical compound CNC(=O)C1=CC=C(C)C(N2C(C(Br)=C(OCC=3C(=CC(F)=CC=3)F)C=C2C)=O)=C1 KCAJXIDMCNPGHZ-UHFFFAOYSA-N 0.000 claims description 7
- 229960003752 oseltamivir Drugs 0.000 claims description 7
- GDTQLZHHDRRBEB-UHFFFAOYSA-N 4-[5-(cyclopropylcarbamoyl)-2-methylanilino]-5-methyl-n-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide Chemical compound C12=C(C)C(C(=O)NCCC)=CN2N=CN=C1NC(C(=CC=1)C)=CC=1C(=O)NC1CC1 GDTQLZHHDRRBEB-UHFFFAOYSA-N 0.000 claims description 6
- IFGWYHGYNVGVRB-UHFFFAOYSA-N 5-(2,4-difluorophenoxy)-n-[2-(dimethylamino)ethyl]-1-(2-methylpropyl)indazole-6-carboxamide Chemical compound CN(C)CCNC(=O)C=1C=C2N(CC(C)C)N=CC2=CC=1OC1=CC=C(F)C=C1F IFGWYHGYNVGVRB-UHFFFAOYSA-N 0.000 claims description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 6
- HEKAIDKUDLCBRU-UHFFFAOYSA-N N-[4-[2-ethyl-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]benzamide Chemical compound S1C(CC)=NC(C=2C=C(C)C=CC=2)=C1C(C=1)=CC=NC=1NC(=O)C1=CC=CC=C1 HEKAIDKUDLCBRU-UHFFFAOYSA-N 0.000 claims description 6
- CDMGBJANTYXAIV-UHFFFAOYSA-N SB 203580 Chemical compound C1=CC(S(=O)C)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 CDMGBJANTYXAIV-UHFFFAOYSA-N 0.000 claims description 6
- 229950003265 losmapimod Drugs 0.000 claims description 6
- JYYLVUFNAHSSFE-UHFFFAOYSA-N pamapimod Chemical compound O=C1N(C)C2=NC(NC(CCO)CCO)=NC=C2C=C1OC1=CC=C(F)C=C1F JYYLVUFNAHSSFE-UHFFFAOYSA-N 0.000 claims description 6
- 229950001749 pamapimod Drugs 0.000 claims description 6
- 102100031780 Endonuclease Human genes 0.000 claims description 5
- 108010042407 Endonucleases Proteins 0.000 claims description 5
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 5
- 229930182566 Gentamicin Natural products 0.000 claims description 5
- 108090000862 Ion Channels Proteins 0.000 claims description 5
- 102000004310 Ion Channels Human genes 0.000 claims description 5
- 229960002518 gentamicin Drugs 0.000 claims description 5
- 230000002452 interceptive effect Effects 0.000 claims description 5
- 229960002194 oseltamivir phosphate Drugs 0.000 claims description 5
- 229960001084 peramivir Drugs 0.000 claims description 5
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims description 5
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims description 4
- RQVKVJIRFKVPBF-VWLOTQADSA-N 2-[[(2s)-2-amino-3-phenylpropyl]amino]-3-methyl-5-naphthalen-2-yl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C([C@H](N)CNC=1N(C(C(C=2C=C3C=CC=CC3=CC=2)=C(C=2C=CN=CC=2)N=1)=O)C)C1=CC=CC=C1 RQVKVJIRFKVPBF-VWLOTQADSA-N 0.000 claims description 4
- 241000194018 Streptococcaceae Species 0.000 claims description 4
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 4
- 229960003805 amantadine Drugs 0.000 claims description 4
- 229960000888 rimantadine Drugs 0.000 claims description 4
- 229960001028 zanamivir Drugs 0.000 claims description 4
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 4
- IHJTWXFNCUDEKM-UHFFFAOYSA-N 2-(4-chlorophenyl)-4-(2-fluorophenyl)-5-pyridin-4-yl-1h-pyrazol-3-one Chemical compound FC1=CC=CC=C1C(C1=O)=C(C=2C=CN=CC=2)NN1C1=CC=C(Cl)C=C1 IHJTWXFNCUDEKM-UHFFFAOYSA-N 0.000 claims description 3
- GUTYHDCSDBBMGW-UHFFFAOYSA-N 2-[6-chloro-5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-1-methylindol-3-yl]-n,n-dimethyl-2-oxoacetamide Chemical compound C1=C2C(C(=O)C(=O)N(C)C)=CN(C)C2=CC(Cl)=C1C(=O)N(CC1)CCC1CC1=CC=C(F)C=C1 GUTYHDCSDBBMGW-UHFFFAOYSA-N 0.000 claims description 3
- ODYAQBDIXCVKAE-UHFFFAOYSA-N 4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide Chemical compound C1=CC(O)=CC=C1NC(=O)CCCC1=CC=C(C=2C(=CC=CC=2)F)C=C1 ODYAQBDIXCVKAE-UHFFFAOYSA-N 0.000 claims description 3
- QSUSKMBNZQHHPA-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-pyridin-4-ylimidazol-2-yl]but-3-yn-1-ol Chemical compound C=1C=CC=CC=1CCCN1C(C#CCCO)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=NC=C1 QSUSKMBNZQHHPA-UHFFFAOYSA-N 0.000 claims description 3
- WOSGGXINSLMASH-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1h-imidazol-5-yl]pyridine;hydrochloride Chemical compound Cl.C1=CC(S(=O)C)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 WOSGGXINSLMASH-UHFFFAOYSA-N 0.000 claims description 3
- XEOVWJYINDYNSM-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)-1H-imidazol-5-yl]pyridine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 XEOVWJYINDYNSM-UHFFFAOYSA-N 0.000 claims description 3
- XOQSUTIMRLPFPB-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]phenol hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 XOQSUTIMRLPFPB-UHFFFAOYSA-N 0.000 claims description 3
- SINQIEAULQKUPD-UHFFFAOYSA-N 4-[4-(6-methoxy-2-naphthalenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine Chemical compound C1=CC2=CC(OC)=CC=C2C=C1C=1N=C(C=2C=CC(=CC=2)S(C)=O)NC=1C1=CC=NC=C1 SINQIEAULQKUPD-UHFFFAOYSA-N 0.000 claims description 3
- VXPWQNBKEIVYIS-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-2-methylsulfanyl-1h-imidazol-4-yl]-n-(1-phenylethyl)pyridin-2-amine Chemical compound N1C(SC)=NC(C=2C=C(NC(C)C=3C=CC=CC=3)N=CC=2)=C1C1=CC=C(F)C=C1 VXPWQNBKEIVYIS-UHFFFAOYSA-N 0.000 claims description 3
- NARMJPIBAXVUIE-UHFFFAOYSA-N 5-[2-tert-butyl-4-(4-fluorophenyl)-1h-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.N1=C2N(CC(C)(C)C)C(N)=NC2=CC=C1C=1N=C(C(C)(C)C)NC=1C1=CC=C(F)C=C1 NARMJPIBAXVUIE-UHFFFAOYSA-N 0.000 claims description 3
- YOELZIQOLWZLQC-UHFFFAOYSA-N 6-(4-fluorophenyl)-5-pyridin-4-yl-2,3-dihydroimidazo[2,1-b]thiazole Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)N2CCSC2=N1 YOELZIQOLWZLQC-UHFFFAOYSA-N 0.000 claims description 3
- BEPGKLOHQTXUHX-UHFFFAOYSA-N CGH 2466 Chemical compound S1C(N)=NC(C=2C=C(Cl)C(Cl)=CC=2)=C1C1=CC=NC=C1 BEPGKLOHQTXUHX-UHFFFAOYSA-N 0.000 claims description 3
- 241000713196 Influenza B virus Species 0.000 claims description 3
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 3
- 229940123066 Polymerase inhibitor Drugs 0.000 claims description 3
- ZQUSFAUAYSEREK-WKILWMFISA-N SB-239063 Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)[C@@H]2CC[C@@H](O)CC2)=N1 ZQUSFAUAYSEREK-WKILWMFISA-N 0.000 claims description 3
- VSPFURGQAYMVAN-UHFFFAOYSA-N SB220025 Chemical compound NC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)C2CCNCC2)=N1 VSPFURGQAYMVAN-UHFFFAOYSA-N 0.000 claims description 3
- 241000295644 Staphylococcaceae Species 0.000 claims description 3
- 108010053950 Teicoplanin Proteins 0.000 claims description 3
- VEPKQEUBKLEPRA-UHFFFAOYSA-N VX-745 Chemical compound FC1=CC(F)=CC=C1SC1=NN2C=NC(=O)C(C=3C(=CC=CC=3Cl)Cl)=C2C=C1 VEPKQEUBKLEPRA-UHFFFAOYSA-N 0.000 claims description 3
- 108010059993 Vancomycin Proteins 0.000 claims description 3
- UKVRKLWCFNTXTF-LZOYIBSKSA-N [(2r,3s,4r,5r,6r)-5-[[2-(aminomethylideneamino)acetyl]-methylamino]-3-hydroxy-2-(hydroxymethyl)-6-[(7-hydroxy-5-methyl-4-oxo-3a,6,7,7a-tetrahydro-1h-imidazo[4,5-c]pyridin-2-yl)amino]oxan-4-yl] carbamate Chemical compound O1[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H](N(C)C(=O)CN=CN)[C@@H]1NC1=NC2C(=O)N(C)CC(O)C2N1 UKVRKLWCFNTXTF-LZOYIBSKSA-N 0.000 claims description 3
- OMGLGPKQUFSRNN-UHFFFAOYSA-N [2-methoxy-4-(methylthio)phenyl]-[4-(phenylmethyl)-1-piperidinyl]methanone Chemical compound COC1=CC(SC)=CC=C1C(=O)N1CCC(CC=2C=CC=CC=2)CC1 OMGLGPKQUFSRNN-UHFFFAOYSA-N 0.000 claims description 3
- HDCLCHNAEZNGNV-UHFFFAOYSA-N [4-(2-amino-4-bromoanilino)-2-chlorophenyl]-(2-methylphenyl)methanone Chemical compound CC1=CC=CC=C1C(=O)C(C(=C1)Cl)=CC=C1NC1=CC=C(Br)C=C1N HDCLCHNAEZNGNV-UHFFFAOYSA-N 0.000 claims description 3
- OWXBJAPOSQSWAO-UHFFFAOYSA-N [4-(2-chloro-4-nitrophenyl)piperazin-1-yl]-(5-methyl-3-phenyl-1,2-oxazol-4-yl)methanone Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C(=O)N(CC1)CCN1C1=CC=C([N+]([O-])=O)C=C1Cl OWXBJAPOSQSWAO-UHFFFAOYSA-N 0.000 claims description 3
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 claims description 3
- 229960003276 erythromycin Drugs 0.000 claims description 3
- NEQZWEXWOFPKOT-UHFFFAOYSA-N f152A1 Natural products C1=CCC(O)C(O)C(=O)C=CCC(C)OC(=O)C=2C1=CC(OC)=CC=2O NEQZWEXWOFPKOT-UHFFFAOYSA-N 0.000 claims description 3
- 229960003376 levofloxacin Drugs 0.000 claims description 3
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims description 3
- 229960001019 oxacillin Drugs 0.000 claims description 3
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 3
- 229960001225 rifampicin Drugs 0.000 claims description 3
- 229960001608 teicoplanin Drugs 0.000 claims description 3
- 229960003165 vancomycin Drugs 0.000 claims description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 3
- 241000678856 Staphylococcaceae bacterium Species 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 62
- 238000011321 prophylaxis Methods 0.000 abstract description 44
- 238000012360 testing method Methods 0.000 abstract description 44
- 238000000338 in vitro Methods 0.000 abstract description 34
- 239000000203 mixture Substances 0.000 abstract description 27
- 210000004748 cultured cell Anatomy 0.000 abstract description 25
- 210000004027 cell Anatomy 0.000 description 112
- 208000015181 infectious disease Diseases 0.000 description 62
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 61
- DVEXZJFMOKTQEZ-JYFOCSDGSA-N U0126 Chemical group C=1C=CC=C(N)C=1SC(\N)=C(/C#N)\C(\C#N)=C(/N)SC1=CC=CC=C1N DVEXZJFMOKTQEZ-JYFOCSDGSA-N 0.000 description 52
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 49
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 49
- 230000001580 bacterial effect Effects 0.000 description 45
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 35
- 239000002904 solvent Substances 0.000 description 34
- 230000009467 reduction Effects 0.000 description 33
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 30
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 30
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 30
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 28
- 210000004072 lung Anatomy 0.000 description 27
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 26
- 210000002919 epithelial cell Anatomy 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 22
- 108010029485 Protein Isoforms Proteins 0.000 description 22
- 102000001708 Protein Isoforms Human genes 0.000 description 22
- 238000011534 incubation Methods 0.000 description 22
- 239000002609 medium Substances 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 22
- 229960002271 cobimetinib Drugs 0.000 description 21
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 20
- 102000043136 MAP kinase family Human genes 0.000 description 19
- 108091054455 MAP kinase family Proteins 0.000 description 19
- 239000007995 HEPES buffer Substances 0.000 description 17
- 108091006905 Human Serum Albumin Proteins 0.000 description 17
- 102000008100 Human Serum Albumin Human genes 0.000 description 17
- 208000036142 Viral infection Diseases 0.000 description 17
- 108090000988 Lysostaphin Proteins 0.000 description 16
- 229940088710 antibiotic agent Drugs 0.000 description 16
- 230000001332 colony forming effect Effects 0.000 description 16
- 206010022000 influenza Diseases 0.000 description 16
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 15
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 15
- 239000012472 biological sample Substances 0.000 description 15
- 229940098773 bovine serum albumin Drugs 0.000 description 15
- 239000001110 calcium chloride Substances 0.000 description 15
- 229910001628 calcium chloride Inorganic materials 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 15
- 229910001629 magnesium chloride Inorganic materials 0.000 description 15
- 229960005322 streptomycin Drugs 0.000 description 15
- 238000010790 dilution Methods 0.000 description 14
- 239000012895 dilution Substances 0.000 description 14
- 230000009545 invasion Effects 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 230000011664 signaling Effects 0.000 description 14
- 230000003834 intracellular effect Effects 0.000 description 13
- 241000191967 Staphylococcus aureus Species 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 12
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 12
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 description 11
- 229940122696 MAP kinase inhibitor Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 229920001817 Agar Polymers 0.000 description 10
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 10
- 229960001138 acetylsalicylic acid Drugs 0.000 description 10
- 239000008272 agar Substances 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- QNZVBFMXWNWVKG-UHFFFAOYSA-N n-(6-benzoyl-1h-benzimidazol-2-yl)-2-(1-thieno[3,2-d]pyrimidin-4-ylpiperidin-4-yl)-1,3-thiazole-4-carboxamide Chemical compound C=1SC(C2CCN(CC2)C=2C=3SC=CC=3N=CN=2)=NC=1C(=O)NC(NC1=CC=2)=NC1=CC=2C(=O)C1=CC=CC=C1 QNZVBFMXWNWVKG-UHFFFAOYSA-N 0.000 description 10
- 238000013207 serial dilution Methods 0.000 description 10
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 10
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 9
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 8
- 241001500351 Influenzavirus A Species 0.000 description 8
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 8
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 8
- 108010057466 NF-kappa B Proteins 0.000 description 7
- 238000000692 Student's t-test Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000012353 t test Methods 0.000 description 7
- 229960003862 vemurafenib Drugs 0.000 description 7
- RCLQNICOARASSR-SECBINFHSA-N 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 description 6
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 229960002725 isoflurane Drugs 0.000 description 6
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 6
- 238000010899 nucleation Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- QFWCYNPOPKQOKV-UHFFFAOYSA-N 2-(2-amino-3-methoxyphenyl)chromen-4-one Chemical compound COC1=CC=CC(C=2OC3=CC=CC=C3C(=O)C=2)=C1N QFWCYNPOPKQOKV-UHFFFAOYSA-N 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 description 5
- 108010078471 Panton-Valentine leukocidin Proteins 0.000 description 5
- 101000761953 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein kinase byr2 Proteins 0.000 description 5
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 5
- 229960001467 bortezomib Drugs 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000386 microscopy Methods 0.000 description 5
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229940061367 tamiflu Drugs 0.000 description 5
- CMWRPDHVGMHLSZ-GFCCVEGCSA-N (10r)-10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one Chemical compound C([C@H](NC1=O)C)NC(C2=C3C=C4)=C1SC2=CC=C3N=C4C1=CC=C(C)N=C1 CMWRPDHVGMHLSZ-GFCCVEGCSA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 4
- BOIPLTNGIAPDBY-UHFFFAOYSA-N 2-[6-(4-chlorophenoxy)hexyl]-1-cyano-3-pyridin-4-ylguanidine Chemical compound C1=CC(Cl)=CC=C1OCCCCCCN=C(NC#N)NC1=CC=NC=C1 BOIPLTNGIAPDBY-UHFFFAOYSA-N 0.000 description 4
- FIMYFEGKMOCQKT-UHFFFAOYSA-N 3,4-difluoro-2-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-5-[(3-oxooxazinan-2-yl)methyl]benzamide Chemical compound FC=1C(F)=C(NC=2C(=CC(I)=CC=2)F)C(C(=O)NOCCO)=CC=1CN1OCCCC1=O FIMYFEGKMOCQKT-UHFFFAOYSA-N 0.000 description 4
- VHKZGNPOHPFPER-ONNFQVAWSA-N BAY11-7085 Chemical compound CC(C)(C)C1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 VHKZGNPOHPFPER-ONNFQVAWSA-N 0.000 description 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 4
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 4
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 4
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- DFYPFJSPLUVPFJ-QJEDTDQSSA-N [(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl] [(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl hydrogen phosphate Chemical compound Cc1cn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)[C@@H](COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)OC3CC(OC3CO)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)O2)c(=O)[nH]c1=O DFYPFJSPLUVPFJ-QJEDTDQSSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000002924 anti-infective effect Effects 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 229940109262 curcumin Drugs 0.000 description 4
- 235000012754 curcumin Nutrition 0.000 description 4
- 239000004148 curcumin Substances 0.000 description 4
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229960002706 gusperimus Drugs 0.000 description 4
- 230000015788 innate immune response Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 4
- 238000012898 one-sample t-test Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229940016667 resveratrol Drugs 0.000 description 4
- 235000021283 resveratrol Nutrition 0.000 description 4
- DAPAQENNNINUPW-IDAMAFBJSA-N rocaglamide Chemical compound C1=CC(OC)=CC=C1[C@]1([C@@H]([C@H]([C@H]2O)C(=O)N(C)C)C=3C=CC=CC=3)[C@]2(O)C2=C(OC)C=C(OC)C=C2O1 DAPAQENNNINUPW-IDAMAFBJSA-N 0.000 description 4
- 229960000953 salsalate Drugs 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 229960004025 sodium salicylate Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 4
- 229960000894 sulindac Drugs 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 229960003433 thalidomide Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- LMMJFBMMJUMSJS-UHFFFAOYSA-N CH5126766 Chemical compound CNS(=O)(=O)NC1=NC=CC(CC=2C(OC3=CC(OC=4N=CC=CN=4)=CC=C3C=2C)=O)=C1F LMMJFBMMJUMSJS-UHFFFAOYSA-N 0.000 description 3
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 3
- 238000000585 Mann–Whitney U test Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- SUDAHWBOROXANE-VIFPVBQESA-N PD 0325901-Cl Chemical compound OC[C@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-VIFPVBQESA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000002223 anti-pathogen Effects 0.000 description 3
- 229960005475 antiinfective agent Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 150000002605 large molecules Chemical class 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 description 2
- ATBAETXFFCOZOY-DAXSKMNVSA-N (4z)-4-(2-amino-4-oxo-1h-imidazol-5-ylidene)-2-bromo-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one Chemical compound N1C(N)=NC(=O)\C1=C/1C(C=C(Br)N2)=C2C(=O)NCC\1 ATBAETXFFCOZOY-DAXSKMNVSA-N 0.000 description 2
- KQJSQWZMSAGSHN-UHFFFAOYSA-N (9beta,13alpha,14beta,20alpha)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(O)=C2C KQJSQWZMSAGSHN-UHFFFAOYSA-N 0.000 description 2
- DOEWDSDBFRHVAP-KRXBUXKQSA-N (E)-3-tosylacrylonitrile Chemical compound CC1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 DOEWDSDBFRHVAP-KRXBUXKQSA-N 0.000 description 2
- CYCGGKILBWERDJ-UHFFFAOYSA-N 1-(3,5-ditert-butyl-4-hydroxyphenyl)-2-[2-(3-hydroxypropylamino)-5,6-dimethyl-1-benzimidazolyl]ethanone Chemical compound C1=2C=C(C)C(C)=CC=2N=C(NCCCO)N1CC(=O)C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 CYCGGKILBWERDJ-UHFFFAOYSA-N 0.000 description 2
- SRFABRWQVPCPRG-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonyl-2-benzimidazolamine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=CC=CC=C2N=C1N SRFABRWQVPCPRG-UHFFFAOYSA-N 0.000 description 2
- ILVFNAZMSMNXJG-RMKNXTFCSA-N 1-fluoro-2-[(e)-2-(4-methoxyphenyl)ethenyl]benzene Chemical compound C1=CC(OC)=CC=C1\C=C\C1=CC=CC=C1F ILVFNAZMSMNXJG-RMKNXTFCSA-N 0.000 description 2
- AYKMXKNVEUMLFQ-UHFFFAOYSA-N 2-(1,8-naphthyridin-2-yl)phenol Chemical compound OC1=CC=CC=C1C1=CC=C(C=CC=N2)C2=N1 AYKMXKNVEUMLFQ-UHFFFAOYSA-N 0.000 description 2
- SAYGKHKXGCPTLX-UHFFFAOYSA-N 2-(carbamoylamino)-5-(4-fluorophenyl)-3-thiophenecarboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C=CC(F)=CC=2)=C1 SAYGKHKXGCPTLX-UHFFFAOYSA-N 0.000 description 2
- AEOGPIJVSQTAII-UHFFFAOYSA-N 4-(furan-2-ylmethyl)-1,4-thiazinane 1,1-dioxide Chemical compound C1CS(=O)(=O)CCN1CC1=CC=CO1 AEOGPIJVSQTAII-UHFFFAOYSA-N 0.000 description 2
- IBAKVEUZKHOWNG-UHFFFAOYSA-N 4-n-[2-(4-phenoxyphenyl)ethyl]quinazoline-4,6-diamine Chemical compound C12=CC(N)=CC=C2N=CN=C1NCCC(C=C1)=CC=C1OC1=CC=CC=C1 IBAKVEUZKHOWNG-UHFFFAOYSA-N 0.000 description 2
- JFSXSNSCPNFCDM-UHFFFAOYSA-N 6-(benzenesulfinyl)tetrazolo[1,5-b]pyridazine Chemical compound C1=CC2=NN=NN2N=C1S(=O)C1=CC=CC=C1 JFSXSNSCPNFCDM-UHFFFAOYSA-N 0.000 description 2
- JUOWWGNRWRLBSV-MEKGRNQZSA-N 8-[[2-[(3s,4r)-3,4-bis(hydroxymethyl)-3,4-dimethylpyrrolidin-1-yl]-5-chloropyridine-4-carbonyl]amino]-1-(4-fluorophenyl)-4,5-dihydrobenzo[g]indazole-3-carboxamide Chemical compound C1[C@@](CO)(C)[C@](C)(CO)CN1C1=CC(C(=O)NC=2C=C3C=4N(N=C(C=4CCC3=CC=2)C(N)=O)C=2C=CC(F)=CC=2)=C(Cl)C=N1 JUOWWGNRWRLBSV-MEKGRNQZSA-N 0.000 description 2
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 2
- YYGRXNOXOVZIKE-UHFFFAOYSA-N Arctigenin Natural products COC1CCC(CC2COC(=O)C2CC3CCC(O)C(C3)OC)CC1OC YYGRXNOXOVZIKE-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- NYSZJNUIVUBQMM-BQYQJAHWSA-N Cardamonin Chemical compound COC1=CC(O)=CC(O)=C1C(=O)\C=C\C1=CC=CC=C1 NYSZJNUIVUBQMM-BQYQJAHWSA-N 0.000 description 2
- AQKDBFWJOPNOKZ-UHFFFAOYSA-N Celastrol Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(=O)C2C AQKDBFWJOPNOKZ-UHFFFAOYSA-N 0.000 description 2
- 102000000013 Chemokine CCL3 Human genes 0.000 description 2
- 241000606069 Chlamydiaceae Species 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- OIFFJDGSLVHPCW-UHFFFAOYSA-N Guayarol Natural products COc1ccc(CC2C(Cc3ccc(O)c(O)c3)COC2=O)cc1OC OIFFJDGSLVHPCW-UHFFFAOYSA-N 0.000 description 2
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 2
- 101000966257 Homo sapiens Limb region 1 protein homolog Proteins 0.000 description 2
- 101000628954 Homo sapiens Mitogen-activated protein kinase 12 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- YMFNPBSZFWXMAD-UHFFFAOYSA-N JSH-23 Chemical compound NC1=CC(C)=CC=C1NCCCC1=CC=CC=C1 YMFNPBSZFWXMAD-UHFFFAOYSA-N 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- NQWVSMVXKMHKTF-UHFFFAOYSA-N L-Arctigenin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-UHFFFAOYSA-N 0.000 description 2
- 241000589246 Legionellaceae Species 0.000 description 2
- 102100040547 Limb region 1 protein homolog Human genes 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 102100026932 Mitogen-activated protein kinase 12 Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000204034 Mycoplasmataceae Species 0.000 description 2
- JZRMBDHPALEPDM-UHFFFAOYSA-N N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-3-pyridinecarboxamide Chemical compound C=12NC3=CN=CC=C3C2=CC(Cl)=CC=1NC(=O)C1=CC=CN=C1 JZRMBDHPALEPDM-UHFFFAOYSA-N 0.000 description 2
- CHILCFMQWMQVAL-UHFFFAOYSA-N N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CHILCFMQWMQVAL-UHFFFAOYSA-N 0.000 description 2
- IEZRNEGTKRQRFV-LFBNJJMOSA-N N-octadecanoyl-4-hydroxysphinganine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC IEZRNEGTKRQRFV-LFBNJJMOSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 101150091206 Nfkbia gene Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- BIVQBWSIGJFXLF-UHFFFAOYSA-N PPM-18 Chemical compound C=1C(=O)C2=CC=CC=C2C(=O)C=1NC(=O)C1=CC=CC=C1 BIVQBWSIGJFXLF-UHFFFAOYSA-N 0.000 description 2
- JTJJGVCUEGCBHL-IWDHFESKSA-N PR-39 Chemical compound C([C@H](NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 JTJJGVCUEGCBHL-IWDHFESKSA-N 0.000 description 2
- 241000606752 Pasteurellaceae Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- JFACETXYABVHFD-WXPPGMDDSA-N Pristimerin Chemical compound CC1=C(O)C(=O)C=C2[C@@](CC[C@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C[C@H]53)(C)C(=O)OC)(C)C4=CC=C21 JFACETXYABVHFD-WXPPGMDDSA-N 0.000 description 2
- FMPJNBPZCVETGY-UHFFFAOYSA-N Pristimerinen Natural products C12=CC=C3C(C)=C(O)C(=O)C=C3C2=C(C)CC2(C)C1(C)CCC1(C)CCC(C(=O)OC)(C)CC12 FMPJNBPZCVETGY-UHFFFAOYSA-N 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 241000947836 Pseudomonadaceae Species 0.000 description 2
- 241001248479 Pseudomonadales Species 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 2
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- WKMYTPCPAWZWII-UHFFFAOYSA-N [2-(4-acetyloxyphenyl)-2-chloroethyl]-methylazanium;chloride Chemical compound Cl.CNCC(Cl)C1=CC=C(OC(C)=O)C=C1 WKMYTPCPAWZWII-UHFFFAOYSA-N 0.000 description 2
- BWZJBXAPRCVCKQ-UHFFFAOYSA-N [4-[[4-(1-benzothiophen-2-yl)-2-pyrimidinyl]amino]phenyl]-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone Chemical compound C=1C=C(NC=2N=C(C=CN=2)C=2SC3=CC=CC=C3C=2)C=CC=1C(=O)N(CC1)CCC1N1CCCC1 BWZJBXAPRCVCKQ-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- NYSZJNUIVUBQMM-UHFFFAOYSA-N alpinetin chalcone Natural products COC1=CC(O)=CC(O)=C1C(=O)C=CC1=CC=CC=C1 NYSZJNUIVUBQMM-UHFFFAOYSA-N 0.000 description 2
- SGRYPYWGNKJSDL-UHFFFAOYSA-N amlexanox Chemical compound NC1=C(C(O)=O)C=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=N1 SGRYPYWGNKJSDL-UHFFFAOYSA-N 0.000 description 2
- 229960003731 amlexanox Drugs 0.000 description 2
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 description 2
- MDDIUTVUBYEEEM-UHFFFAOYSA-N azane;pyrrolidine-1-carbodithioic acid Chemical compound N.SC(=S)N1CCCC1 MDDIUTVUBYEEEM-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- WWVKQTNONPWVEL-UHFFFAOYSA-N caffeic acid phenethyl ester Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- DYVFBWXIOCLHPP-UHFFFAOYSA-N chembl368427 Chemical compound N#CC=1C(N)=NC(C=2C(=CC=CC=2O)OCC2CC2)=CC=1C1CCNCC1 DYVFBWXIOCLHPP-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- SSQJFGMEZBFMNV-PMACEKPBSA-N dexanabinol Chemical compound C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940125436 dual inhibitor Drugs 0.000 description 2
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 2
- DAPAQENNNINUPW-UHFFFAOYSA-N endo rocaglamide Natural products C1=CC(OC)=CC=C1C1(C(C(C2O)C(=O)N(C)C)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 DAPAQENNNINUPW-UHFFFAOYSA-N 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- WDKYDMULARNCIS-UHFFFAOYSA-N ethyl caffeoate Natural products CCOC(=O)C=CC1=CC=C(O)C(O)=C1 WDKYDMULARNCIS-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- FIVPIPIDMRVLAY-RBJBARPLSA-N gliotoxin Chemical compound C1C2=CC=C[C@H](O)[C@H]2N2[C@]1(SS1)C(=O)N(C)[C@@]1(CO)C2=O FIVPIPIDMRVLAY-RBJBARPLSA-N 0.000 description 2
- 229940103893 gliotoxin Drugs 0.000 description 2
- 229930190252 gliotoxin Natural products 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 2
- VVOAZFWZEDHOOU-UHFFFAOYSA-N honokiol Natural products OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 2
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 2
- 235000009498 luteolin Nutrition 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- NWFYESYCEQICQP-UHFFFAOYSA-N methylmatairesinol Natural products C1=C(OC)C(OC)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(OC)=C1 NWFYESYCEQICQP-UHFFFAOYSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000005937 nuclear translocation Effects 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- SWUARLUWKZWEBQ-VQHVLOKHSA-N phenethyl caffeate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-VQHVLOKHSA-N 0.000 description 2
- SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- IXWGHMMOEFOOFA-UHFFFAOYSA-N pristimerin Natural products COC(=O)C1(C)CCC2(C)CCC3(C)C4CC=C5C(=C(O)C(=O)C=C5C4(C)CCC3(C)C2C1)C IXWGHMMOEFOOFA-UHFFFAOYSA-N 0.000 description 2
- JFACETXYABVHFD-UHFFFAOYSA-N pristimerine Natural products CC1=C(O)C(=O)C=C2C(CCC3(C)C4(C)CCC5(C)CCC(CC53)(C)C(=O)OC)(C)C4=CC=C21 JFACETXYABVHFD-UHFFFAOYSA-N 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 231100000272 reduced body weight Toxicity 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000003375 selectivity assay Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 229960004066 trametinib Drugs 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- YCGBUPXEBUFYFV-UHFFFAOYSA-N withaferin A Natural products CC(C1CC(=C(CO)C(=O)O1)C)C2CCC3C4CC5OC56C(O)C=CC(O)C6(C)C4CCC23C YCGBUPXEBUFYFV-UHFFFAOYSA-N 0.000 description 2
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- CAVTXAUZYYVGML-UHFFFAOYSA-N 1,2-dihydropyridine-5-carboxamide Chemical compound NC(=O)C1=CNCC=C1 CAVTXAUZYYVGML-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- JBNWDYGOTHQHOZ-UHFFFAOYSA-N 2-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-6-methoxy-1-methylindol-3-yl]-n,n-dimethyl-2-oxoacetamide Chemical compound COC1=CC=2N(C)C=C(C(=O)C(=O)N(C)C)C=2C=C1C(=O)N(CC1)CCC1CC1=CC=C(F)C=C1 JBNWDYGOTHQHOZ-UHFFFAOYSA-N 0.000 description 1
- IUOMATKBBPCLFR-TUAOUCFPSA-N 2-hydroxy-n-[(1s,2s,6s)-2-hydroxy-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]benzamide Chemical compound O=C([C@H]1O[C@H]1[C@H]1O)C=C1NC(=O)C1=CC=CC=C1O IUOMATKBBPCLFR-TUAOUCFPSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- VMAKTIDYMSNPOV-UHFFFAOYSA-N 4,6-bis(4-fluorophenyl)-2-methyl-5-pyridin-4-ylpyrazolo[3,4-b]pyridine Chemical compound C=1C=NC=CC=1C=1C(C=2C=CC(F)=CC=2)=NC2=NN(C)C=C2C=1C1=CC=C(F)C=C1 VMAKTIDYMSNPOV-UHFFFAOYSA-N 0.000 description 1
- ATUBIBZJAGAIBW-WGEALTPQSA-N 4-[(2r,5s,6e,8z)-2-hydroxy-5,7-dimethyl-4-oxodeca-6,8-dienyl]piperidine-2,6-dione Chemical compound C\C=C/C(/C)=C/[C@H](C)C(=O)C[C@H](O)CC1CC(=O)NC(=O)C1 ATUBIBZJAGAIBW-WGEALTPQSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- ATUBIBZJAGAIBW-TXTWTNGRSA-N 9-methylstreptimidone Natural products CC=C/C(=C/C(C)C(=O)CC(O)CC1CC(=O)NC(=O)C1)/C ATUBIBZJAGAIBW-TXTWTNGRSA-N 0.000 description 1
- 102100029374 Adapter molecule crk Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 241001136800 Anas acuta Species 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- OSSDUQKWVVZIGP-UHFFFAOYSA-N Aromaticin Natural products CC1CC2OC(=O)C(=C)C2CC2(C)C(=O)C=CC12 OSSDUQKWVVZIGP-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- GXXTWVQJEMQFOY-UHFFFAOYSA-N COc1cc(F)c(F)c(Cc2ccc(I)cc2F)c1NS(=O)(=O)C1(CC(O)CO)CC1 Chemical compound COc1cc(F)c(F)c(Cc2ccc(I)cc2F)c1NS(=O)(=O)C1(CC(O)CO)CC1 GXXTWVQJEMQFOY-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- BVMZBFGSSMFRKD-UHFFFAOYSA-N Cc1c(Cc2ccnc(NS(N)(=O)=O)c2F)c(=O)oc2cc(Oc3ncccn3)ccc12 Chemical compound Cc1c(Cc2ccnc(NS(N)(=O)=O)c2F)c(=O)oc2cc(Oc3ncccn3)ccc12 BVMZBFGSSMFRKD-UHFFFAOYSA-N 0.000 description 1
- GMYTVGLQLMSTOA-UHFFFAOYSA-N Cc1cc(C(=O)COCCO)c(Cc2ccc(I)cc2F)n(C)c1=O Chemical compound Cc1cc(C(=O)COCCO)c(Cc2ccc(I)cc2F)n(C)c1=O GMYTVGLQLMSTOA-UHFFFAOYSA-N 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000000362 Chlamydial Pneumonia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- ZAMCWIQSMACDPM-UHFFFAOYSA-N Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)COCCO)cc21 Chemical compound Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)COCCO)cc21 ZAMCWIQSMACDPM-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101100457345 Danio rerio mapk14a gene Proteins 0.000 description 1
- 101100457347 Danio rerio mapk14b gene Proteins 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 101100508533 Drosophila melanogaster IKKbeta gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- ZVLOPMNVFLSSAA-UHFFFAOYSA-N Heleanalin Natural products CC1CC2OC(=O)C(=C)C2C(O)C2(C)C(=O)C=CC12 ZVLOPMNVFLSSAA-UHFFFAOYSA-N 0.000 description 1
- RFBYGVGDYMSKTD-UHFFFAOYSA-N Helenalin Natural products CC1CC2OC(=O)C(=C)C2C(O)C3C(C)C(=O)C=C13 RFBYGVGDYMSKTD-UHFFFAOYSA-N 0.000 description 1
- 101100457336 Homo sapiens MAPK12 gene Proteins 0.000 description 1
- 101000628967 Homo sapiens Mitogen-activated protein kinase 11 Proteins 0.000 description 1
- 108060006678 I-kappa-B kinase Proteins 0.000 description 1
- 102000001284 I-kappa-B kinase Human genes 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 102100024067 Inhibitor of growth protein 2 Human genes 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000272168 Laridae Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- 108700012928 MAPK14 Proteins 0.000 description 1
- 230000005723 MEK inhibition Effects 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101150003941 Mapk14 gene Proteins 0.000 description 1
- AFTUDGRDUWDYHE-UHFFFAOYSA-N Mexicanin I Natural products CC1CC2OC(=O)C(=C)C2C(O)C3(C)C1CC=C3C AFTUDGRDUWDYHE-UHFFFAOYSA-N 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- 102100026929 Mitogen-activated protein kinase 11 Human genes 0.000 description 1
- 102000056243 Mitogen-activated protein kinase 12 Human genes 0.000 description 1
- 108700015929 Mitogen-activated protein kinase 12 Proteins 0.000 description 1
- 102000056248 Mitogen-activated protein kinase 13 Human genes 0.000 description 1
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 1
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 description 1
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 1
- PSPFQEBFYXJZEV-UHFFFAOYSA-N N'-(1,8-dimethyl-4-imidazo[1,2-a]quinoxalinyl)ethane-1,2-diamine Chemical compound C1=C(C)C=C2N3C(C)=CN=C3C(NCCN)=NC2=C1 PSPFQEBFYXJZEV-UHFFFAOYSA-N 0.000 description 1
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 description 1
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 241000272458 Numididae Species 0.000 description 1
- CPOCTKXTRVUTBH-UHFFFAOYSA-N O=C(COCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Cc1ccc(I)cc1F Chemical compound O=C(COCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Cc1ccc(I)cc1F CPOCTKXTRVUTBH-UHFFFAOYSA-N 0.000 description 1
- QKCGAZHZHDGWSR-GFCCVEGCSA-N O=C(COC[C@H](O)CO)c1ccc(F)c(F)c1Cc1ccc(I)cc1F Chemical compound O=C(COC[C@H](O)CO)c1ccc(F)c(F)c1Cc1ccc(I)cc1F QKCGAZHZHDGWSR-GFCCVEGCSA-N 0.000 description 1
- QWLQZANNQMLAID-ZDUSSCGKSA-N O=C(NC[C@H](O)CO)c1ccncc1Cc1ccc(I)cc1F Chemical compound O=C(NC[C@H](O)CO)c1ccncc1Cc1ccc(I)cc1F QWLQZANNQMLAID-ZDUSSCGKSA-N 0.000 description 1
- FIAWSLMDMMCNMU-HHCSFTFJSA-N O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)C1CC(O)([C@@H]2CCCCN2)C1 Chemical compound O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)C1CC(O)([C@@H]2CCCCN2)C1 FIAWSLMDMMCNMU-HHCSFTFJSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 101710151911 Phosphoprotein p30 Proteins 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 1
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001134658 Streptococcus mitis Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- BSMCAPRUBJMWDF-UHFFFAOYSA-N [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-(3-hydroxy-3-piperidin-2-ylazetidin-1-yl)methanone Chemical compound C1C(O)(C2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000009925 apoptotic mechanism Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000005735 apoptotic response Effects 0.000 description 1
- 230000007320 autophagy mechanism Effects 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004993 binary fission Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000003503 early effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- ZVLOPMNVFLSSAA-XEPQRQSNSA-N helenalin Chemical compound C[C@@H]1C[C@H]2OC(=O)C(=C)[C@H]2[C@H](O)[C@]2(C)C(=O)C=C[C@@H]12 ZVLOPMNVFLSSAA-XEPQRQSNSA-N 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229950002736 marizomib Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- AWKOVWFBTRXQLW-UHFFFAOYSA-N n-(6-chloro-7-methoxy-9h-pyrido[3,4-b]indol-8-yl)-2-methylpyridine-3-carboxamide;dihydrochloride Chemical compound Cl.Cl.COC1=C(Cl)C=C2C3=CC=NC=C3NC2=C1NC(=O)C1=CC=CN=C1C AWKOVWFBTRXQLW-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000006656 viral protein synthesis Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940034727 zelboraf Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to MEK inhibit, p 38 inhibitor and/or NF ⁇ B inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. Also provided are compositions comprising such inhibitors for use in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone.
- an in vitro test system wherein the test system comprises cultured cells infected with an influenza virus and a bacterium or with a bacterium alone is provided.
- Influenza A viruses are the causative agents of severe respiratory diseases resulting in significant morbidity and mortality. Most of the fatal cases in the course of an influenza virus (IV) infection are actually a result of secondary pneumonia caused by different bacteria, such as Staphylococcus aureus ( S. aureus ), Streptococcus pneumoniae and Haemophilus influenzae (Morens et al., 2008, Chertow et al., 2013). The most striking problems of bacterial co-infection are the suddenly increased pathogenicity (Iwao et at., 2012, Paddock et al., 2012, Parker et al., 2012) and a limited arsenal of potent anti-infectives against the different pathogens.
- IV influenza virus
- influenza viruses The high variability of influenza viruses and the continuous emergence of new strains (Neumann et al., 2009, Taubenberger et al., 2010, Parry, 2013), specific characteristics of the bacterial strains (Grundmann et al., 2006, Moran et al., 2008, Gillet et al., 2007, Shio et al., 2011), as well as the rapid resistance development of both, influenza viruses (Hayden et al., 1992, Bright et al., 2006, Pinto et al., 2006, De Clercq et al., 2007, Pinto et al., 2007) and bacteria (Grundmann et al., 2006, Moran et al., 2006, Shilo et al., 2011) against the available drugs/antibiotics are the major reasons for the poor treatment options Moreover, it is incidental that treatment of coinfections with influenza viruses and bacteria is not possible with a single compound, so far.
- the current invention solves this problem in that it proposes a novel anti-infective strategy against IV and S. aureus co-infections by using single drugs. Furthermore, the present invention solves the problem of rapid resistance development of bacteria by providing drug that targets cellular factors rather than the bacterium itself.
- the present invention relates to a MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection.
- the present invention relates to a MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor for use in a method for the prophylaxis and/or treatment of a bacterial infection.
- Bacterial co-infections usually occur within the first six days of an IV infection, resulting in even more fulminant illness, pneumonia and higher mortality (Iverson et al., 2011, Chertow et al, 2013). However in same cases bacterial co-infection comes up, when virus-infection already seems to be cleared. For treatment of viral/bacterial co-infections only limited possibilities exist.
- IV as intracellular pathogens, strongly depend on the cellular signaling machinery (Gong et al., 2009, Ludwig, 2009). IV acquired the ability to highjack cellular factors for its own purpose (Ludwig et al.,2003). Furthermore, IV are able to suppress the innate immune response of their hosts. Given these dependencies, cellular virus-supportive functions are most promising candidates for novel antiviral intervention (Ludwig et al, 2003, Ludwig, 2011, Planz, 2013).
- Targeting cellular rather than viral factors prevents the problem of resistance because the pathogen cannot replace the missing cellular function.
- chemical compounds are available and although in an early stage, some of them have entered clinical testing or are even already licensed.
- S. aureus division is host-cell independent. Novel antibacterial alternatives do not target essential gene products elaborated by the pathogen, but inhibit virulence factors during S. aureus infection without killing the bacterium or boosting host immunity (Park et al., 2012). Other strategies prevent colonization of S. aureus in the human host (Park et al., 2012). These compounds also exhibit a lower potential to induce resistance. Recently, there is accumulating evidence that S. aureus also uses cellular signaling for its own benefits during infection (Oviedo-Boyso et al., 2011), but such bacterial-supportive cellular factors have not yet been characterized as targets for antibacterial therapy in detail.
- the present inventors surprisingly observed, that drugs against intracellular signaling factors, such as NF ⁇ B, MEK or p38 MAP kinase, that were previously shown to possess anti influenza activity, also exhibit anti S. aureus activity and reduces both viral- and bacterial titers in a coinfection scenario.
- these signaling inhibitors are most promising candidates for the treatment of IV or S. aureus infections alone, but, most importantly also against severe influenza accompanied with bacterial coinfection.
- the MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention, wherein the the bacterial infection is mediated by a bacterium selected from the group consisting of Staphylococcaceae, Streptococcaceae, Legionellaceae, Pseudomonadaceae, Chlamydiaceae, Mycoplasmataceae, Enterobacteriaceae, Pseudomonadales and/or Pasteurellaceae.
- a bacterium selected from the group consisting of Staphylococcaceae, Streptococcaceae, Legionellaceae, Pseudomonadaceae, Chlamydiaceae, Mycoplasmataceae, Enterobacteriaceae, Pseudomonadales and/or Pasteurellaceae.
- the MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection of the present invention, wherein the influenza virus infection is mediated by influenza A virus or influenza B virus, preferably the influenza A virus is H1N1, H2N2, H3N2, H6N1, H7N7, H7N9, H9N2 H10N7, H10N8 or H5N1.
- the influenza A virus is H1N1.
- the influenza A virus is H3N2, H5N1 and H7N9.
- the influenza A virus is H3N2, H5N1, H1N1 and H7N9.
- the MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention
- the MEK inhibitor is selected from the group consisting of U0126, PLX-4032, AZD6244, AZD8330, AS-703026, GSK-1120212, RDEA-119, RO-5126766, RO-4987655, CI-1040, PD-0325901, GDC-0973, TAK-733, PD98059, ARRY-438162, PF-3644022 and PD184352, preferably AZD8330, GSK-1120212, U0126, GDC-0973, CI-1040, PD0325901, ARRY438162, PF-3644022 and AZD6244, most preferably U0126, GDC-0973, CI-1040, AZD8330 and GSK-1120212.
- the MFK inhibitor, p32 inhibitor and/or NF ⁇ B inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention
- the p38 inhibitor is selected from the group consisting of SB202190, LY2228820, CAY10571, SB 203580, Tie2 Kinase Inhibitor, 2-(4-Chlorophenyl)-4-(fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one, CGH 2466, SB220025, Antibiotic LL Z1640-2, TAK 715, SB202190 hydrochloride, SKF 86002, AMG548, CMPD-1, EO 1428, JX 401, ML 3403, RWJ 67657, SB 202190, SB 203580, SB 203580 hydrochloride, SB 239063, SCIO 469, SX 011, TAK 715, Pam
- the MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention
- the NF ⁇ B inhibitor is selected from the group consisting of LASAG (also called LG-ASA), SC75741, MG 132, TPCA-1, PCTC, IMD 0354, Luteolin, Caffeic acid phenethyl ester, Cardamonin, PF 184, IKK 16, SC 514, Withaferin A, Arctigenin, Bay 11-7085, PSI, PR 39, Ro 106-9920, Bay 11-7821, ML-130, Celastrol, Tanshinone IIA, HU 211, Gliotoxin, CID 2858522, Honokiol, Andrographolide, 10Z-Hymenialdisine, ACHP, Pristimerin, Sulfasalazine, ML 120B dihydr
- the MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention, wherein the MEK inhibitor is combined with another MEK inhibitor, the p38 inhibitor and/or the NF ⁇ B inhibitor; the p38 inhibitor is combined with another p38 inhibitor, the MEK inhibitor and/or the NF ⁇ B inhibitor or the NF ⁇ B inhibitor is combined with another NF ⁇ B inhibitor, the p38 inhibitor and/or the MEK inhibitor.
- the MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection of the present invention, wherein the MEK inhibitor, the p38 inhibitor and/or the NF ⁇ B inhibitor are combined with one or more inhibitors targeting the influenza virus and/or the bacterium.
- the MEK inhibitor, the p38 inhibitor and/or the NF ⁇ B inhibitor is/are administered contemporaneously, previously or subsequently to the one or more inhibitors targeting the influenza virus and/or the bacterium.
- the MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor can be combined with 1, 2, 3, 4, 5, 6, 7, or 8 inhibitors targeting the influenza virus.
- the MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor can be combined with 1, 2, 3, 4, 5, 6, 7, or 8 inhibitors targeting the bacterium.
- the one or more inhibitors targeting the influenza virus is a neuraminidase inhibitor, preferably oseltamivir phosphate, zanamivir, oseltamivir or peramivir.
- the one or more inhibitors targeting the influenza virus is a compound targeting an ion channel protein (M2), preferably amantadine and/or rimantadine.
- M2 ion channel protein
- the one or more inhibitors targeting the influenza virus is a compound targeting polymerase or endonuclease activity via interfering with a component of the viral polymerase complex, PB1, PB2, PA or NP, preferably NP blocker Nucleozin or polymerase inhibitor T-705.
- the MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a bacterial infection of the present invention, wherein the MEK inhibitor, the p38 inhibitor and/or the NF ⁇ B inhibitor are combined with one or more inhibitors targeting the bacterium.
- the MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention
- the one or more inhibitor targeting the bacterium is an antibiotic, preferably Gentamicin, Rifampicin, Lysosthaphin, Erythromycin, Levofloxacin Vancomycin, Teicoplanin, Penicillin and Oxacillin.
- the MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention is in a subject, preferably a vertebrate.
- compositions comprising a MEK inhibitor, a p38 inhibitor and/or a NF ⁇ B inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection.
- the composition further comprises a carrier.
- the present invention also relates to a composition, comprising a MEK inhibitor, a p38 inhibitor and/or a NF ⁇ B inhibitor for use in a method for the prophylaxis and/or treatment of a bacterial infection.
- the composition further comprises a carrier.
- compositions comprising a MEK inhibitor, a p38 inhibitor and/or a NF ⁇ B inhibitor and one or more inhibitors targeting the influenza virus and/or the bacterium for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection.
- the composition further comprises a carrier.
- the present invention also relates to a composition, comprising a MEK inhibitor, a p38 inhibitor and/or a NF ⁇ B inhibitor and one or more inhibitors targeting the bacterium for use in a method for the prophylaxis and/or treatment of a a bacterial infection
- the composition further comprises a carrier.
- the MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection of the present invention, wherein the MEK inhibitor, the p38 inhibitor and/or the NF ⁇ B inhibitor reduces both the viral and bacterial infection, when contacting it/them with an in vitro test system, wherein the test system comprises cultured cells infected with
- the reduction of the viral infection is a reduction in plaque forming units (pfu)/ml and the reduction in the bacterial infection is a reduction in colony forming units (CFU)/ml.
- the MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a bacterial infection of the present invention, wherein the MEK inhibitor, the p38 inhibitor and/or the NE ⁇ B inhibitor reduces the bacterial infection, when contacting it/them with an in vitro test system, wherein the test system comprises cultured cells infected with a bacterium, when compared to the in vitro test system before the contacting.
- the present invention also relates to an in vitro test system, wherein the test system comprises
- the invention also provides for the use of the in vitro test system of of the present invention for the determination of inhibitors effective in reducing a coinfection comprising a bacterial infection and an influenza virus infection.
- the reduction of the viral infection is a reduction in plaque forming units (pfu)/ml and the reduction in the bacterial infection is a reduction in colony forming units (CFU)/ml.
- the present invention relates to a method for detecting molecules effective in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection comprising contacting the in vitro test system of the present invention with a compound of interest, wherein the compound of interest reduces both the viral and bacterial infection, compared to the in vitro test system before the contacting.
- the present invention also provides for an in vitro test system, wherein the in vitro test system comprises cultured cells infected with a bacterium.
- the present invention in addition, relates to a use of the in vitro test system of the present invention for the determination of inhibitors effective in reducing a bacterial infection.
- the present invention relates to the use of the in vitro test systems of the present invention for the examination of innate host cell responses, which optionally includes examination of the level of signal transduction, resulting cytokine and chemokine expression, induction of apoptosis and necrosis and/or redox hemostasis regulating health and disease.
- Also provided for by the present invention is a method for detecting molecules effective in the prophylaxis and/or treatment a bacterial infection comprising contacting the in vitro test system of the present invention with a compound of interest, wherein the compound of interest reduces the bacterial infection, compared to the in vitro test system before the contacting.
- the present invention furthermore relates to a cultured cell infected with an influenza virus and a bacterium.
- Also provided for is a cultured cell infected with a bacterium.
- FIG. 1 Time scale of co-infection procedure. Cells were infected with IV for 30 min. Co-infection with S. aureus 6850 was conducted or cells were mock-treated. Extracellular bacteria were lysed and removed by antibiotic treatment 3 h post bacterial infection. After a PBS wash, cells were supplemented with fresh medium (DMEM/INV) and incubated up to 18 hrs of viral infection
- DMEM/INV fresh medium
- FIG. 2 The MEK inhibitor U0126 reduces IV titers (A/Puerto Rico/8/34) and S. aureus load, even in a co-infection situation.
- Human lung epithelial cells were seeded in 6-well plates (8 ⁇ 10 5 cells/well) in 2 ml DMEM (10% FCS).
- IV titers and intracellular bacteria were determined as described in (Hrincius et al., 2010, Tuchscherr et al., 2011). IV titers are depicted as plaque forming units (pfu)/ml (A, C) and S. aureus titers are depicted as colonie forming units (CFU)/ml (B, D). Data represent the means ⁇ SD of three independent experiments with two biological samples. Statistical significance was evaluated by a two-tailed two sample t-test (*p ⁇ 0.05; **p ⁇ 0.01; ***p ⁇ 0.001). (E) S. aureus in presence of 50 ⁇ M U0126 results in reduced bacterial titers 18 hrs upon incubation in comparison to DMSO treated bacteria.
- S. aureus 6850 suspension culture was diluted in DMEM/INV supplemented with 50 ⁇ M U0126 or DMSO and incubated at 37° C. for 18 hrs. Bacteria were diluted and determined by serial dilution on agar plates. Data represent the means ⁇ SD of three independent experiments with two biological samples. Statistical significance was evaluated by a two-tailed two sample t-test (*p ⁇ 0.05; **p ⁇ 0.01; ***p ⁇ 0.001).
- FIG. 3 The MEK inhibitor U0126 reduces IV titers (A/FPV/Bratislava/79) and S. aureus load, even in a co-infection situation.
- Human lung epithelial cells were seeded in 6-well plates (8 ⁇ 10 5 cells/well) in 2 ml DMEM [10% FCS].
- 3 hrs post bacterial infection cells were treated with antibiotics to remove extracellular bacteria. Therefore cells were rinsed with PBS and subsequently incubated with DMEM/INVantibiotics [2 ⁇ g/ml lysostaphin (Sigma)] (1 ml per 6 well) for 20 min at 37° C. After an additional wash with PBS cells were supplemented with DMEM/INV containing 50 ⁇ M U0126 or DMSO. After an incubation period of further 14 hrs at 37° C.
- IV titers and intracellular bacteria were determined as described in (Hrincius et al., 2010; Tuchscherr et al., 2011). IV titers are depicted as plaque forming units (pfu)/ml (A, C) and S. aureus titers are depicted as colonie forming units (CFU)/ml (B, D). Data represent the means ⁇ SD of two independent experiments with two biological samples. Statistical significance was evaluated by a two-tailed two sample t-test (*p ⁇ 0.05; **p ⁇ 0.01; ***p ⁇ 0.001).
- FIG. 4 The p38 inhibitor SB202190 reduces IV titers and S. aureus load, even in a co-infection situation.
- Human lung epithelial cells were seeded in 6-well plates (8 ⁇ 10 5 cells/well) in 2 ml DMEM [10% FCS].
- IV titers and intracellular bacteria were determined as described in (Hrincius et al., 2010; Tuchscherr et al., 2011). IV titers are depicted as plaque forming units (pfu)/ml (A, C) and S. aureus titers are depicted as colonie forming units (CFU)/ml (B, D). Data represent the means ⁇ SD of three independent experiments with two biological samples. Statistical significance was evaluated by a two-tailed two sample t-test (*p ⁇ 0.05; **p ⁇ 0.01; ***p ⁇ 0.001).
- FIG. 5 The NF-kappaB (NF ⁇ B) inhibitor LG-ASA reduces IV titers and S. aureus load, even in a co-infection situation.
- Human lung epithelial cells were seeded in 6-well plates (8 ⁇ 10 5 cells/well) in 2 ml DMEM (10% FCS).
- Water was used as solvent control. 3 hrs post bacterial infection cells were treated with antibiotics to remove extracellular bacteria. Therefore cells were rinsed with PBS and subsequently incubated with DMEM/INVantibiotics [10% FBS, 2 ⁇ g/ml lysostaphin (Sigma)] (1 ml per 6 well) for 20 min at 37° C. After an additional wash with PBS cells were supplemented with DMEM/INV containing 5 mM LG-ASA or water and 0.333 ⁇ g/ml Trypsin (Invitrogen). After an incubation period of further 14 hrs at 37° C.
- IV titers and intracellular bacteria were determined as described in (Hrincius et al., 2010, Tuchscherr et al., 2011). IV titers are depicted as plaque forming units (pfu)/ml (A, C) and S. aureus titers are depicted as colonie forming units (CFU)/ml (B, D). Data represent the means ⁇ SD of two independent experiments (virus titer) and three independent experiments (bacterial titer) with two biological samples. Statistical significance was evaluated by a two-tailed two sample t-test (*p ⁇ 0.05; **p ⁇ 0.01; ***p ⁇ 0.001).
- FIG. 6 The viral neuraminidase inhibitor tamiflu reduces IV replication but enhances S. aureus load.
- Human lung epithelial cells were seeded in 6-well plates (8 ⁇ 10 5 cells/well) in 2 ml DMEM [10% FCS].
- FIG. 7 Titers of intracellular S. aureus 6850 are reduced upon LG-ASA treatment.
- Human lung epithelial cells A549) were infected with 0.5 MOI S. aureus 6850 DMEM/INV [1% human serum albumin, 25 nmol/l HEPES] for 3 h in presence (A, C) and absence (B, D) of the indicated amounts of LG-ASA.
- DMEM/INVantibiotics [2 ⁇ g/ml lysostaphin (Sigma)] to remove non-internalized bacteria and subsequently cells were supplemented with DMEM/INV containing the indicated amounts of LG-ASA.
- Cell morphology was monitored by light microscopy (A, B) and amounts of internalized bacteria were determined by serial dilution on agar plates 18 hours post infection (C, D).
- FIG. 8 Table 2: p38 inhibitors.
- FIG. 9 Table 3: NF ⁇ B inhibitors.
- FIG. 10 Table 4: NF ⁇ B inhibitors.
- FIG. 11 Table 5: antibiotics.
- FIG. 12 Time scale of the co-infection procedure in vitro.
- Human lung epithelial cells A549) were infected with influenza A virus (IAV) for 30 min at a multiplicity of infection (MOI) indicated, dissolved in PBS/BA [0.2% bovine serum albumin, 1 mM MgCl 2 , 0.9 mM CaCl 2 , 100 U/ml penicillin, 0.1 mg/ml streptomycin] at 37° C. After 30 min incubation, the virus dilution was aspirated, cells were rinsed with PBS. Afterwards bacterial infection with Staphylococcus aureus 6850 ( S. aureus ) was performed or cells were mock-treated.
- IAV influenza A virus
- DMEM/INV 1% human serum albumin, 25 nmol/l HEPES
- S. aureus in addition to the indicated amounts of inhibitor (U0126 or CI-1040) or solvent control.
- 3 hrs post bacterial infection an antibiotic wash [DMEM, 10% FBS, 2 ⁇ g/ml Lysostaphin or 100 ⁇ g/ml Gentamicin, 20 min] was introduced to remove non-internalized bacteria.
- cells were supplemented with infection medium DMEM (0.2% BA, 1 mM MgCl 2 , 0.9 mM CaCl 2 , 100 U/ml penicillin, 0.1 mg/ml streptomycin) in presence or absence of the inhibitor and were incubated up to 18 hrs post viral infection at 37° C.
- infection medium DMEM 0.2% BA, 1 mM MgCl 2 , 0.9 mM CaCl 2 , 100 U/ml penicillin, 0.1 mg/ml streptomycin
- FIG. 13 Inhibition of the MEK/ERK signaling results in enhanced cell survival after singular and co-infection.
- DMEM/INV containing 1% human serum albumin, 25 nM HEPES
- FIG. 14 Inhibition of MEK/ERK signaling results in reduced viral titers during singular viral and co-infection.
- DMEM/INV containing 1% human serum albumin, 25 nM HEPES
- Viral titers are depicted as plaque forming units/ml (PFU/ml) with a linear (A, B) or logarithmic scale (C, D). Data represent the means ⁇ SD of four independent experiments with two biological samples. Statistical significance was evaluated by a two-tailed one sample t-test (*p ⁇ 0.05; **p ⁇ 0.01).
- FIG. 15 MEK inhibition by administration of U0126 results in reduced bacterial growth.
- DMEM/INV containing 1% human serum albumin, 25 nM HEPES
- U0126 The impact of U0126 on bacterial growth was analyzed by administration of U0126 as indicated to an over-night culture of S. aureus 6850 (100 CFU/ml). After 16 hrs serial dilutions were plated on BHI agar (B, D). Bacterial titers are depicted as colony forming units/ml (CFU/ml) with a linear (A, B) or logarithmic scale (C, D). Data represent the means ⁇ SD of four (A, C) or three (B, D) independent experiments with two biological samples. Statistical significance was evaluated by a two-tailed two sample t-test (***p ⁇ 0.001).
- FIG. 16 Inhibition of the MEK/ERK signaling leads to reduction of viral proteins and pro-inflammatory chemokines.
- DMEM/FBS containing 10% human serum albumin, 100 ⁇ g/ml Gentamicin
- FIG. 17 Administration of U0126 leads to reduced bacterial titers in vivo independent of viral titers.
- mice 12 weeks old Balb/C mice were infected with 50 PFU of the influenza virus strain A/Puerto Rico/8/34 (PR8, H1N1) on day 0 (anesthesized with Isoflurane). Starting on day 1 mice were treated daily with i.p. injection of 30 mg/kg/day U0126 or solvent control (10% DMSO, 30% Cremophor EL, 60% PBS). On day 3 mice were infected with 5*10 7 CFU of Staphylococcus aureus 6850 under anesthesia with Isoflurane and directly treated with U0126 or solvent control. On day 4 lungs were removed and homogenized in PBS (0.1 g per 1000 ⁇ l PBS).
- FIG. 18 The specific MEK inhibitor CI-4040 reduces viral titers in singular and co-infection.
- DMEM/INV containing 1% human serum albumin, 25 nM HEPES
- FIG. 19 Administration of CI-1040 has an inhibitory effect on bacterial growth in vitro.
- CI-1040 The impact of CI-1040 on bacterial growth was analyzed by administration of CI-1040 in different concentrations (as indicated) to an over-night culture of S. aureus 6850 (100 CFU/ml). After 16 hrs serial dilutions were plated on BHI agar (A, B). Bacterial titers are depicted as colony forming units/ml (CFU/ml) with a linear (A) or logarithmic scale (B). Data represent preliminary data with two biological samples.
- FIG. 20 Treatment with the specific MEK inhibitor Cobimetinib (GDC-0973) reduces pathogen load in vivo.
- mice 8 weeks old Balb/C mice (5 per group) were infected with 50 PFU of influenza virus strain A/Puerto Rico/8/34 (PR8, H1N1) on day 0 (anesthesized with Isoflurane). 6 hrs post viral infection mice were treated with oral administration of 10 mg/kg/day Cobimetinib or solvent control (10% DMSO, 5% Tween 20, 85% PBS), Treatment was then performed daily. On day 3 mice were infected with 5*10 7 CFU of Staphylococcus aureus 6850 under anesthesia with Isoflurane and 6 hrs later treated with Cobimetinib or solvent control. On day 4 lungs were removed and homogenized in PBS (0.1 g per 1000 ⁇ l PBS). For calculation of bacterial titers serial dilutions of the homogenate were plated on BHI agar. For determination of viral titers a standard plaque assay was performed. Statistical analysis was done using Mann-Whitney U test.
- FIG. 21 LG-ASA improves cell morphology upon infection with influenza A virus (IAV) and/or Staphylococcus aureus ( S. aureus )
- IAV influenza A virus
- S. aureus Staphylococcus aureus
- PBS/BA 0.2% bovine serum albumin, 1 mM MgCl 2 , 0.9 mM CaCl 2 , 100 U/ml penicillin, 0.1 mg/ml streptomycin
- 3 hrs post bacterial infection cells were treated with antibiotics [DMEM, 10% FBS, 2 ⁇ g/ml lysostaphin, 20 min] to remove extracellular bacteria.
- PBS cells were supplemented with DMEM/INV containing 5 mM LG-ASA or solvent.
- cell morphology was monitored by light microscopy.
- FIG. 22 The NF ⁇ B inhibitor LG-ASA reduces influenza virus titers and S. aureus load
- PBS/BA 0.2% bovine serum albumin, 1 mM MgCl 2 , 0.9 mM CaCl 2 , 100 U/ml penicillin, 0.1 mg/ml streptomycin
- 3 hrs post bacterial infection cells were treated with antibiotics [DMEM, 10% FBS, 2 ⁇ g/ml lysostaphin, 20 min] to remove extracellular bacteria. After an additional wash with PBS cells were supplemented with DMEM/INV containing 5 mM LG-ASA or solvent. After an incubation period of 8 hrs (A, B, E, F) or 18 hrs (C, D, G, H) at 37° C.
- IAV titers (A, C, E, G) were determined by standard plaque assays. Cells were lysed by a hypotonic shock and amounts of internalized bacteria (B, D, F, H) were determined by serial dilution on agar plates. Data represent the means ⁇ SD of three (A-H) with two biological samples. Statistical significance was evaluated by a two-tailed one sample t-test (*p ⁇ 0.05; **p ⁇ 0.01).
- FIG. 23 The NF ⁇ B inhibitor LG-ASA reduces influenza virus titers and S. aureus load
- FIG. 24 Inhibition of NF ⁇ B signaling results in reduced bacterial internalisation
- Amounts of internalized bacteria were determined by serial dilution on agar plates (A-D).
- Data (A, C) represent the means ⁇ SD of three independent experiments with two biological samples.
- D the untreated controls of each experiment were arbitrarily set as 100% and then the means were calculated.
- Statistical significance was evaluated by a two-tailed one sample t-test (*p ⁇ 0.05; **p ⁇ 0.01; ***p ⁇ 0.001).
- FIG. 25 Stimulation of NF ⁇ B signaling results in enhanced bacterial internalization
- DMEM 10% FBS, 2 ⁇ g/ml lysostaphin, 20 min
- FIG. 26 Treatment of IAV/ S. aureus co-infected mice with LG-ASA results in enhanced survival and reduced body weight loss
- mice 4 mice per group were infected with 50 PFU of the influenza virus A/Puerto Rico/8/34 at day 0. On day 6 after influenza virus infection mice were additionally infected with 10 8 CFU S. aureus 6850. On day 7 after influenza virus infection co-infected mice were treated once a day with LG-ASA (1M, 10 min) via inhalation. Survival was monitored for 14 days. While (4/4) (black line) untreated co-infected mice died 1 day after co-infection, (2/4) LG-ASA treated co-infected mice survived (grey line). (B) Two independent experiments are depicted.
- mice 9 weeks old Balb/C mice (4 mice per group) were infected with 50 PFU of influenza virus A/Puerto Rico/8/34 on day 0 (anesthesized with Isoflurane) in the morning. 6 hrs post viral infection mice were weighed and treated with aerosolic H 2 O or 1M LG-ASA in an inhalation chamber for 10 min. This treatment was also performed on day 1, 2 and 3 at the same time as on day 0. On day 3 in the morning mice were infected with 5*10 7 CFU of Staphylococcus aureus 6850 under anesthesia with Isoflurane. On day 4 mice were weighed the last time. Statistical analysis was done using Mann-Whitney U Test (*p ⁇ 0.05).
- the present invention relates to a MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection.
- the present invention relates to a MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor for use in a method for the prophylaxis and/or treatment of a bacterial infection.
- a “MEK inhibitor” may also be designated as a Mitogen Activated Protein kinase (MAPK) kinase inhibitor.
- MAPK Mitogen Activated Protein kinase
- MEK inhibitors of the invention preferably inhibit MEK1/2 of a subject, such as a mammal or bird as described herein.
- a MEK inhibitor of the invention does not only inhibit a MEK, preferably MEK1/2, but also its upstream kinase (i.e. MAPKKK), thereby exerting a dual inhibition.
- MAPKKK upstream kinase
- PLX-4032 may be such a dual inhibitor.
- a MEK inhibitor of the invention may in a preferred aspect by a dual inhibitor, thereby inhibiting a MEK, preferably MEK1/2 and the corresponding upstream MAPKKK.
- MEK1/2 is the MAPKK in the Ras/Raf pathway, whereby Ras/Raf acts as MAPKKK and ERK1/2 acts as MAPK.
- a MEK inhibitor can be a small molecule, large molecule, peptide, oligonucleotide, and the like.
- the MEK inhibitor may be a protein or fragment thereof or a nucleic acid molecule.
- Also included by the term MEK inhibitor is a pharmaceutically acceptable salt of the MEK inhibitor.
- the determination of whether or not a compound is a MEK inhibitor is within the skill of one of ordinary skill in the art.
- the MEK inhibitors are selected from the group consisting of the compounds/inhibitors listed in table 1.
- the MEK inhibitors of the invention are selected preferably from U0126, PLX-4032, AZD6244, AZD8330, AS-703026, GSK-1120212, RDEA-119, RO-5126766, RO-4987655, CI-1040, PD-0325901, GDC-0973, TAK-733, PD98059, PD184352 ARRY-438162 and PF-3644022, preferably AZD8330, GSK-1120212, U0126, GDC-0973, CI-1040, PD0325901, ARRY-438162, PF-3644022 and AZD6244 and most preferably U0126, CI-1040, GDC-0973 (Cobimetinib), AZD8330, GSK-1120212, most preferably U0126, GDC-0973, CI-1040, AZD8330 and GSK-1120212.
- Structural formula I Cl-1040 2-(2-chloro-4-iodophenylamino)-N- (cyclopropylmethoxy)- 3,4-difluorobenzamide
- Structural formula II PD0325901 (R)-N-(2,3-dihydroxypropoxy)- 3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)benzamide
- Structural formula III AZD6244 6-(4-bromo-2-chlorophenylamino)- 7-fluoro-N-(2-hydroxyethoxy)-3-methyl- 3H-benzo[d]imidazole-5-carboxamide
- Structural formula IV GDC-0973 [3,4-difluoro-2-[(2-fluoro-4- iodophenyl)amino]phenyl] [3-hydroxy-3-[(2S)-2-piperidinyl]-1- a
- PLX-4032 AZD6244, AZD8330, GDC-0973, RDEA119, GSK1120212, RO51267766, RO4987655, TAK-733, and AS703026. Even more preferably, they are selected from AZD6244, AZD8330, GSK1120212 and PLX-4032 or from PD-0325901, AZD-6244, AZD-8330 and RDEA-119.
- MEK inhibitors are known in the art and, for example, described in Table 1 of Fremin and Meloche (2010), J. Hematol. Oncol. 11;3:8.
- the MEK inhibitor U0126 and CI-1040 disclosed herein show an effect in co-infection scenarios as well as on bacterial infection alone.
- a p38 inhibitor is provided for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention.
- a “p38 MAP kinase inhibitor” is well known in the art.
- the terms “p38 inhibitor,” “p38 kinase inhibitor,” and “p38 MAP kinase inhibitor” are used interchangeably herein.
- a p38 MAP kinase inhibitor inhibits p38 MAP kinase.
- the p38 MAP kinase inhibitor inhibits one of the isoforms of p38 MAP kinase, preferably one of the four isoforms ( ⁇ , ⁇ , ⁇ or ⁇ ) of p38 MAP kinase with the ⁇ -isoform being preferred, more preferably it inhibits any combination of two isoforms of p38 MAP kinase, even more preferably it inhibits any combination of three isoforms of p38 MAP kinase and most preferably, it inhibits all isoforms or the ⁇ , ⁇ , ⁇ and ⁇ isoform of p38 MAP kinase.
- the p38 MAP kinase inhibitor inhibits the isoform of p38 that is involved in inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, viral diseases or neurodegenerative diseases. It is reported that the ⁇ -isoform of p38 MAP kinase is involved in inflammation, proliferation, differentiation and apoptosis, whereas the biological functions of p38 ⁇ , p38 ⁇ and p38 ⁇ are not yet understood completely. Accordingly, it is preferred herein that the p38 MAP kinase inhibitor inhibits the ⁇ -isoform.
- a p38 MAP kinase inhibitor can be a small molecule, large molecule, peptide, oligonucleotide, and the like.
- the p38 MAP kinase inhibitor may be a protein or fragment thereof or a nucleic acid molecule.
- Also included by the term p38 inhibitor is a pharmaceutically acceptable salt of the 38 inhibitor.
- Another p38 MAP kinase inhibitor is BIRB 796 BS (1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)- naphthalen-1-yl]-urea); see Branger (2002), J. Immunol. 168:4070-4077 or U.S. Pat. No. 6,319,921 for further p39 MAP kinase inhibitors.
- p38 MAP kinase inhibitors are AMG 548 (Amgen), BIRB 796 (Boehringer Ingelheim), VX 702 (Vertex/Kissei), SCIO 469, SCIO 323 (Scios Inc.), SB 681323 (GlaxoSmithKline), PH-797804 (Pfizer) and Org-48762-0 (Organon NV); see, for example, Lee and Dominguez in Curr Med Chem. 2005; 12(25):2979-2994 and Dominguez in Curr Opin Drug Discov Devel. 2005 July; 8(4):421-430.
- the inhibitor may exhibit its regulatory effect upstream or downstream of p38 MAP kinase or on p38 MAP kinase directly, with the latter mode of action being preferred.
- inhibitor regulated p38 MAP kinase activity include those where the inhibitor may decrease transcription and/or translation of p38 MAP kinase, may decrease or inhibit post-translational modification and/or cellular trafficking of p38 MAP kinase, or may shorten the half-life of p38 MAP kinase.
- the inhibitor may also reversibly or irreversibly bind p38 MAP kinase, inhibit its activation, inactivate its enzymatic activity, or otherwise interfere with its interaction with downstream substrates.
- an inhibitor of p38 MAP kinase that is specific for the ⁇ -isoform of the kinase possesses at least three categories of structural features that are theorized to permit isoform specific inhibition.
- Selective binding of a candidate p38 MAP kinase inhibitor can be determined by a variety of methods.
- the genes for the various isoforms of p38 MAP kinase are known in the art.
- One of ordinary skill in the art could readily clone and express the various isoforms of the kinase, purify them, and then perform binding studies with candidate compounds to determine isoform binding characteristics. This series of experiments was performed for the ⁇ -isoform of p38 MAP kinase and provided in U.S. Pat. No. 6,617,324 B1.
- a p38 MAP kinase inhibitor inhibits one of the four isoforms of p38 MAP kinase, more preferably it inhibits any combination of two isoforms of p38 MAP kinase, even more preferably it inhibits any combination of three isoforms of p38 MAP kinase, e.g., p38- ⁇ (MAPK14), - ⁇ (MAPK11), - ⁇ (MAPK12 or ERK6). Alternatively, but also preferred, it inhibits all four isoforms of p38 MAP kinase.
- the p38 inhibitor is selected from the group consisting of the inhibitors listed in table 2 ( FIG. 8 ). In another embodiment, the p38 inhibitor is selected from the group consisting of SB202190, LY2228820, CAY10571, SB 203580, Tie2 Kinase Inhibitor, 2-(4-Chlorophenyl)-4-(fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one, CGH 2466, SB220025, Antibiotic LL Z1640-2, TAK 715, SB202190 hydrochloride, SKF 86002, AMG548, CMPD-1, EO 1428, JX 401, ML 3403, RWJ 67657, SB 202190, SB 203580, SB 203580 hydrochloride, SB 239063, SCIO 469, SX 011, TAK 715, Pamapimod, Losmapimod (GW856553), Dilmapimod (SB681323)
- the present invention is also directed to a NF ⁇ B (NF ⁇ B/NFkappaB) inhibitor for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention.
- NF ⁇ B NF ⁇ B/NFkappaB
- the determination of whether or not a compound is a NF ⁇ B inhibitor is within the skill of one of ordinary skill in the art.
- NF- ⁇ B nuclear factor kappa-light-chain-enhancer of activated B cells
- NF- ⁇ B is a protein complex that controls transcription of DNA.
- NF- ⁇ B is found in almost all animal cell types and is involved in cellular responses to stimuli such as stress, cytokines, free radicals, ultraviolet irradiation, oxidized LDL, and bacterial or viral antigens.
- Vertebrate NF ⁇ B transcription complexes can be any of a variety of homo- and heterodimers formed by the subunits p50 (NF ⁇ B1), p52 (NF ⁇ B2), c-Rel, RelA (p65) and RelB (Gilmore T D. (2006) Oncogene 25: 6680-6684).
- NF- ⁇ B dimers are located in the cytoplasm in an inactive form through association with any of several I ⁇ B inhibitor proteins (I ⁇ B ⁇ , ⁇ , ⁇ , ⁇ , p105 and p100).
- I ⁇ B ⁇ , ⁇ , ⁇ , ⁇ , p105 and p100 I ⁇ B inhibitor proteins
- IKK I ⁇ B kinase
- NEMO aka IKK ⁇
- the inhibitor may exhibit its regulatory effect upstream or downstream of NF ⁇ B or directly on NF ⁇ B, with the latter mode of action being preferred.
- inhibitors regulating NF ⁇ B activity include those where the inhibitor may decrease transcription and/or translation of NF ⁇ B, or may shorten the half-life of NF ⁇ B.
- the inhibitor may also reversibly or irreversibly bind NF ⁇ B, inhibit its activation, inactivate its activity, or otherwise interfere with its interaction with downstream targets, such as targets on genes.
- an NF ⁇ B inhibitor can inhibit protein kinases such as molecules which inhibit IkBa phosphorylation by e.g. IKK inhibition.
- NF ⁇ B inhibitors may inhibit protein phosphatases, or inhibit the proteasome, or ubiquitination.
- NF ⁇ B inhibitors which may also serve as reference compounds include protein tyrosine phosphatase inhibitors, boronate, bortezomib, NPI-0052.
- a NF ⁇ B inhibitor may block the nuclear translocation of NF ⁇ B, or its binding to DNA. Examples of such inhibitors include, which may also serve as reference compounds, SN50, dehydroxymethylepoxyquinomicin and NF ⁇ B decoy ODNs.
- a NF ⁇ B inhibitor can be a small molecule, large molecule, peptide, oligonucleotide, and the like.
- the NF ⁇ B inhibitor may be a protein or fragment thereof or a nucleic acid molecule.
- Also included by the term NF ⁇ B inhibitor is a pharmaceutically acceptable salt of the NF ⁇ B inhibitor.
- the NF ⁇ B inhibitor is selected from the group consisting of the inhibitors/molecules as listed in tables 3 and 4 in FIGS. 9 and 10 .
- the NF ⁇ B inhibitor is selected from the group consisting of the inhibitors/molecules as listed in table 3 in FIG. 9 .
- the NF ⁇ B inhibitor is selected from the group consisting of the inhibitors/molecules as listed in table 4 in FIG. 10 .
- the NF ⁇ B inhibitor is selected from the group consisting of LASAG, SC75741 (and derivatives), MG 132, TPCA-1, PCTC, IMD 0354, Luteolin, Caffeic acid phenethyl ester, Cardamonin, PF 184, IKK 16, SC 514, Withaferin A, Arctigenin, Bay 11-7085, PSI, PR 39, Ro 106-9920, Bay 11-7821, ML-130, Celastrol, Tanshinone IIA, HU 211, Gliotoxin, CID 2858522, Honokiol, Andrographolide, 10Z-Hymenialdisine, ACHP, Pristimerin, Sulfasalazine, ML 120B dihydrochioride, Amlexanox, 9-Methylstreptimidone, N-Stearoyl phytosphingosine, 2-(1,8-naphthyridin-2-y
- SC75741 or “SC75741 (and derivates)” in addition to SC75741 also derivates of SC75741 are envisaged by the present invention.
- a person skilled in the art knows how to find out if a compound is an MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor.
- a further example of how one could determine if a compound is a MEK inhibitor and/or p38 inhibitor would be to isolate the MEK and/or p38 NF ⁇ B protein.
- the protein can be isolated from cells where the MEK and/or p38 protein is naturally expressed or where it has been overexpressed by means of transfection of an oligonucleotide or infection with a virus that directs the expression of the MEK and/or p38 protein, Additionally, MEK and/or p38 protein can also be expressed recombinantly.
- a person of ordinary skill in the art can measure the activity of the kinase in the presence or absence of a potential MEK and/or p38 inhibitor. If the kinase activity is less in the presence than in the absence of an alleged inhibitor, that inhibitor is a MEK and/or p38, respectively.
- the inhibitor should exhibit an IC50 value of about 5 ⁇ M or less, preferably 500 nm or less, more preferably 100 nm or less.
- the inhibitor should exhibit an IC50 value relative to the p38- ⁇ isoform that is preferably at least ten fold less than that observed when the same inhibitor is tested against other p38 MAP kinase isoforms in the same or comparable assay. It should be noted that IC50 values are assay dependent and may change from determination to determination. It is more important to look at relative relationships of compounds' IC50 values rather than the exact values themselves.
- An IC50 is the concentration of compound which inhibits the enzyme to 50% of the activity as measured in the absence of an inhibitor.
- IC50 values are calculated using the concentration of inhibitor that causes a 50% decrease as compared to a control. IC50 values are assay dependent and will vary from measurement to measurement. As such, IC50 values are relative values. The values assigned to a particular inhibitor are to be compared generally rather than on an absolute basis.
- Samples or assays comprising MAP and/or MAPK kinase that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition.
- Control samples untreated with inhibitors
- Inhibition of MAP and/or MAPK kinase is achieved when the MAP and/or MAPK kinase activity value relative to the control is about 80%, optionally 50% or 25-0%.
- MAP and/or MAPK kinase activity value relative to the control is 110%, optionally 150%, optionally 200-500%, or 1000-3000% higher.
- MAP kinase binding activity assays of the present invention are: a MAP and/or MAPK kinase ligand blot assay (Aymerich et al., Invest Opthalmol Vis Sci. 42:3287-93, 2001); a MAP and/or MAPK kinase affinity column chromatography assay (Alberdi et al., J Biol Chem.
- the selectivity of the inhibitors may be measured by a kinase selectivity assay is described in Mihara (2008), Br. J. Pharmacol. 154(1):153-164.
- NF ⁇ B inhibitor In the case of the NF ⁇ B inhibitor one can measure for example the gene products (proteins) of target genes of NF ⁇ B in a non-treated control cell and compare the expression of these target gene products to a cell, which has been treated with a NF ⁇ B Inhibitor.
- Some target genes are described in Oeckinghaus and Ghosh (2009) The NF- ⁇ B Family of Transcription Factors and Its Regulation. Cold Spring Harb Perspect Biol. October 2009; 1(4): a000034.
- the expression level is reduced, when the cell treated with the inhibitor.
- Other strategies may be to detect IkBa degradation together with p-p65 accumulation and nuclear translocation of NF ⁇ B by Westernblot.
- NF ⁇ B interactions with DNA of cells not treated with an inhibitor compared to cells that have been treated with an inhibitor may be analysed by using an electrophoretic mobility shift assay (EMSA).
- ESA electrophoretic mobility shift assay
- the inhibitory properties of a molecule can also be analysed by comparing its action to a reference compound.
- a “reference compound” as referred to herein means a compound, which may be used as a positive control for the determination if a molecule has MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor properties. As such also any of the inhibitors listed herein may be used as such a reference compound.
- a possible test may be one in which cells, which are e.g. stimulated to activate the MEK, p38 and or NF ⁇ B pathway are treated with a reference compound and in parallel e.g. in a different well with a compound of interest.
- the inhibitors of the present invention can be used in a method for treating and/or prophylaxis.
- treating or “treatment” includes administration of a MEK inhibitor, p38 Inhibitor, and/or NF ⁇ B inhibitor preferably in the form of a medicament, to a subject suffering from a coinfection comprising a bacterial infection and an influenza virus infection for the purpose of ameliorating or improving symptoms.
- administration of a MEK inhibitor, p38 Inhibitor, and/or NF ⁇ B inhibitor preferably in the form of a medicament, to a subject suffering from a bacterial infection for the purpose of ameliorating or improving symptoms.
- the terms “prophylaxis” as used herein refers to any medical or public health procedure whose purpose is to prevent a disease.
- the terms “prevent”, “prevention” and “preventing” refer to the reduction in the risk of acquiring or developing a given condition, namely a coninfection comprising an influenza virus infection and a bacterial infection or a bacterial infection alone.
- a “co-infection” as used herein comprises an influenza virus infection and a bacterial infection.
- Such a coinfection can take place by simultaneous infection of a host e.g. a subject and/or single cell with a bacterium and an influenza virus. It can also be that a host e.g. a subject and/or cell is simultaneously infected with one or more viral particles and one or more bacteria. However, such a coinfection can also take place sequentially. In such a case is firstly infected with one or more viral particles and later in time the same host and/or cell becomes infected with one or more bacteria or vice versa.
- the time period between the two infections can be a time period of at most 14 days, 13 days, 12 days, 11 days, 10 days, 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days, 2 days, 1 day, 12 hours, 6 hours, 3 hours, 1.5 hours or at minimum 30 minutes.
- Such a situation may also be a superinfection, in which a second infection is superimposed on an earlier one especially by a different microbial agent of exogenous or endogenous origin that is resistant to the treatment used against the first infection.
- influenza virus infection can be mediated by influenza A virus or influenza B virus, preferably the influenza A virus is H1N1, H2N2, H3N2, H6N1, H7N7, H7N9, H9N2 H10N7, H10N8 or H5N1.
- influenza A virus is H1N1.
- influenza A virus is H3N2, H5N1 and H7N9.
- influenza A virus is H3N2, H5N1, H1N1 and H7N9.
- the present invention also relates to a “bacterial infection” which can take place in the setting of a co-infection described above or can occur as the only infection present in a host e.g. a subject and/or cell.
- the bacterial infection can be mediated by any bacterium, preferably it is mediated by a bacterium selected from the group consisting of Staphylococcaceae, Streptococcaceae, Legionellaceae, Pseudomonadaceae, Chlamydiaceae, Mycoplasmataceae, Enterobacteriaceae, Pseudomonadales and/or Pasteurellaceae.
- the bacterial infection is mediated by a bacterium selected from the group consisting of of Staphylococcus , preferably Staphylococcus aureus , methicillin sensitive and methicillin resistant Staphylococcus aureus , Panton-Valentine leukocidin (PVL)-expressing Staphylococcus aureus and/or Streptococcaceae, preferably Streptococcus mitis, Streptococcus pyogenes or Streptococcus pneumonia, Legionella , preferably Legionella pneumophila, Pseudomonas , preferably Pseudomonas aeruginosa, Chlamydophila , preferably Chlamydophila pneumonia, Mycoplasma , preferably Mycoplasma pneumonia, Klebsiella , preferably Klebsiella pneumonia, Moraxella , preferably Moraxella catarrhalis and/or Haemophilus , preferably Haemophil
- the inhibitors can be combined with each other.
- the MEK inhibitor is combined with another MEK inhibitor, the p38 inhibitor and/or the NF ⁇ B inhibitor.
- the p38 inhibitor is combined with another p38 inhibitor, the MEK inhibitor and/or the NF ⁇ B inhibitor.
- the NF ⁇ B inhibitor is combined with another NF ⁇ B inhibitor, the p38 inhibitor and/or the MEK inhibitor.
- the term “another inhibitor” is used to clarify that e.g. one MEK inhibitor can also be combined with another MEK inhibitor, while these two MEK inhibitors are not the same.
- the MEK inhibitor CI-1040 can be combined with the MEK inhibitor GDC-0973. This equally relates to the p38 and NF ⁇ B inhibitors.
- the MEK inhibitor, the p38 inhibitor and/or the NF ⁇ B inhibitor is/are administered contemporaneously, previously or subsequently to the one or more additional inhibitors targeting the influenza virus and the bacterium.
- the MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection of the present invention, wherein the MEK inhibitor, the p38 inhibitor and/or the NF ⁇ B inhibitor are combined with one or more inhibitors targeting the influenza virus and/or the bacterium.
- the MEK inhibitor, the p38 inhibitor and/or the NF ⁇ B inhibitor is/are administered contemporaneously, previously or subsequently to the one or more inhibitors targeting the influenza virus and/or the bacterium.
- an inhibitor targeting the influenza virus is any inhibitor or medicament effective in influenza therapy.
- Different substances are known to be effective in reducing an influenza infection. Among them are for example neuraminidase inhibitors, compounds targeting an ion channel protein (M2) and compounds targeting polymerase or endonuclease activity via interfering with a component of the viral polymerase complex, PB1, PB2, PA or NP.
- M2 ion channel protein
- NP ion channel protein
- pharmaceutically acceptable salts of these inhibitors are envisioned.
- a “neuraminidase inhibitor” is an antiviral drug targeted at influenza virus, which works by blocking the function of the viral neuraminidase protein, thus preventing the virus from binding to a cell it aims to infect and/or preventing the virus from reproducing by budding from the host cell, since the newly produced viruses cannot bud off from the cell in which they have replicated.
- pharmaceutically acceptable salts of a neuraminidase inhibitor are oseltamivir, zanamivir, peramivir, or a pharmaceutically acceptable salt of any of these substances, such as oseltamivir phosphate, oseltamivir carboxylate, etc.
- Most preferred neuraminidase inhibitors are oseltamivir phosphate, zanamivir, oseltamivir or peramivir.
- Compounds targeting an ion channel protein are for example amantadine and/or rimantadine, while compounds targeting polymerase or endonuclease activity via interfering with a component of the viral polymerase complex, PB1, PB2, PA or NP are for example the NP blocker Nucleozin or the polymerase inhibitor T-705.
- the MEK inhibitor, p38 inhibitor and/or NF ⁇ B inhibitor can be combined with one or more inhibitors targeting the bacterium.
- An inhibitor targeting the bacterium can be any inhibitor effective in reducing bacterial infection.
- a preferred inhibitor, well known to the skilled artesian is an antibiotic.
- Preferred antibiotics can be obtained from table 5 ( FIG. 11 ).
- the antibiotic is selected from the group consisting of the antibiotics as listed in table 5 ( FIG. 11 ).
- the antibiotic is selected from the group consisting of the class of antibiotics as listed in table 5 ( FIG. 11 ).
- the antibiotic is selected from the group consisting of the generic name of the antibiotics as listed in table 5 ( FIG. 11 ). More preferred are antibiotics selected from Gentamicin, Rifampicin, Lysosthaphin, Erythromycin, Levofloxacin, Vancomycin, Teicoplanin, Penicillin and Oxacillin.
- the “subject”, which may be treated by the inhibitors or combinations of inhibitors of the present invention preferably, is a vertebrate.
- the term “subject” means an individual in need of a treatment of a co-infection or a bacterial infection alone.
- the subject is a patient suffering from a co-infection or a bacterial infection alone or being at a risk thereof.
- the patient is a vertebrate, more preferably a mammal. Mammals include, but are not limited to, farm animals, sport animals, pets, primates, mice and rats.
- a mammal is as a human, dog, cat, cow, pig, mouse, rat etc., particularly preferred, it is a human.
- the subject is a human subject, which optionally is more than 1 year old and less than 14 years old; between the ages of 50 and 65, or older than 65 years of age.
- the subject is a human subject, which is selected from the group consisting of subjects who are at least 50 years old, subjects who reside in chronic care facilities, subjects who have chronic disorders of the pulmonary or cardiovascular system, subjects who required regular medical follow-up or hospitalization during the preceding year because of chronic metabolic diseases, renal dysfunction, hemoglobinopathies, or immunosuppression, subjects with less than 14 years of age, subjects between 6 months and 18 years of age who are receiving long-term aspirin therapy, and women who will be in the second or third trimester of pregnancy during the influenza season.
- the MEK inhibitor, p38 inhibitor or NF ⁇ B inhibitor as well as the inhibitor targeting the influenza virus and the inhibitor targeting the bacterium may be administered orally, intravenously, intrapleurally, intramuscularly, topically or via inhalation.
- the MEK inhibitor is administered via nasal inhalation or orally.
- the present invention also envisages different compositions.
- the present invention relates to a composition comprising a MFK inhibitor, a p38 inhibitor and/or a NF ⁇ B inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection.
- the present invention similarly relates composition comprising a MEK inhibitor, a p38 inhibitor and/or a NF ⁇ B inhibitor for use in a method for the prophylaxis and/or treatment of a bacterial infection.
- compositions comprising a MEK inhibitor, a p38 inhibitor and/or a NF ⁇ B inhibitor and one or more inhibitors targeting the influenza virus and/or the bacterium for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection.
- present invention relates to a composition comprising a MEK inhibitor, a p38 inhibitor and/or a NF ⁇ B inhibitor and one or more inhibitors targeting the the bacterium for use in a method for the prophylaxis and/or treatment of a bacterial infection.
- compositions comprising the MEK inhibitor, the p38 inhibitor and/or the NF ⁇ B inhibitor and additionally eventually one or more inhibitors targeting the the bacterium and/or one or more inhibitors targeting the influenza virus may be a pharmaceutical composition.
- such compositions further comprise a carrier, preferably a pharmaceutically acceptable carrier.
- the composition can be in the form of orally administrable suspensions or tablets; nasal sprays, sterile injectable preparations (intravenously, intrapleurally, intramuscularly), for example, as sterile injectable aqueous or oleaginous suspensions or suppositories.
- these compositions When administered orally as a suspension, these compositions are prepared according to techniques available in the art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners/flavoring agents known in the art.
- these compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents, and lubricants known in the art.
- the injectable solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
- suitable non-toxic, parenterally acceptable diluents or solvents such as mannitol, 1,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
- the inhibitor or inhibitors are preferably administered in a therapeutically effective amount.
- the pharmaceutical composition for the use of the invention and comprising a MEK inhibitor, a p38 inhibitor and/or a NF ⁇ B inhibitor and optionally one or more inhibitors targeting an influenza virus and/or one or more inhibitors targeting a bacterium is administered to a patient which is a mammal or a bird.
- suitable mammals include, but are not limited to, a mouse, a rat, a cow, a goat, a sheep, a pig, a dog, a cat, a horse, a guinea pig, a canine, a hamster, a mink, a seal, a whale, a camel, a chimpanzee, a rhesus monkey and a human, with human being preferred.
- suitable birds include, but are not limited to, a turkey, a chicken, a goose, a duck, a teal, a mallard, a starling, a Northern pintail, a gull, a swan, a Guinea fowl or water fowl to name a few.
- Human patients are a particular embodiment of the present invention.
- the “therapeutically effective amount” for each active compound/inhibitor can vary with factors including but not limited to the activity of the compound used, stability of the active compound in the patient's body, the severity of the conditions to be alleviated, the total weight of the patient treated, the route of administration, the ease of absorption, distribution, and excretion of the active compound by the body, the age and sensitivity of the patient to be treated, adverse events, and the like, as will be apparent to a skilled artisan.
- the amount of administration can be adjusted as the various factors change over time.
- the inhibitors, methods and uses described herein are applicable to both human therapy and veterinary applications.
- the compounds described herein, in particular, MEK inhibitor, a p38 inhibitor and/or a NF ⁇ B inhibitor and optionally one or more inhibitors targeting an influenza virus and/or one or more inhibitors targeting a bacterium having the desired therapeutic activity may be administered in a physiologically acceptable carrier to a subject, as described herein.
- the compounds may be formulated in a variety of ways as discussed below.
- the concentration of therapeutically active compound in the formulation may vary from about 0.1-100 wt %.
- the agents maybe administered alone or in combination with other treatments.
- Suitable oral formulations can be in the form of tablets, capsules, suspension, syrup, chewing gum, wafer, elixir, and the like.
- Pharmaceutically acceptable carriers such as binders, excipients, lubricants, and sweetening or flavoring agents can be included in the oral pharmaceutical compositions. If desired, conventional agents for modifying tastes, colors, and shapes of the special forms can also be included.
- the pharmaceutical compositions can be in lyophilized powder in admixture with suitable excipients in a suitable vial or tube.
- the drugs Before use in the clinic, the drugs may be reconstituted by dissolving the lyophilized powder in a suitable solvent system to form a composition suitable for intravenous or intramuscular injection.
- a pharmaceutical composition comprising a therapeutically effective amount of a a MEK inhibitor, a p38 inhibitor and/or a NF ⁇ B inhibitor as well as a therapeutically effective amount of a neuraminidase inhibitor chosen from the group of oseltamivir, oseltamivir phosphate, zenamivir and peramivir.
- the composition can be in an orally administrable form (e.g., tablet or capsule or syrup etc.) with a therapeutically effective amount (e.g., from 0.1 mg to 2000 mg, 0.1 mg to 1000 mg, 0.1 to 500 mg, 0.1 to 200 mg, 30 to 300 mg, 0.1 to 75 mg, 0.1 to 30 mg) of a MEK inhibitor, a p38 inhibitor and/or a NF ⁇ B inhibitor and a therapeutically effective amount (e.g., from 0.1 mg to 2000 mg, 0.1 mg to 1000 mg, 0.1 to 500 mg, 0.1 to 200 mg, 30 to 300 mg, 0.1 to 75 mg, 0.1 to 30 mg) of neuraminidase inhibitor as described above.
- a therapeutically effective amount e.g., from 0.1 mg to 2000 mg, 0.1 mg to 1000 mg, 0.1 to 500 mg, 0.1 to 200 mg, 30 to 300 mg, 0.1 to 75 mg, 0.1 to 30 mg
- a therapeutically effective amount e.g., from 0.1 mg to 2000 mg
- the MEK inhibitor, p38 inhibitor and/or NF ⁇ B Inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection of the present invention, wherein the MEK inhibitor, the p38 inhibitor and/or the NF ⁇ B inhibitor reduces both the viral and bacterial infection, when contacting it/them with an in vitro test system, wherein the test system comprises cultured cells infected with
- test system comprises cultured cells infected with
- the in vitro test system includes a viral and bacterial infection
- these infections can be taking place sequentially or simultaneously.
- a “cultured cell” or “cultured cells” is/are cells, which are not present in their natural environment e.g. within a plant or animal. Rather a cultured cell may be a primary cell culture, which comprises cells isolated from their natural environment, or a cell line. Preferably the cultured cells are human lung epithelial cells.
- the cultured cells are seeded at a density of about 1 ⁇ 10 5 , 2 ⁇ 10 5 , 3 ⁇ 10 5 , 4 ⁇ 10 5 , 5 ⁇ 10 5 , 6 ⁇ 10 5 , 7 ⁇ 10 5 , 8 ⁇ 10 5 , 9 ⁇ 10 5 , 10 ⁇ 10 5 , 11 ⁇ 10 5 most preferably 8 ⁇ 10 5 cells in 0.5 ml, 1 ml, 1.5 ml, 2 ml, 2.5 ml, 3 ml, 3.5 ml, 4 ml medium such as DMEM. Most preferred is a density of 8 ⁇ 10 5 cells per in 2 ml DMEM.
- Such cultured cells are infected with a virus and a bacterium or in other embodiments with a bacterium alone.
- a co-infection can take place in a sequential or simultaneous manner.
- the cultured cells may be infected first with the influenza virus and 30 minutes later with bacterium/bacteria. It is also possible to additionally add an antibiotic to the culture after 3 hours, to remove extracellular bacteria. In such a scenario the antibioticum would then become washed off again.
- the cells are only infected with a bacterium.
- contacting refers to the bringing of a cell comprising an influenza virus and a bacterium spatially into close proximity to a MEK inhibitor, a p38 inhibitor and/or a NF ⁇ B inhibitor.
- the inhibitor Upon contacting then, if the inhibitor is active, the viral infection as well as the bacterial infection becomes reduced.
- the inhibitor of the present invention is used to reduce only a bacterial infection in the absence of an influence virus infection.
- the reduction of the viral infection is a reduction in plaque forming units (pfu)/ml and the reduction in the bacterial infection is a reduction in colony forming units (CFU)/ml.
- the “plaque forming units (pfu)/ml” is a measure of the number of particles capable of forming plaques per unit volume, such as virus particles. It is a functional measurement rather than a measurement of the absolute quantity of particles: viral particles that are defective or which fail to infect their target cell will not produce a plaque and thus will not be counted.
- a solution of influenza virus with a concentration of 1,000 PFU/ ⁇ l indicates that 1 ⁇ l of the solution contains enough virus particles to produce 1000 infectious plaques in a cell monolayer.
- a cell culture treated with an inhibitor shows a reduced number of plaque forming units in a culture after the treatment, when compared to a culture before the treatment with an inhibitor of the present invention.
- a possible “reduction in plaque forming units (pfu)/ml” is analysed in the following way. First the cultured cells, which are co-infected with an influenza virus and a bacterium are analysed for their ability to generate plaque forming units (pfu)/ml by e.g. sucking of some cells from the petridish and plating them for counting the bacterial plaques that will form. This result is then compared to the number of plaque forming units (pfu)/ml generated by cells of the same culture after the inhibitor was applied. If the number of the plaque forming units (pfu)/ml is reduced after the treatment with an inhibitor compared to the number generated before the application of the inhibitor, there is a reduction in the plaque forming units.
- the “colony forming units (CFU)/ml” estimates the number of viable bacteria in a sample. Different methods exist. For example to generate colony forming units a sample (e.g. cultured cells in a small volume) are spread across the surface of a nutrient agar plate and allowed to dry before incubation for counting. A viable bacterium is defined as the ability to multiply via binary fission under the controlled conditions. The visual appearance of a colony in a cell culture requires significant growth—when counting colonies it is uncertain if the colony arose from one cell or 1,000 cells. Therefore results are reported as CFU/ml (colony-forming units per milliliter) for liquids, and CFU/g (colony-forming units per gram) for solids to reflect this uncertainty (rather than cells/ml or cells/g).
- CFU/ml colony-forming units per milliliter
- CFU/g colony-forming units per gram
- Colony forming units (CFU)/ml can be analysed in the following way. First the cultured cells, which are co-infected with an influenza virus and a bacterium or with a bacterium alone are analysed for their ability to generate colony forming units (CFU)/ml by e.g. sucking of some cells from the petridish and plating them for counting. This result is then compared to the number of colony forming units (CFU)/ml generated by cells of the same culture after the inhibitor was applied. If the number of the colony forming units (CFU)/ml is reduced to the number generated before the application of the inhibitor, there is a reduction.
- CFU colony forming units
- the invention also provides for the use of the in vitro test system of of the present invention for the determination of inhibitors effective in reducing a coinfection comprising a bacterial infection and an influenza virus infection.
- the reduction of the viral infection is a reduction in plaque forming units (pfu)/ml and the reduction in the bacterial infection is a reduction in colony forming units (CFU)/ml.
- the present invention relates to a method for detecting molecules effective in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection comprising contacting the in vitro test system of the present invention with a compound of interest, wherein the compound of interest reduces both the viral and bacterial infection, compared to the in vitro test system before the contacting.
- the reduction of the viral infection is a reduction in plaque forming units (pfu)/ml and the reduction in the bacterial infection is a reduction in colony forming units (CFU)/ml.
- the present invention in addition, relates to a use of the in vitro test system of the present invention for the determination of inhibitors effective in reducing a bacterial infection.
- the present invention relates to the use of the in vitro test systems of the present invention for the examination of innate host cell responses, which optionally includes examination of the level of signal transduction, resulting cytokine and chemokine expression, induction of apoptosis and necrosis and/or redox hemostasis regulating health and disease.
- Item 5 Also provided for by the present invention is a method for detecting molecules effective in the prophylaxis and/or treatment a bacterial infection comprising contacting the in vitro test system of the present invention with a compound of interest, wherein the compound of interest reduces the bacterial infection, compared to the in vitro test system before the contacting.
- the present invention furthermore relates to a cultured cell infected with an influenza virus and a bacterium.
- Item 7 Also provided for is a cultured cell infected with a bacterium.
- the present invention also relates to a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection in a subject, comprising administering a therapeutically effective amount of a MEK inhibitor, a p38 inhibitor and/or a NF ⁇ B inhibitor of the present invention or a pharmaceutical composition of the present invention to said subject.
- the present invention provides for a use of a MEK inhibitor, a p38 inhibitor and/or a NF ⁇ B inhibitor of the present invention or a composition of the present invention for the preparation of a medicament.
- the present invention relates to a use of a MEK inhibitor, a p38 inhibitor and/or a NF ⁇ B inhibitor of the present invention or a composition of the present invention for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection.
- the present invention also provides for a method for the prophylaxis and/or treatment of a bacterial infection in a subject, comprising administering a therapeutically effective amount of a MEK inhibitor, a p38 inhibitor and/or a NF ⁇ B inhibitor of the present invention or a pharmaceutical composition of the present invention to said subject.
- the present invention relates to a use of a MEK inhibitor, a p38 inhibitor and/or a NF ⁇ B inhibitor of the present invention or a composition of the present invention for the prophylaxis and/or treatment of a bacterial infection.
- Human lung epithelial cells were seeded in 6-well plates (8 ⁇ 10 5 cells/well) in 2 ml DMEM [10% FCS]. 16-20 hrs after seeding, cells were rinsed and incubated with PBS/BA [0.2% bovine serum albumin (BSA), 1 mM MgCl 2 , 0.9 mM CaCl 2 , 100 U/mI penicillin, 0.1 mg/ml streptomycin] (500 ⁇ l per 6 well) or PBS/BA containing the virus at the indicated multiplicity of infection (MOI) at 37° C.
- BSA bovine serum albumin
- MOI multiplicity of infection
- DMEM/INV 1% human serum albumin, 25 nmol/l HEPES
- 3 hrs post bacterial infection cells were treated with antibiotics to remove extracellular bacteria. Therefore cells were rinsed with PBS and subsequently incubated with DMEM/INVantibiotics [2 ⁇ g/ml lysostaphin (Sigma)] (1 ml per 6 well) for 20 min at 37° C..
- IV titers are depicted as plaque forming units (pfu)/ml and S. aureus titers are depicted as colonie forming untits (CFU)/ml.
- Data represent the means ⁇ SD of two to three independent experiments with two biological samples. Statistical significance was evaluated by a two-tailed two sample t-test (*p ⁇ 0.05; **p ⁇ 0.01; ***p ⁇ 0001).
- FIG. 12 The co-infection procedure is depicted in FIG. 12 .
- cell morphology was monitored 18 hrs upon infection by light microscopy ( FIG. 13 ), the time at which the pathogen load was determined ( FIG. 14 ).
- CCL3 also known as macrophage inflammatory protein 1 ⁇ (MIP1 ⁇ )
- CCL5 also known as RANTES
- FIG. 16A , B The IAV-induced CCL3 mRNA synthesis, which was increased in presence of S. aureus 6850, was reduced in presence of U0126.
- the IAV-induced CCL5 mRNA synthesis which was reduced in presence of S. aureus , was further reduced in presence of U0126 (50 ⁇ M).
- influenza virus-infected mice were left untreated or treated with U0126 daily and superinfected with S. aureus 6850 ( FIG. 17 ).
- the administration of U0126 led to a reduction in bacterial titers in vivo independent of viral titers.
- the fail of reduced virus titers might be explained by the late administration of U0126 at a time point when virus titers are already decreasing in the infection course.
- Former experiments have indicated that the inhibitor has a higher inhibitory effect, when it is given before influenza virus infection. Nonetheless, the bacterial titers were significantly reduced upon application of U0126.
- Cobimetinib was tested in an in vivo mouse model, influenza virus-infected mice were left untreated or treated daily with Cobimetinib and were super-infected with S. aureus 6850 ( FIG. 20 ).
- the administration of Cobimetinib led to a slight but clearly detectable reduction in viral and bacterial titers in vivo. Since it has been shown recently that the maximal tolerated dose of Cobimetinib is 30 mg/kg/day. Thus, the inhibitory effect might be improved by higher dosages than used in the present experiment (10 mg/kg/day), which was far less from the maximal tolerated dosage.
- FIG. 21 The co-infection procedure is depicted in FIG. 21 (upper part).
- LG-ASA 5 mM
- cell morphology was monitored 18 hrs upon infection by light microscopy ( FIG. 21 ). While infection with IAV and/or S. aureus in absence of LG-ASA (left panel) results in cell destruction, cell morphology was improved in presence of LG-ASA (right panel).
- the effect of the NF ⁇ B-inhibitor LG-ASA (5 mM) against influenza virus replication A/Puerto Rico/8/34 (H1N1) was determined in human lung epithelial cells in a singular or co-infection situation ( FIG. 22 / 23 ) 8 h ( FIGS. 22 / 23 A, B, E, F) and 18 h ( FIG. 22 / 23 C, D, G, H) post infection.
- Two different S. aureus strains were used for infection (a) S. aureus SH1000 ( FIG. 22 / 23 A-D) and (b) S. aureus 6850 ( FIG. 22 / 23 E-H).
- FIG. 24C A concentration dependent inhibitory effect of LG-ASA could be further demonstrated on the bacterial strain S. aureus USA300 ( FIG. 24C , D).
- FIG. 24A C the untreated controls of the three independent experiments were arbitrarily set as 100% and the mean is depicted ( FIG. 24B , D).
- NF ⁇ B was induced by TNF- ⁇ stimulation 4 hours prior bacterial infection.
- the activation of NF ⁇ B resulted in the enhanced uptake of S. aureus 6850 and S. aureus USA300.
- As a control TNF- ⁇ -induced activation was simultaneously blocked by LG-ASA, which resulted in the inhibition of TNF- ⁇ -promoted bacterial uptake, as expected ( FIG. 25 ).
- FIG. 26 treatment of IAV/ S. aureus co-infected mice with LG-ASA results in enhanced survival ( FIG. 26A ) and reduced body weight loss ( FIG. 26B ).
- the NF-kappaB inhibitor SC75741 efficiently blocks influenza virus propagation and confers a high barrier for development of viral resistance.
- Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses. Journal of virology 81, 3058-3067.
- EGFR epidermal growth factor receptor
- the NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus. Antiviral research 99, 336-344.
- Influenza virus primes mice for pneumonia from Staphylococcus aureus .
- Acetylsalicylic acid blocks influenza virus propagation via its NF-kappaB-inhibiting activity.
- NF-kappaB-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagation.
- TRAIL tumor necrosis factor-related apoptosis-inducing ligand
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- General Physics & Mathematics (AREA)
Abstract
The present invention relates to MEK inhibitor, p38 inhibitor and/or NFκB inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. Also provided are compositions comprising such inhibitors for use in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. In addition an in vitro test system, wherein the test system comprises cultured cells infected with an influenza virus and a bacterium or with a bacterium alone is provided.
Description
- This application is a continuation of U.S. application Ser. No. 16/571,550, filed Sep. 16, 2019, which is a continuation of U.S. application Ser. No. 15/310,838, filed Nov. 14, 2016, now U.S. Pat. No. 10,458,440 which claims priority to International Application No. PCT/IB2015/053644, filed May 18, 2015, which claims priority to Luxembourg Application No. 92455, filed May 16, 2014 wherein the contents of said applications are incorporated herein by reference in their entireties.
- The present invention relates to MEK inhibit, p38 inhibitor and/or NFκB inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. Also provided are compositions comprising such inhibitors for use in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. In addition an in vitro test system, wherein the test system comprises cultured cells infected with an influenza virus and a bacterium or with a bacterium alone is provided.
- Influenza A viruses are the causative agents of severe respiratory diseases resulting in significant morbidity and mortality. Most of the fatal cases in the course of an influenza virus (IV) infection are actually a result of secondary pneumonia caused by different bacteria, such as Staphylococcus aureus (S. aureus), Streptococcus pneumoniae and Haemophilus influenzae (Morens et al., 2008, Chertow et al., 2013). The most striking problems of bacterial co-infection are the suddenly increased pathogenicity (Iwao et at., 2012, Paddock et al., 2012, Parker et al., 2012) and a limited arsenal of potent anti-infectives against the different pathogens. The high variability of influenza viruses and the continuous emergence of new strains (Neumann et al., 2009, Taubenberger et al., 2010, Parry, 2013), specific characteristics of the bacterial strains (Grundmann et al., 2006, Moran et al., 2008, Gillet et al., 2007, Shio et al., 2011), as well as the rapid resistance development of both, influenza viruses (Hayden et al., 1992, Bright et al., 2006, Pinto et al., 2006, De Clercq et al., 2007, Pinto et al., 2007) and bacteria (Grundmann et al., 2006, Moran et al., 2006, Shilo et al., 2011) against the available drugs/antibiotics are the major reasons for the poor treatment options Moreover, it is incidental that treatment of coinfections with influenza viruses and bacteria is not possible with a single compound, so far. The current invention solves this problem in that it proposes a novel anti-infective strategy against IV and S. aureus co-infections by using single drugs. Furthermore, the present invention solves the problem of rapid resistance development of bacteria by providing drug that targets cellular factors rather than the bacterium itself.
- The technical problem is solved by the embodiments reflected in the claims, described in the description, and illustrated in the Examples and Figures.
- The above being said, the present invention relates to a MEK inhibitor, p38 inhibitor and/or NFκB inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection.
- In addition the present invention relates to a MEK inhibitor, p38 inhibitor and/or NFκB inhibitor for use in a method for the prophylaxis and/or treatment of a bacterial infection.
- Despite intensive research in the last century, IV still represent a severe threat to mankind. Seasonal outbreaks that are especially dangerous for the elderly and immunocompromised individuals are due to infections with influenza A or B viruses.
- Within the last decades, there is an increasing incidence of methicillin-resistant S. aureus strains, causing problems especially in infants and children who were concomitantly infected with IV (Iverson et al., 2011, Thorburn et al., 2012). One major problem occurring upon bacterial co-infections is the sudden and highly increased pathogenicity, which is probably caused by accelerated cytokine expression, also resulting in tissue damage. Particularly, upon co-infection with Panton-Valentine leukocidin (PVL)-expressing S. aureus severe lung epithelium damage is observed, due to uncontrolled release of proteases after PVL-mediated neutrophil killing (Gillet et al, 2007, Niemann et al., 2012). Bacterial co-infections usually occur within the first six days of an IV infection, resulting in even more fulminant illness, pneumonia and higher mortality (Iverson et al., 2011, Chertow et al, 2013). However in same cases bacterial co-infection comes up, when virus-infection already seems to be cleared. For treatment of viral/bacterial co-infections only limited possibilities exist.
- One promising antiviral strategy to fight influenza is based on the fact that IV, as intracellular pathogens, strongly depend on the cellular signaling machinery (Gong et al., 2009, Ludwig, 2009). IV acquired the ability to highjack cellular factors for its own purpose (Ludwig et al.,2003). Furthermore, IV are able to suppress the innate immune response of their hosts. Given these dependencies, cellular virus-supportive functions are most promising candidates for novel antiviral intervention (Ludwig et al, 2003, Ludwig, 2011, Planz, 2013). During the last years we and others identified the Raf/MEK/ERK mitogenic kinase cascade (Pleschka et al., 2001, Ludwig et al., 2004, Olschlager et al., 2004, Marjuki et al., 2006, Ludwig, 2009, Droebner et al., 2011), the IKK/NFκB module (Pleschka et al., 2001, Wurzer et al., 2004, Marjuki et al., 2006, Mazur et al., 2007, Ludwig et al., 2008, Dudek et al., 2010, Droebner et al., 2011, Ehrhardt et al., 2013, Haasbach et al., 2013), the p38-(Borgeling et al., 2014) and also the PI3K-signaling (Ehrhardt et at., 2006, Ehrhardt et al., 2007a, Ehrhardt et al., 2007b, Ehrhardt et al., 2009, Eierhoff et al., 2010) pathways as suitable targets for an anti-viral approach.
- Targeting cellular rather than viral factors prevents the problem of resistance because the pathogen cannot replace the missing cellular function. For several cellular factors chemical compounds are available and although in an early stage, some of them have entered clinical testing or are even already licensed.
- In contrast to IV replication, S. aureus division is host-cell independent. Novel antibacterial alternatives do not target essential gene products elaborated by the pathogen, but inhibit virulence factors during S. aureus infection without killing the bacterium or boosting host immunity (Park et al., 2012). Other strategies prevent colonization of S. aureus in the human host (Park et al., 2012). These compounds also exhibit a lower potential to induce resistance. Recently, there is accumulating evidence that S. aureus also uses cellular signaling for its own benefits during infection (Oviedo-Boyso et al., 2011), but such bacterial-supportive cellular factors have not yet been characterized as targets for antibacterial therapy in detail.
- The present inventors surprisingly observed, that drugs against intracellular signaling factors, such as NFκB, MEK or p38 MAP kinase, that were previously shown to possess anti influenza activity, also exhibit anti S. aureus activity and reduces both viral- and bacterial titers in a coinfection scenario. Thus, these signaling inhibitors are most promising candidates for the treatment of IV or S. aureus infections alone, but, most importantly also against severe influenza accompanied with bacterial coinfection.
- In one embodiment, the MEK inhibitor, p38 inhibitor and/or NFκB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention, wherein the the bacterial infection is mediated by a bacterium selected from the group consisting of Staphylococcaceae, Streptococcaceae, Legionellaceae, Pseudomonadaceae, Chlamydiaceae, Mycoplasmataceae, Enterobacteriaceae, Pseudomonadales and/or Pasteurellaceae.
- In another embodiment the MEK inhibitor, p38 inhibitor and/or NFκB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection of the present invention, wherein the influenza virus infection is mediated by influenza A virus or influenza B virus, preferably the influenza A virus is H1N1, H2N2, H3N2, H6N1, H7N7, H7N9, H9N2 H10N7, H10N8 or H5N1. In one embodiment, the influenza A virus is H1N1. In other embodiments, the influenza A virus is H3N2, H5N1 and H7N9. In additional embodiments, the influenza A virus is H3N2, H5N1, H1N1 and H7N9.
- In a further embodiment the MEK inhibitor, p38 inhibitor and/or NFκB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention, wherein the MEK inhibitor is selected from the group consisting of U0126, PLX-4032, AZD6244, AZD8330, AS-703026, GSK-1120212, RDEA-119, RO-5126766, RO-4987655, CI-1040, PD-0325901, GDC-0973, TAK-733, PD98059, ARRY-438162, PF-3644022 and PD184352, preferably AZD8330, GSK-1120212, U0126, GDC-0973, CI-1040, PD0325901, ARRY438162, PF-3644022 and AZD6244, most preferably U0126, GDC-0973, CI-1040, AZD8330 and GSK-1120212.
- In another embodiment the MFK inhibitor, p32 inhibitor and/or NFκB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention, wherein the p38 inhibitor is selected from the group consisting of SB202190, LY2228820, CAY10571,
SB 203580, Tie2 Kinase Inhibitor, 2-(4-Chlorophenyl)-4-(fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one, CGH 2466, SB220025, Antibiotic LL Z1640-2, TAK 715, SB202190 hydrochloride, SKF 86002, AMG548, CMPD-1, EO 1428, JX 401, ML 3403, RWJ 67657, SB 202190, SB 203580, SB 203580 hydrochloride, SB 239063, SCIO 469, SX 011, TAK 715, Pamapimod, Losmapimod (GW856553), Dilmapimod (SB681323), VX 702, VX 745, Doramapimod (BIRB 796), BMS-582949, ARRY-797, PH797804 preferably VX-702, SB202190, Pamapimod, losmapimod (GW856553), Dilmapimod (SB681323), Doramapimod (BIRB 796), BMS-582949, ARRY-797, PH797804 and SCIO-469. - In another embodiment the MEK inhibitor, p38 inhibitor and/or NFκB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention, wherein the NFκB inhibitor is selected from the group consisting of LASAG (also called LG-ASA), SC75741, MG 132, TPCA-1, PCTC, IMD 0354, Luteolin, Caffeic acid phenethyl ester, Cardamonin, PF 184, IKK 16, SC 514, Withaferin A, Arctigenin, Bay 11-7085, PSI, PR 39, Ro 106-9920, Bay 11-7821, ML-130, Celastrol, Tanshinone IIA, HU 211, Gliotoxin, CID 2858522, Honokiol, Andrographolide, 10Z-Hymenialdisine, ACHP, Pristimerin, Sulfasalazine, ML 120B dihydrochloride, Amlexanox, 9-Methyistreptimidone, N-Stearoyl phytosphingosine, 2-(1,8-naphthyridin-2-yl)-Phenol, 5-Aminosalicylic acid, BAY 11-7085,
Ethyl 3,4-Dihydroxycinnamate, Helanalin, NF-κB Activation Inhibitor 11, JSH-23, Glucocorticoid Receptor Modulator, CpdA, PPM-18, aspirin (ASA), Pyrrolidinedithiocarbamic acid ammonium salt, (R)-MG132, SC75741 Rocaglamide, Sodium salicylate, QNZ, PS-1145, CAY10512, bortezomib, salsalate, resveratrol, deoxyspergualin, sulindac, thalidomide, AGRO-100, CHS 828 and/or Curcumin preferably, bortezomib, curcumin, aspirin (ASA), salsalate, resveratrol, sodium salicylate, LASAG (also called LG-ASA), deoxyspergualin, sulindac, thalidomide, AGRO-100, CHS 828 even more preferably SC75741, ASA and LASAG (also called LG-ASA) and most preferably LASAG (also called LG-ASA). - In additional embodiments, the MEK inhibitor, p38 inhibitor and/or NFκB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention, wherein the MEK inhibitor is combined with another MEK inhibitor, the p38 inhibitor and/or the NFκB inhibitor; the p38 inhibitor is combined with another p38 inhibitor, the MEK inhibitor and/or the NFκB inhibitor or the NFκB inhibitor is combined with another NFκB inhibitor, the p38 inhibitor and/or the MEK inhibitor.
- In further embodiments, the MEK inhibitor, p38 inhibitor and/or NFκB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection of the present invention, wherein the MEK inhibitor, the p38 inhibitor and/or the NFκB inhibitor are combined with one or more inhibitors targeting the influenza virus and/or the bacterium. In one embodiment, the MEK inhibitor, the p38 inhibitor and/or the NFκB inhibitor is/are administered contemporaneously, previously or subsequently to the one or more inhibitors targeting the influenza virus and/or the bacterium. As such the MEK inhibitor, p38 inhibitor and/or NFκB inhibitor can be combined with 1, 2, 3, 4, 5, 6, 7, or 8 inhibitors targeting the influenza virus. Similarly, the MEK inhibitor, p38 inhibitor and/or NFκB inhibitor can be combined with 1, 2, 3, 4, 5, 6, 7, or 8 inhibitors targeting the bacterium.
- In one embodiment, the one or more inhibitors targeting the influenza virus is a neuraminidase inhibitor, preferably oseltamivir phosphate, zanamivir, oseltamivir or peramivir.
- In another embodiment, the one or more inhibitors targeting the influenza virus is a compound targeting an ion channel protein (M2), preferably amantadine and/or rimantadine. In further embodiments, the one or more inhibitors targeting the influenza virus is a compound targeting polymerase or endonuclease activity via interfering with a component of the viral polymerase complex, PB1, PB2, PA or NP, preferably NP blocker Nucleozin or polymerase inhibitor T-705.
- In further embodiments, the MEK inhibitor, p38 inhibitor and/or NFκB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a bacterial infection of the present invention, wherein the MEK inhibitor, the p38 inhibitor and/or the NFκB inhibitor are combined with one or more inhibitors targeting the bacterium.
- In another embodiment, the MEK inhibitor, p38 inhibitor and/or NFκB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention, the one or more inhibitor targeting the bacterium is an antibiotic, preferably Gentamicin, Rifampicin, Lysosthaphin, Erythromycin, Levofloxacin Vancomycin, Teicoplanin, Penicillin and Oxacillin.
- In additional embodiments, the MEK inhibitor, p38 inhibitor and/or NFκB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention is in a subject, preferably a vertebrate.
- Also provided for by the present invention is a composition, comprising a MEK inhibitor, a p38 inhibitor and/or a NFκB inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection. Preferably, the composition further comprises a carrier.
- The present invention also relates to a composition, comprising a MEK inhibitor, a p38 inhibitor and/or a NFκB inhibitor for use in a method for the prophylaxis and/or treatment of a bacterial infection. Preferably, the composition further comprises a carrier.
- Also provided for by the present invention is a composition, comprising a MEK inhibitor, a p38 inhibitor and/or a NFκB inhibitor and one or more inhibitors targeting the influenza virus and/or the bacterium for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection. Preferably, the composition further comprises a carrier.
- The present invention also relates to a composition, comprising a MEK inhibitor, a p38 inhibitor and/or a NFκB inhibitor and one or more inhibitors targeting the bacterium for use in a method for the prophylaxis and/or treatment of a a bacterial infection, Preferably, the composition further comprises a carrier.
- In further embodiments, the MEK inhibitor, p38 inhibitor and/or NFκB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection of the present invention, wherein the MEK inhibitor, the p38 inhibitor and/or the NFκB inhibitor reduces both the viral and bacterial infection, when contacting it/them with an in vitro test system, wherein the test system comprises cultured cells infected with
-
- a) an influenza virus and
- b) a bacterium
when compared to the in vitro test system before the contacting.
- In one embodiment, the reduction of the viral infection is a reduction in plaque forming units (pfu)/ml and the reduction in the bacterial infection is a reduction in colony forming units (CFU)/ml.
- In another embodiment, the MEK inhibitor, p38 inhibitor and/or NFκB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a bacterial infection of the present invention, wherein the MEK inhibitor, the p38 inhibitor and/or the NEκB inhibitor reduces the bacterial infection, when contacting it/them with an in vitro test system, wherein the test system comprises cultured cells infected with a bacterium, when compared to the in vitro test system before the contacting.
- The present invention also relates to an in vitro test system, wherein the test system comprises
-
- cultured cells infected with
- a) an influenza virus and
- b) a bacterium.
- The invention also provides for the use of the in vitro test system of of the present invention for the determination of inhibitors effective in reducing a coinfection comprising a bacterial infection and an influenza virus infection. In one embodiment, the reduction of the viral infection is a reduction in plaque forming units (pfu)/ml and the reduction in the bacterial infection is a reduction in colony forming units (CFU)/ml.
- In addition the present invention relates to a method for detecting molecules effective in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection comprising contacting the in vitro test system of the present invention with a compound of interest, wherein the compound of interest reduces both the viral and bacterial infection, compared to the in vitro test system before the contacting.
- The present invention also provides for an in vitro test system, wherein the in vitro test system comprises cultured cells infected with a bacterium.
- The present invention, in addition, relates to a use of the in vitro test system of the present invention for the determination of inhibitors effective in reducing a bacterial infection.
- Furthermore, the present invention relates to the use of the in vitro test systems of the present invention for the examination of innate host cell responses, which optionally includes examination of the level of signal transduction, resulting cytokine and chemokine expression, induction of apoptosis and necrosis and/or redox hemostasis regulating health and disease.
- Also provided for by the present invention is a method for detecting molecules effective in the prophylaxis and/or treatment a bacterial infection comprising contacting the in vitro test system of the present invention with a compound of interest, wherein the compound of interest reduces the bacterial infection, compared to the in vitro test system before the contacting.
- The present invention furthermore relates to a cultured cell infected with an influenza virus and a bacterium.
- Also provided for is a cultured cell infected with a bacterium.
- The figures show:
-
FIG. 1 : Time scale of co-infection procedure. Cells were infected with IV for 30 min. Co-infection withS. aureus 6850 was conducted or cells were mock-treated. Extracellular bacteria were lysed and removed by antibiotic treatment 3 h post bacterial infection. After a PBS wash, cells were supplemented with fresh medium (DMEM/INV) and incubated up to 18 hrs of viral infection -
FIG. 2 : The MEK inhibitor U0126 reduces IV titers (A/Puerto Rico/8/34) and S. aureus load, even in a co-infection situation. Human lung epithelial cells were seeded in 6-well plates (8×105 cells/well) in 2 ml DMEM (10% FCS). 16-20 hrs after seeding, cells were rinsed and incubated with PBS/BA [0.2% bovine serum albumin (BSA), 1 mM MgCl2, 0.9 mM CaCl2, 100 U/ml penicillin, 0.1 mg/ml streptomycin] (500 μl per 6 well) or PBS/BA containing the influenza virus A/Puerto Rico/8/34 at a multiplicity of infection (MOI=0.1) at 37° C. After 30 min incubation, the virus dilution was aspirated, cells were rinsed with PBS and supplemented with invasion medium DMEM/INV [1% human serum albumin, 25 nmol/l HEPES] (2 ml per 6 well) with or without S. aureus 6850 (MOI=0.5) in presence of 50 μM U0126 or DMSO (solvent control). 3 hrs post bacterial infection cells were treated with antibiotics to remove extracellular bacteria. Therefore cells were rinsed with PBS and subsequently incubated with DMEM/INVantibiotics [2 μg/ml lysostaphin (Sigma)] (1 ml per 6 well) for 20 min at 37° C. After an additional wash with PBS cells were supplemented with DMEM/INV containing 50 μM U0126 or DMSO and 0.333 μg/ml Trypsin (Invitrogen). After an incubation period of further 14 hrs at 37° C. IV titers and intracellular bacteria were determined as described in (Hrincius et al., 2010, Tuchscherr et al., 2011). IV titers are depicted as plaque forming units (pfu)/ml (A, C) and S. aureus titers are depicted as colonie forming units (CFU)/ml (B, D). Data represent the means±SD of three independent experiments with two biological samples. Statistical significance was evaluated by a two-tailed two sample t-test (*p<0.05; **p<0.01; ***p<0.001). (E) S. aureus in presence of 50 μM U0126 results in reducedbacterial titers 18 hrs upon incubation in comparison to DMSO treated bacteria. A defined amount ofS. aureus 6850 suspension culture was diluted in DMEM/INV supplemented with 50 μM U0126 or DMSO and incubated at 37° C. for 18 hrs. Bacteria were diluted and determined by serial dilution on agar plates. Data represent the means±SD of three independent experiments with two biological samples. Statistical significance was evaluated by a two-tailed two sample t-test (*p<0.05; **p<0.01; ***p<0.001). -
FIG. 3 : The MEK inhibitor U0126 reduces IV titers (A/FPV/Bratislava/79) and S. aureus load, even in a co-infection situation. Human lung epithelial cells were seeded in 6-well plates (8×105cells/well) in 2 ml DMEM [10% FCS]. 16-20 hrs after seeding, cells were rinsed and incubated with PBS/BA [0.2% bovine serum albumin (BSA), 1 mM MgCl2, 0.9 mM CaCl2, 100 U/ml penicillin, 0.1 mg/ml streptomycin] (500 μl per 6 well) or PBS/BA containing the Influenza virus A/FPV/Bratislava/79 at a multiplicity of infection (MOI=0.001) at 37° C. After 30 min incubation, the virus dilution was aspirated, cells were rinsed with PBS and supplemented with invasion medium DMEM/INV [1% human serum albumin, 25 nmol/l HEPES] (2 ml per 6 well) with or without S. aureus 6850 (MOI=0.5) in presence of 50 μM U0126 or DMSO (solvent control). 3 hrs post bacterial infection cells were treated with antibiotics to remove extracellular bacteria. Therefore cells were rinsed with PBS and subsequently incubated with DMEM/INVantibiotics [2 μg/ml lysostaphin (Sigma)] (1 ml per 6 well) for 20 min at 37° C. After an additional wash with PBS cells were supplemented with DMEM/INV containing 50 μM U0126 or DMSO. After an incubation period of further 14 hrs at 37° C. IV titers and intracellular bacteria were determined as described in (Hrincius et al., 2010; Tuchscherr et al., 2011). IV titers are depicted as plaque forming units (pfu)/ml (A, C) and S. aureus titers are depicted as colonie forming units (CFU)/ml (B, D). Data represent the means±SD of two independent experiments with two biological samples. Statistical significance was evaluated by a two-tailed two sample t-test (*p<0.05; **p<0.01; ***p<0.001). -
FIG. 4 : The p38 inhibitor SB202190 reduces IV titers and S. aureus load, even in a co-infection situation. Human lung epithelial cells were seeded in 6-well plates (8×105 cells/well) in 2 ml DMEM [10% FCS]. 16-20 hrs after seeding, cells were rinsed and incubated with PBS/BA [0.2% bovine serum albumin (BSA), 1 mM MgCl2, 0.9 mM CaCl2, 100 U/ml penicillin, 0.1 mg/ml streptomycin] (500 μl per 6 well) or PBS/BA containing the Influenza virus A/Puerto Rico/8/34 at a multiplicity of infection (MOI=0.1) at 37° C. After 30 min incubation, the virus dilution was aspirated, cells were rinsed with PBS and supplemented with Invasion medium DMEM/INV [1% human serum albumin, 25 nmol/l HEPES] (2 ml per 6 well) with or without S. aureus 6850 (MOI=0.5) in presence of 10 μM SB202190 or DMSO (solvent control). 3 hrs post bacterial infection cells were treated with antibiotics to remove extracellular bacteria. Therefore cells were rinsed with PBS and subsequently incubated with DMEM/INVantibiotics [2 μg/ml lysostaphin (Sigma)] (1 ml per 6 well) for 20 min at 37° C. After an additional wash with PBS cells were supplemented with DMEM/INV containing 10 μM SB202190 or DMSO and 0.333 μg/ml Trypsin (Invitrogen). After an Incubation period of further 14 hrs at 37° C. IV titers and intracellular bacteria were determined as described in (Hrincius et al., 2010; Tuchscherr et al., 2011). IV titers are depicted as plaque forming units (pfu)/ml (A, C) and S. aureus titers are depicted as colonie forming units (CFU)/ml (B, D). Data represent the means±SD of three independent experiments with two biological samples. Statistical significance was evaluated by a two-tailed two sample t-test (*p<0.05; **p<0.01; ***p<0.001). -
FIG. 5 : The NF-kappaB (NFκB) inhibitor LG-ASA reduces IV titers and S. aureus load, even in a co-infection situation. Human lung epithelial cells were seeded in 6-well plates (8×105 cells/well) in 2 ml DMEM (10% FCS). 16-20 hrs after seeding, cells were rinsed and incubated with PBS/BA [0.2% bovine serum albumin (BSA), 1 mM MgCl2, 0.9 mM CaCl2, 100 U/ml penicillin, 0.1 mg/ml streptomycin] (500 μl per 6 well) or PBS/BA containing the influenza virus A/Puerto Rico/8/34 at a multiplicity of infection (MOI=0.1) at 37° C. After 30 min incubation, the virus dilution was aspirated, cells were rinsed with PBS and supplemented with invasion medium DMEM/INV [1% human serum albumin, 25 nmol/l HEPES] (2 ml per 6 well) with or without S. aureus 6850 (MOI=0.5) in presence of 5 mM LG-ASA. Water was used as solvent control. 3 hrs post bacterial infection cells were treated with antibiotics to remove extracellular bacteria. Therefore cells were rinsed with PBS and subsequently incubated with DMEM/INVantibiotics [10% FBS, 2 μg/ml lysostaphin (Sigma)] (1 ml per 6 well) for 20 min at 37° C. After an additional wash with PBS cells were supplemented with DMEM/INV containing 5 mM LG-ASA or water and 0.333 μg/ml Trypsin (Invitrogen). After an incubation period of further 14 hrs at 37° C. IV titers and intracellular bacteria were determined as described in (Hrincius et al., 2010, Tuchscherr et al., 2011). IV titers are depicted as plaque forming units (pfu)/ml (A, C) and S. aureus titers are depicted as colonie forming units (CFU)/ml (B, D). Data represent the means±SD of two independent experiments (virus titer) and three independent experiments (bacterial titer) with two biological samples. Statistical significance was evaluated by a two-tailed two sample t-test (*p<0.05; **p<0.01; ***p<0.001). -
FIG. 6 : The viral neuraminidase inhibitor tamiflu reduces IV replication but enhances S. aureus load. Human lung epithelial cells were seeded in 6-well plates (8×105 cells/well) in 2 ml DMEM [10% FCS]. 16-20 hrs after seeding, cells were rinsed and incubated with PBS/BA [0.2% bovine serum albumin (BSA), 1 mM MgCl2, 0.9 mM CaCl2, 100 U/ml penicillin, 0.1 mg/ml streptomycin] (500 μl per 6 well) or PBS/BA containing the Influenza virus A/FPV/Bratislava/79 at a multiplicity of infection (MOI=0.001) at 37° C. After 30 min incubation, the virus dilution was aspirated, cells were rinsed with PBS and supplemented with invasion medium DMEM/INV [1% human serum albumin, 25 nmol/l HEPES] (2 ml per 6 well) with or without S. aureus 6850 (MOI=0.5) in presence of 2 μM tamiflu or Hepes (solvent control). 3 hrs post bacterial infection cells were treated with antibiotics to remove extracellular bacteria. Therefore cells were rinsed with PBS and subsequently incubated with DMEM/INVantibiotics (2 μg/ml lysostaphin (Sigma)] (1 ml per 6 well) for 20 min at 37° C. After an additional wash with PBS cells were supplemented with DMEM/INV containing 2 μM tamiflu or Hepes. After an incubation period of further 14 hrs at 37° C. IV titers and intracellular bacteria were determined as described in (Hrincius et al., 2010; Tuchscherr et al., 2011). -
FIG. 7 : Titers ofintracellular S. aureus 6850 are reduced upon LG-ASA treatment. Human lung epithelial cells (A549) were infected with 0.5MOI S. aureus 6850 DMEM/INV [1% human serum albumin, 25 nmol/l HEPES] for 3 h in presence (A, C) and absence (B, D) of the indicated amounts of LG-ASA. Three hours post infection an antibiotic wash was included using DMEM/INVantibiotics [2 μg/ml lysostaphin (Sigma)] to remove non-internalized bacteria and subsequently cells were supplemented with DMEM/INV containing the indicated amounts of LG-ASA. Cell morphology was monitored by light microscopy (A, B) and amounts of internalized bacteria were determined by serial dilution onagar plates 18 hours post infection (C, D). -
FIG. 8 : Table 2: p38 inhibitors. -
FIG. 9 : Table 3: NFκB inhibitors. -
FIG. 10 : Table 4: NFκB inhibitors. -
FIG. 11 : Table 5: antibiotics. -
FIG. 12 : Time scale of the co-infection procedure in vitro. Human lung epithelial cells (A549) were infected with influenza A virus (IAV) for 30 min at a multiplicity of infection (MOI) indicated, dissolved in PBS/BA [0.2% bovine serum albumin, 1 mM MgCl2, 0.9 mM CaCl2, 100 U/ml penicillin, 0.1 mg/ml streptomycin] at 37° C. After 30 min incubation, the virus dilution was aspirated, cells were rinsed with PBS. Afterwards bacterial infection with Staphylococcus aureus 6850 (S. aureus) was performed or cells were mock-treated. Therefore cells were supplemented with invasion medium DMEM/INV [1% human serum albumin, 25 nmol/l HEPES] with or without S. aureus in addition to the indicated amounts of inhibitor (U0126 or CI-1040) or solvent control. 3 hrs post bacterial infection an antibiotic wash [DMEM, 10% FBS, 2 μg/ml Lysostaphin or 100 μg/ml Gentamicin, 20 min] was introduced to remove non-internalized bacteria. After an additional PBS wash, cells were supplemented with infection medium DMEM (0.2% BA, 1 mM MgCl2, 0.9 mM CaCl2, 100 U/ml penicillin, 0.1 mg/ml streptomycin) in presence or absence of the inhibitor and were incubated up to 18 hrs post viral infection at 37° C. -
FIG. 13 : Inhibition of the MEK/ERK signaling results in enhanced cell survival after singular and co-infection. - Human lung epithelial cells (A549) were infected with the avian influenza virus strain A/FPV/Bratislava/79 (H7N7) (FPV) or the human influenza virus strain A/Wisconsin/67/2005 (H3N2) at a multiplicity of infection (MOI=0.01) (H7N7) or (MOI=0.5) (H3N2) at 37° C.. After 30 min the virus dilution was removed, cells were rinsed with PBS and supplemented with invasion medium DMEM/INV (containing 1% human serum albumin, 25 nM HEPES) with or without S. aureus 6850 (MOI=0.1) in presence of 50 μM U0126 or solvent control. 3 hrs post bacterial infection cells were treated with DMEM/FBS containing 10% FBS, 2 μg/ml lysostaphin for 20 min to remove non-internalized bacteria. After an additional wash with PBS cells were supplemented with infection medium DMEM/BA (0.2% BA, 1 mM MgCl2, 0.9 mM CaCl2, 100 U/ml penicillin, 0.1 mg/ml streptomycin) containing 50 μM U0126 or solvent. After an incubation period of 18 hrs at 37° C. cell morphology was monitored by light microscopy,
-
FIG. 14 : Inhibition of MEK/ERK signaling results in reduced viral titers during singular viral and co-infection. - Human lung epithelial cells (A549) were infected with the avian influenza virus strain A/FPV/Bratislava/79 (H7N7) (A, C) or the human influenza virus strain A/Wisconsin/67/2005 (H3N2) (B, D) at a multiplicity of infection (MOI=0.01) (A, C), (MOI=0.5) (B, D) at 37° C. After 30 min the virus dilution was removed, cells were rinsed with PBS and supplemented with invasion medium DMEM/INV (containing 1% human serum albumin, 25 nM HEPES) with or without S. aureus 6850 (MOI=0.1) in presence of 50 μM U0126 or solvent control. 3 hrs post bacterial infection cells were treated with DMEM/FBS containing 10% FBS, 2 μg/ml lysostaphin for 20 min to remove extracellular bacteria. After an additional wash with PBS cells were supplemented with infection medium DMEM/BA (0.2% BA, 1 mM MgCl2, 0.9 mM CaCl2, 100U/ml penicillin, 0.1 mg/ml streptomycin) containing 50 μM U0126 or solvent. After an incubation period of 18 hrs at 37° C. viral titers were determined by standard plaque assay. Viral titers are depicted as plaque forming units/ml (PFU/ml) with a linear (A, B) or logarithmic scale (C, D). Data represent the means±SD of four independent experiments with two biological samples. Statistical significance was evaluated by a two-tailed one sample t-test (*p<0.05; **p<0.01).
-
FIG. 15 : MEK inhibition by administration of U0126 results in reduced bacterial growth. - Human lung epithelial cells (A549) were infected with the avian influenza virus strain A/FPV/Bratislava/79 (H7N7) or the human influenza virus strain A/Wisconsin/67/2005 (H3N2) (A, C) at a multiplicity of infection (MOI=0.01) (H7N7) or (MOI=0.5) (H3N2) at 37° C. After 30 min the virus dilution was removed, cells were rinsed with PBS and supplemented with invasion medium DMEM/INV (containing 1% human serum albumin, 25 nM HEPES) with or without S. aureus 6850 (MOI=0.1) (A) in presence of 50 μM U0126 or solvent control. 3 hrs post bacterial infection cells were treated with DMEM/FBS containing 10% FBS, 2 μg/ml lysostaphin for 20 min (A, C) to remove non-internalized bacteria. After an additional wash with PBS cells were supplemented with infection medium DMEM/BA (0.2% BA, 1 mM MgCl2, 0.9 mM CaCl2, 100 U/ml penicillin, 0.1 mg/ml streptomycin) containing 50 μM U0126 or solvent. Amounts of internalized bacteria were determined by serial dilution of cell lysates on
agar plates 18 hrs post infection (A, C). The impact of U0126 on bacterial growth was analyzed by administration of U0126 as indicated to an over-night culture of S. aureus 6850 (100 CFU/ml). After 16 hrs serial dilutions were plated on BHI agar (B, D). Bacterial titers are depicted as colony forming units/ml (CFU/ml) with a linear (A, B) or logarithmic scale (C, D). Data represent the means±SD of four (A, C) or three (B, D) independent experiments with two biological samples. Statistical significance was evaluated by a two-tailed two sample t-test (***p<0.001). -
FIG. 16 : Inhibition of the MEK/ERK signaling leads to reduction of viral proteins and pro-inflammatory chemokines. - Human lung epithelial cells (A549) were infected with the human influenza virus strain A/Wisconsin/67/2005 (H3N2) at a multiplicity of infection (MOI=5) at 37° C. After 30 min the virus dilution was removed, cells were rinsed with PBS and supplemented with invasion medium DMEM/INV (containing 1% human serum albumin, 25 nM HEPES) with or without S. aureus 6850 (MOI=50) in presence of 50 μM U0126 or solvent control. 3 hrs post bacterial infection cells were treated with DMEM/FBS containing 10% FBS, 100 μg/ml Gentamicin for 30 min to remove extracellular bacteria. After an additional wash with PBS cells were supplemented with infection medium DMEM/BA (0.2% BA, 1 mM MgCl2, 0.9 mM CaCl2, 100 U/ml penicillin, 0.1 mg/ml streptomycin) containing 50 μM U0126 or solvent. After an incubation period of 8 hrs at 37° C. mRNA levels of CCL3 and CCL5 were analyzed by qRT-PCR with specific primers (A, B). Viral protein expression (PB-1) and the level of ERK-1/2 phosphorylation, as well as bacterial cell wall components (PGN) were determined by western blot analysis (C). Data represent preliminary results of three biological samples and two technical replicates within one experiment.
-
FIG. 17 : Administration of U0126 leads to reduced bacterial titers in vivo independent of viral titers. - 12 weeks old Balb/C mice were infected with 50 PFU of the influenza virus strain A/Puerto Rico/8/34 (PR8, H1N1) on day 0 (anesthesized with Isoflurane). Starting on
day 1 mice were treated daily with i.p. injection of 30 mg/kg/day U0126 or solvent control (10% DMSO, 30% Cremophor EL, 60% PBS). Onday 3 mice were infected with 5*107 CFU ofStaphylococcus aureus 6850 under anesthesia with Isoflurane and directly treated with U0126 or solvent control. Onday 4 lungs were removed and homogenized in PBS (0.1 g per 1000 μl PBS). For calculation of bacterial titers serial dilutions of the homogenate were plated on BHI agar. For determination of viral titers a standard plaque assay was performed. Statistical analysis was done using Mann-Whitney U Test (*p<0.05). -
FIG. 18 : The specific MEK inhibitor CI-4040 reduces viral titers in singular and co-infection. - Human lung epithelial cells (A549) were infected with the avian influenza virus strain A/FPV/Bratislava/79 (H7N7) (A, C) or the human influenza virus strain A/Puerto Rico/8/34 (H1N1) (B, D) at a multiplicity of infection (MOI=0.0) at 37° C. After 30 min the virus dilution was removed, cells were rinsed with PBS and supplemented with invasion medium DMEM/INV (containing 1% human serum albumin, 25 nM HEPES) with or without S. aureus 6850 (MOI=0.1) in presence of 10 μM CI-1040 or solvent control. 3 hrs pod bacterial infection relic were treated with DMEM/FBS containing 10% FBS, 2 μg/ml lysostaphin for 20 min to remove extracellular bacteria. After an additional wash with PBS cells were supplemented with infection medium DMEM/BA (0.2% BA, 1 mM MgCl2, 0.9 mM CaCl2, 100 U/ml penicillin, 0.1 mg/ml streptomycin) containing 10 μM CI-1040 or solvent. After an incubation period of 18 hrs at 37° C. viral titers were determined by standard plaque assay. Viral titers are depicted as plaque forming units/ml (PFU/ml) with a linear (A, B) or logarithmic scale (C, D). Data represent the means of two independent experiments with two biological samples.
-
FIG. 19 : Administration of CI-1040 has an inhibitory effect on bacterial growth in vitro. - The impact of CI-1040 on bacterial growth was analyzed by administration of CI-1040 in different concentrations (as indicated) to an over-night culture of S. aureus 6850 (100 CFU/ml). After 16 hrs serial dilutions were plated on BHI agar (A, B). Bacterial titers are depicted as colony forming units/ml (CFU/ml) with a linear (A) or logarithmic scale (B). Data represent preliminary data with two biological samples.
-
FIG. 20 : Treatment with the specific MEK inhibitor Cobimetinib (GDC-0973) reduces pathogen load in vivo. - 8 weeks old Balb/C mice (5 per group) were infected with 50 PFU of influenza virus strain A/Puerto Rico/8/34 (PR8, H1N1) on day 0 (anesthesized with Isoflurane). 6 hrs post viral infection mice were treated with oral administration of 10 mg/kg/day Cobimetinib or solvent control (10% DMSO, 5
% Tween 20, 85% PBS), Treatment was then performed daily. Onday 3 mice were infected with 5*107 CFU ofStaphylococcus aureus 6850 under anesthesia with Isoflurane and 6 hrs later treated with Cobimetinib or solvent control. Onday 4 lungs were removed and homogenized in PBS (0.1 g per 1000 μl PBS). For calculation of bacterial titers serial dilutions of the homogenate were plated on BHI agar. For determination of viral titers a standard plaque assay was performed. Statistical analysis was done using Mann-Whitney U test. -
FIG. 21 : LG-ASA improves cell morphology upon infection with influenza A virus (IAV) and/or Staphylococcus aureus (S. aureus) - Human lung epithelial cells (A549) were infected with the influenza virus strain A/Puerto Rico/8/34 (H1N1) at a multiplicity of infection (MOI=0.1) dissolved in PBS/BA [0.2% bovine serum albumin, 1 mM MgCl2, 0.9 mM CaCl2, 100 U/ml penicillin, 0.1 mg/ml streptomycin] at 37° C. After 30 min incubation, the virus dilution was aspirated, cells were rinsed with PBS and supplemented with invasion medium DMEM/INV [1% human serum albumin, 25 nmol/l HEPES] with or without S. aureus SH1000 (MOI=0.1) in presence of 5 mM LG-ASA or solvent control. 3 hrs post bacterial infection cells were treated with antibiotics [DMEM, 10% FBS, 2 μg/ml lysostaphin, 20 min] to remove extracellular bacteria. After an additional wash with PBS cells were supplemented with DMEM/INV containing 5 mM LG-ASA or solvent. After an incubation period of 18 hrs at 37° C. cell morphology was monitored by light microscopy.
-
FIG. 22 : The NFκB inhibitor LG-ASA reduces influenza virus titers and S. aureus load - Human lung epithelial cells (A549) were infected with the influenza virus strain A/Puerto Rico/8/34 (H1N1) at a multiplicity of infection (MOI=0.1) dissolved in PBS/BA [0.2% bovine serum albumin, 1 mM MgCl2, 0.9 mM CaCl2, 100 U/ml penicillin, 0.1 mg/ml streptomycin] at 37° C. (A-H). After 30 min incubation, the virus dilution was aspirated, cells were rinsed with PBS and supplemented with invasion medium DMEM/INV [1% human serum albumin, 25 nmol/l HEPES] with or without S. aureus SH1000 (MOI=50) (A, B), (MOI=0.01) (C-D), S. aureus 6850 (MOI=50) (E, F), (MOI=0.1) (G, H) in presence of 5 mM LG-ASA or solvent control. 3 hrs post bacterial infection cells were treated with antibiotics [DMEM, 10% FBS, 2 μg/ml lysostaphin, 20 min] to remove extracellular bacteria. After an additional wash with PBS cells were supplemented with DMEM/INV containing 5 mM LG-ASA or solvent. After an incubation period of 8 hrs (A, B, E, F) or 18 hrs (C, D, G, H) at 37° C. IAV titers (A, C, E, G) were determined by standard plaque assays. Cells were lysed by a hypotonic shock and amounts of internalized bacteria (B, D, F, H) were determined by serial dilution on agar plates. Data represent the means±SD of three (A-H) with two biological samples. Statistical significance was evaluated by a two-tailed one sample t-test (*p<0.05; **p<0.01).
-
FIG. 23 : The NFκB inhibitor LG-ASA reduces influenza virus titers and S. aureus load - This figure presents data obtained as in
FIG. 22 in a different way. In particular, the untreated controls of each experiment were arbitrarily set as 100% and then the means were calculated. Statistical significance was evaluated by a two-tailed one sample t-test (*p<0.05; ** p<0.01). -
FIG. 24 : Inhibition of NFκB signaling results in reduced bacterial internalisation - Human lung epithelial cells (A549) were preincubated with 5 mM (A-D) and 10 mM (C, D) LG-ASA for 4 h and then infected with S. aureus 6850 (MOI=50) (A, B) for 30-120 min and USA 300 (MOI=5) (C, D) for 120 min in presence and absence of the indicated amounts of LG-ASA dissolved in DMEM/INV [1% human serum albumin, 25 nmol/l HEPES]. 30-120 min post infection an antibiotic wash [DMEM, 10% FBS, 2 μg/ml lysostaphin, 20 min] was included to remove non-internalized bacteria. Cells were washed with PBS three times and lysed by hypotonic shock. Amounts of internalized bacteria were determined by serial dilution on agar plates (A-D). Data (A, C) represent the means±SD of three independent experiments with two biological samples. In
FIG. 24 B, D the untreated controls of each experiment were arbitrarily set as 100% and then the means were calculated. Statistical significance was evaluated by a two-tailed one sample t-test (*p<0.05; **p<0.01; ***p<0.001). -
FIG. 25 : Stimulation of NFκB signaling results in enhanced bacterial internalization Human lung epithelial cells (A549) were preincubated with 5 mM LG-ASA and 2.5 ng/ml TNF-alpha for 4 h and then infected with (A)S. aureus 6850 or (B) S. aureus USA300 (MOI=5) for 120 min in presence and absence of the indicated amounts of LG-ASA and TNF-alpha dissolved in DMEM/INV [1% human serum albumin, 25 nmol/l HEPES] (A). 120 min post infection an antibiotic wash [DMEM, 10% FBS, 2 μg/ml lysostaphin, 20 min] was included to remove non-internalized bacteria. Cells were washed with PBS three times and lysed by hypotonic shock. Amounts of internalized bacteria were determined by serial dilution on agar plates (A) 120 min post infection. (A) Data represent the means±SD of four independent experiments with two biological samples. Statistical significance was evaluated by an one-way ANOVA followed by a multiple comparison test (*p<0.05; **p<0.01; ***p<0.001). (B) Data represent the means±SD of three independent experiments with three biological samples whereby the untreated controls of each experiment were arbitrarily set as 100% and then the means were calculated. -
FIG. 26 : Treatment of IAV/S. aureus co-infected mice with LG-ASA results in enhanced survival and reduced body weight loss - (A) BALB/c mice (4 mice per group) were infected with 50 PFU of the influenza virus A/Puerto Rico/8/34 at
day 0. Onday 6 after influenza virus infection mice were additionally infected with 108CFU S. aureus 6850. Onday 7 after influenza virus infection co-infected mice were treated once a day with LG-ASA (1M, 10 min) via inhalation. Survival was monitored for 14 days. While (4/4) (black line) untreated co-infected mice died 1 day after co-infection, (2/4) LG-ASA treated co-infected mice survived (grey line).
(B) Two independent experiments are depicted. 9 weeks old Balb/C mice (4 mice per group) were infected with 50 PFU of influenza virus A/Puerto Rico/8/34 on day 0 (anesthesized with Isoflurane) in the morning. 6 hrs post viral infection mice were weighed and treated with aerosolic H2O or 1M LG-ASA in an inhalation chamber for 10 min. This treatment was also performed onday day 0. Onday 3 in the morning mice were infected with 5*107 CFU ofStaphylococcus aureus 6850 under anesthesia with Isoflurane. Onday 4 mice were weighed the last time. Statistical analysis was done using Mann-Whitney U Test (*p<0.05). - The following description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed inventions, or that any publication specifically or implicitly referenced is prior art.
- The above being said, the present invention relates to a MEK inhibitor, p38 inhibitor and/or NFκB inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection.
- In addition the present invention relates to a MEK inhibitor, p38 inhibitor and/or NFκB inhibitor for use in a method for the prophylaxis and/or treatment of a bacterial infection.
- When used herein, a “MEK inhibitor” may also be designated as a Mitogen Activated Protein kinase (MAPK) kinase inhibitor. It is known that in a MAPK pathway, a MAPK kinase kinase (MAPKKK) activates a MAPK kinase (MAPKK) which in turn activates a MAPK which transduces a signal to, for example, a transcription factor or other kinases or effector/signal transducing protein; see, for example,
FIG. 1 of Fremin and Meloche (Fremin and Meloche (2010), J. Hematol. Oncol. 11;3:8). MEK inhibitors of the invention preferably inhibit MEK1/2 of a subject, such as a mammal or bird as described herein. However, it may be that a MEK inhibitor of the invention does not only inhibit a MEK, preferably MEK1/2, but also its upstream kinase (i.e. MAPKKK), thereby exerting a dual inhibition. Without being bound by theory, PLX-4032 may be such a dual inhibitor. Hence, a MEK inhibitor of the invention may in a preferred aspect by a dual inhibitor, thereby inhibiting a MEK, preferably MEK1/2 and the corresponding upstream MAPKKK. MEK1/2 is the MAPKK in the Ras/Raf pathway, whereby Ras/Raf acts as MAPKKK and ERK1/2 acts as MAPK. - A MEK inhibitor can be a small molecule, large molecule, peptide, oligonucleotide, and the like. The MEK inhibitor may be a protein or fragment thereof or a nucleic acid molecule. Also included by the term MEK inhibitor is a pharmaceutically acceptable salt of the MEK inhibitor.
- The determination of whether or not a compound is a MEK inhibitor is within the skill of one of ordinary skill in the art. In one embodiment, the MEK inhibitors are selected from the group consisting of the compounds/inhibitors listed in table 1.
- The MEK inhibitors of the invention are selected preferably from U0126, PLX-4032, AZD6244, AZD8330, AS-703026, GSK-1120212, RDEA-119, RO-5126766, RO-4987655, CI-1040, PD-0325901, GDC-0973, TAK-733, PD98059, PD184352 ARRY-438162 and PF-3644022, preferably AZD8330, GSK-1120212, U0126, GDC-0973, CI-1040, PD0325901, ARRY-438162, PF-3644022 and AZD6244 and most preferably U0126, CI-1040, GDC-0973 (Cobimetinib), AZD8330, GSK-1120212, most preferably U0126, GDC-0973, CI-1040, AZD8330 and GSK-1120212.
- Some of these inhibitors are further described in table 1 below.
-
TABLE 1 MEK inhibitors. Structural formula I Cl-1040 2-(2-chloro-4-iodophenylamino)-N- (cyclopropylmethoxy)- 3,4-difluorobenzamide Structural formula II PD0325901 (R)-N-(2,3-dihydroxypropoxy)- 3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)benzamide Structural formula III AZD6244 6-(4-bromo-2-chlorophenylamino)- 7-fluoro-N-(2-hydroxyethoxy)-3-methyl- 3H-benzo[d]imidazole-5-carboxamide Structural formula IV GDC-0973 [3,4-difluoro-2-[(2-fluoro-4- iodophenyl)amino]phenyl] [3-hydroxy-3-[(2S)-2-piperidinyl]-1- azetidinyl]methanone Structural formula V RDEA-119 (S)-N-(3,4-difluoro-2- (2-fluoro-4-iodophenyl- amino)-6-methoxyphenyl)-1-(2,3- dihydroxypropyl)cyclopropane- 1-sulfonamide Structural formula VI GSK-1120212 N-(3-(3-cyclopropyl-5-(2- fluoro-4-iodophenylamino)- 6,8-dimethyl-2,4,7-trioxo- 3,4,6,7-tetrahydropyrido [4,3-d]pyrimidin-1(2H)- yl)phenyl)acetamide Structural formula VII AZD8330 2-(2-fluoro-4-iodophenylamino)-N- (2-hydroxyethoxy)-1,5-dimethyl-6-oxo- 1,6-dihydropyridine-3-carboxamide Structural formula VIII RO5126766 C20H16FN5O5S Structural formula IX RO4987655 C20H19F3IN3O5 Structural formula X TAK-733 (R)-3-(2,3-dihydroxypropyl)-6-fluoro-5- (2-fluoro-4-iodophenylamino)-8- methylpyrido[2,3-d] pyrimidine-4,7(3H,8H)-dione Structural formula XI PLX-4032 N-[3-[[5-(4-Chlorophenyl)- 1H-pyrrolo[2,3-b]pyridin-3- yl]carbonyl]-2,4-difluorophenyl]-1- propanesulfonamide Zelboraf (vemurafenib) Structural formula XII AS703026 (S)-N-(2,3-dihydroxypropyl)-3- (2-fluoro-4-iodophenylamino) isonicotinamide Structural formula XIII PD98059 2-(2-amino-3-methoxyphenyl)- 4H-chromen-4-one Structural formula XIV PD184352 2-(2-chloro-4-iodophenylamino)- N-(cyclopropylmethoxy)- 3,4-difluorobenzamide - Also preferred is a selection from PLX-4032, AZD6244, AZD8330, GDC-0973, RDEA119, GSK1120212, RO51267766, RO4987655, TAK-733, and AS703026. Even more preferably, they are selected from AZD6244, AZD8330, GSK1120212 and PLX-4032 or from PD-0325901, AZD-6244, AZD-8330 and RDEA-119. These MEK inhibitors are known in the art and, for example, described in Table 1 of Fremin and Meloche (2010), J. Hematol. Oncol. 11;3:8.
- More information on some of these inhibitors can also be obtained from Arthur and Ley (2013) Mitogen-activated protein kinases in innate immunity; Nature Reviews Immunology 13,679-692 (2013).
- Indeed, as demonstrated in the appended Examples, the MEK inhibitor U0126 and CI-1040 disclosed herein show an effect in co-infection scenarios as well as on bacterial infection alone.
- Also a p38 inhibitor is provided for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention. A “p38 MAP kinase inhibitor” is well known in the art. The terms “p38 inhibitor,” “p38 kinase inhibitor,” and “p38 MAP kinase inhibitor” are used interchangeably herein. In the context of the present invention a p38 MAP kinase inhibitor inhibits p38 MAP kinase. Preferably, the p38 MAP kinase inhibitor inhibits one of the isoforms of p38 MAP kinase, preferably one of the four isoforms (α, β, γ or δ) of p38 MAP kinase with the α-isoform being preferred, more preferably it inhibits any combination of two isoforms of p38 MAP kinase, even more preferably it inhibits any combination of three isoforms of p38 MAP kinase and most preferably, it inhibits all isoforms or the α, β, γ and δ isoform of p38 MAP kinase. In some embodiments, the p38 MAP kinase inhibitor inhibits the isoform of p38 that is involved in inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, viral diseases or neurodegenerative diseases. It is reported that the α-isoform of p38 MAP kinase is involved in inflammation, proliferation, differentiation and apoptosis, whereas the biological functions of p38β, p38δ and p38γ are not yet understood completely. Accordingly, it is preferred herein that the p38 MAP kinase inhibitor inhibits the α-isoform.
- A p38 MAP kinase inhibitor can be a small molecule, large molecule, peptide, oligonucleotide, and the like. The p38 MAP kinase inhibitor may be a protein or fragment thereof or a nucleic acid molecule. Also included by the term p38 inhibitor is a pharmaceutically acceptable salt of the 38 inhibitor.
- The determination of whether or not a compound is a p38 kinase inhibitor is within the skill of one of ordinary skill in the art.
- There are many examples of p38 inhibitors in the art. U.S. Pat. Nos. 5,965,583, 6,040,320, 6,147,096, 6,214,830, 6,469,174, 6,521,655 disclose compounds that are p38 inhibitors. U.S. Pat. Nos. 6,410,540, 6,476,031 and 6,448,257 also disclose compounds that are p38 inhibitors. Similarly, U.S. Pat. Nos. 6,410,540, 6,479,507 and 6,509,361 disclose compounds that are asserted to be p38 inhibitors. U.S. Published Application Nos. 20020198214 and 20020132843 disclose compounds that are said to be p38 inhibitors. Another p38 MAP kinase inhibitor is
BIRB 796 BS (1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)- naphthalen-1-yl]-urea); see Branger (2002), J. Immunol. 168:4070-4077 or U.S. Pat. No. 6,319,921 for further p39 MAP kinase inhibitors. - Other p38 MAP kinase inhibitors are AMG 548 (Amgen), BIRB 796 (Boehringer Ingelheim), VX 702 (Vertex/Kissei),
SCIO 469, SCIO 323 (Scios Inc.), SB 681323 (GlaxoSmithKline), PH-797804 (Pfizer) and Org-48762-0 (Organon NV); see, for example, Lee and Dominguez in Curr Med Chem. 2005; 12(25):2979-2994 and Dominguez in Curr Opin Drug Discov Devel. 2005 July; 8(4):421-430. - According to the present invention, the inhibitor may exhibit its regulatory effect upstream or downstream of p38 MAP kinase or on p38 MAP kinase directly, with the latter mode of action being preferred. Examples of inhibitor regulated p38 MAP kinase activity include those where the inhibitor may decrease transcription and/or translation of p38 MAP kinase, may decrease or inhibit post-translational modification and/or cellular trafficking of p38 MAP kinase, or may shorten the half-life of p38 MAP kinase. The inhibitor may also reversibly or irreversibly bind p38 MAP kinase, inhibit its activation, inactivate its enzymatic activity, or otherwise interfere with its interaction with downstream substrates.
- The four isoforms of the p38 MAP kinase share a high level of sequence homology. The alpha and beta isoforms of the p38 MAP kinase are closely related while the gamma and delta isoforms are more divergent. Given the high degree of structural similarity, it is not surprising that certain compounds with the ability to inhibit one p38 MAP kinase isoform can often inhibit other isoforms of the MAP kinase. Accordingly, in some embodiments, an inhibitor of p38 MAP kinase that is specific for the α-isoform of the kinase possesses at least three categories of structural features that are theorized to permit isoform specific inhibition.
- Selective binding of a candidate p38 MAP kinase inhibitor can be determined by a variety of methods. The genes for the various isoforms of p38 MAP kinase are known in the art. One of ordinary skill in the art could readily clone and express the various isoforms of the kinase, purify them, and then perform binding studies with candidate compounds to determine isoform binding characteristics. This series of experiments was performed for the α-isoform of p38 MAP kinase and provided in U.S. Pat. No. 6,617,324 B1.
- Another kinase selectivity assay is described in Mihara (2008), Br. J. Pharmacol. 154(1):153-164. In some embodiments herein, a p38 MAP kinase inhibitor inhibits one of the four isoforms of p38 MAP kinase, more preferably it inhibits any combination of two isoforms of p38 MAP kinase, even more preferably it inhibits any combination of three isoforms of p38 MAP kinase, e.g., p38-α(MAPK14), -β(MAPK11), -γ(MAPK12 or ERK6). Alternatively, but also preferred, it inhibits all four isoforms of p38 MAP kinase.
- In one embodiment, the p38 inhibitor is selected from the group consisting of the inhibitors listed in table 2 (
FIG. 8 ). In another embodiment, the p38 inhibitor is selected from the group consisting of SB202190, LY2228820, CAY10571,SB 203580, Tie2 Kinase Inhibitor, 2-(4-Chlorophenyl)-4-(fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one,CGH 2466, SB220025, Antibiotic LL Z1640-2,TAK 715, SB202190 hydrochloride,SKF 86002, AMG548, CMPD-1,EO 1428,JX 401,ML 3403,RWJ 67657,SB 202190,SB 203580,SB 203580 hydrochloride,SB 239063,SCIO 469,SX 011,TAK 715, Pamapimod, Losmapimod (GW856553), Dilmapimod (SB681323),VX 702,VX 745, Doramapimod (BIRB 796), BMS-582949, ARRY-797, PH797804, SCIO-469, preferably VX-702, SB202190, Pamapimod, Losmapimod (GW856553), Dilmapimod (SB681323), Doramapimod (BIRB 796), BMS-582949, ARRY-797, PH797804 and SCIO-469. - More information on some of these inhibitors can also be obtained from Arthur and Ley (2013) Mitogen-activated protein kinases in innate immunity; Nature Reviews Immunology 13,679-692 (2013).
- In addition to the MEK inhibitor and the p38 inhibitor, the present invention is also directed to a NFκB (NFκB/NFkappaB) inhibitor for use in the methods for the prophylaxis and/or treatment of a co-infection or bacterial infection of the present invention. The determination of whether or not a compound is a NFκB inhibitor is within the skill of one of ordinary skill in the art.
- NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein complex that controls transcription of DNA. NF-κB is found in almost all animal cell types and is involved in cellular responses to stimuli such as stress, cytokines, free radicals, ultraviolet irradiation, oxidized LDL, and bacterial or viral antigens. Vertebrate NFκB transcription complexes can be any of a variety of homo- and heterodimers formed by the subunits p50 (NFκB1), p52 (NFκB2), c-Rel, RelA (p65) and RelB (Gilmore T D. (2006) Oncogene 25: 6680-6684). These complexes bind to DNA regulatory sites called κB sites, generally to activate specific target gene expression. In most cell types, NF-κB dimers are located in the cytoplasm in an inactive form through association with any of several IκB inhibitor proteins (IκB α, β, ϵ, γ, p105 and p100). In response to a wide array of stimuli IκB is rapidly phosphorylated, ubiquitinated and degraded by the proteasome. The freed NF-κB dimer then translocates to the nucleus where it can modulate specific gene expression.
- The phosphorylation and degradation of IκB is important for the regulation of NFκB complexes, which is mediated by the IκB kinase (IKK) complex containing two kinase subunits, IKKα and IKKβ, and an associated scaffold-like regulatory protein called NEMO (aka IKKγ) (Gilmore and Herscovich (2006) Inhibitors of NF-κB signaling: 785 and counting Oncogene. 25, 6887-6899). Notably, as for example shown in Example 3 of the present invention, NE-κB signaling is also important for bacterial (such as S. aureus) internalisation into cells.
- According to the present invention, the inhibitor may exhibit its regulatory effect upstream or downstream of NFκB or directly on NFκB, with the latter mode of action being preferred. Examples of inhibitors regulating NFκB activity include those where the inhibitor may decrease transcription and/or translation of NFκB, or may shorten the half-life of NFκB. The inhibitor may also reversibly or irreversibly bind NFκB, inhibit its activation, inactivate its activity, or otherwise interfere with its interaction with downstream targets, such as targets on genes. Also, an NFκB inhibitor can inhibit protein kinases such as molecules which inhibit IkBa phosphorylation by e.g. IKK inhibition. Compounds that have such an activity are SC-893, BMS-345541, which may serve as reference compounds. Also a NFκB inhibitor may inhibit protein phosphatases, or inhibit the proteasome, or ubiquitination. Examples of such NFκB inhibitors, which may also serve as reference compounds include protein tyrosine phosphatase inhibitors, boronate, bortezomib, NPI-0052. Alternatively, a NFκB inhibitor may block the nuclear translocation of NFκB, or its binding to DNA. Examples of such inhibitors include, which may also serve as reference compounds, SN50, dehydroxymethylepoxyquinomicin and NFκB decoy ODNs. Further information on inhibitor of NFκB can be obtained from Gupta et al. (2010) (Gupta et al. (2010) Inhibiting NFκB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta. 1799(10-12): 775-787).
- A NFκB inhibitor can be a small molecule, large molecule, peptide, oligonucleotide, and the like. The NFκB inhibitor may be a protein or fragment thereof or a nucleic acid molecule. Also included by the term NFκB inhibitor is a pharmaceutically acceptable salt of the NFκB inhibitor. In one embodiment, the NFκB inhibitor is selected from the group consisting of the inhibitors/molecules as listed in tables 3 and 4 in
FIGS. 9 and 10 . In another embodiment, the NFκB inhibitor is selected from the group consisting of the inhibitors/molecules as listed in table 3 inFIG. 9 . In another embodiment, the NFκB inhibitor is selected from the group consisting of the inhibitors/molecules as listed in table 4 inFIG. 10 . - In another embodiment, the NFκB inhibitor is selected from the group consisting of LASAG, SC75741 (and derivatives), MG 132, TPCA-1, PCTC, IMD 0354, Luteolin, Caffeic acid phenethyl ester, Cardamonin, PF 184, IKK 16, SC 514, Withaferin A, Arctigenin, Bay 11-7085, PSI, PR 39, Ro 106-9920, Bay 11-7821, ML-130, Celastrol, Tanshinone IIA, HU 211, Gliotoxin, CID 2858522, Honokiol, Andrographolide, 10Z-Hymenialdisine, ACHP, Pristimerin, Sulfasalazine, ML 120B dihydrochioride, Amlexanox, 9-Methylstreptimidone, N-Stearoyl phytosphingosine, 2-(1,8-naphthyridin-2-yl)-Phenol, 5-Aminosalicylic acid, BAY 11-7085, Ethyl 3,4-Dihydroxycinnamate, Helenalin, NF-κB Activation Inhibitor II, JSH-23, Glucocorticoid Receptor Modulator, CpdA, PPM-18, aspirin (ASA), Pyrrolidinedithiocarbamic acid ammonium salt, (R)-MG132, SC75741 (and derivatives), Rocaglamide, Sodium salicylate, QNZ, PS-1145, CAY10512, bortezomib, salsalate, resveratrol, LASAG, deoxyspergualin, sulindac, thalidomide, AGRO-100, CHS 828 and/or Curcumin, preferably bortezomib, curcumin, salsalate, resveratrol, sodium salicylate, LASAG, ASA, deoxyspergualin, sulindac, thalidomide, AGRO-100, CHS 828 even more preferably SC75741 (and derivatives) ASA and LASAG and most preferably LASAG.
- With the term “SC75741” or “SC75741 (and derivates)” in addition to SC75741 also derivates of SC75741 are envisaged by the present invention.
- In general a person skilled in the art knows how to find out if a compound is an MEK inhibitor, p38 inhibitor and/or NFκB inhibitor. A further example of how one could determine if a compound is a MEK inhibitor and/or p38 inhibitor would be to isolate the MEK and/or p38 NFκB protein. The protein can be isolated from cells where the MEK and/or p38 protein is naturally expressed or where it has been overexpressed by means of transfection of an oligonucleotide or infection with a virus that directs the expression of the MEK and/or p38 protein, Additionally, MEK and/or p38 protein can also be expressed recombinantly. Upon isolating the protein a person of ordinary skill in the art can measure the activity of the kinase in the presence or absence of a potential MEK and/or p38 inhibitor. If the kinase activity is less in the presence than in the absence of an alleged inhibitor, that inhibitor is a MEK and/or p38, respectively.
- If acting on MEK and/or p38 directly, the inhibitor should exhibit an IC50 value of about 5 μM or less, preferably 500 nm or less, more preferably 100 nm or less. In a related embodiment, the inhibitor should exhibit an IC50 value relative to the p38-α isoform that is preferably at least ten fold less than that observed when the same inhibitor is tested against other p38 MAP kinase isoforms in the same or comparable assay. It should be noted that IC50 values are assay dependent and may change from determination to determination. It is more important to look at relative relationships of compounds' IC50 values rather than the exact values themselves.
- An IC50 is the concentration of compound which inhibits the enzyme to 50% of the activity as measured in the absence of an inhibitor.
- IC50 values are calculated using the concentration of inhibitor that causes a 50% decrease as compared to a control. IC50 values are assay dependent and will vary from measurement to measurement. As such, IC50 values are relative values. The values assigned to a particular inhibitor are to be compared generally rather than on an absolute basis.
- Samples or assays comprising MAP and/or MAPK kinase that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with inhibitors) can be assigned a relative MAP and/or MAPK kinase activity value of 100%. Inhibition of MAP and/or MAPK kinase is achieved when the MAP and/or MAPK kinase activity value relative to the control is about 80%, optionally 50% or 25-0%. Activation of MAP and/or MAPK kinase is achieved when the MAP kinase activity value relative to the control is 110%, optionally 150%, optionally 200-500%, or 1000-3000% higher. Exemplary MAP kinase binding activity assays of the present invention are: a MAP and/or MAPK kinase ligand blot assay (Aymerich et al., Invest Opthalmol Vis Sci. 42:3287-93, 2001); a MAP and/or MAPK kinase affinity column chromatography assay (Alberdi et al., J Biol Chem. 274:31605-12, 1999) and a MAP and/or MAPK kinase ligand binding assay (Alberdi et al., J Biol Chem. 274:31605-12, 1999). Each incorporated by reference in their entirety.
- Also the selectivity of the inhibitors may be measured by a kinase selectivity assay is described in Mihara (2008), Br. J. Pharmacol. 154(1):153-164.
- In the case of the NFκB inhibitor one can measure for example the gene products (proteins) of target genes of NFκB in a non-treated control cell and compare the expression of these target gene products to a cell, which has been treated with a NFκB Inhibitor. Some target genes are described in Oeckinghaus and Ghosh (2009) The NF-κB Family of Transcription Factors and Its Regulation. Cold Spring Harb Perspect Biol. October 2009; 1(4): a000034.
- The expression level is reduced, when the cell treated with the inhibitor. Other strategies may be to detect IkBa degradation together with p-p65 accumulation and nuclear translocation of NFκB by Westernblot. Also NFκB interactions with DNA of cells not treated with an inhibitor compared to cells that have been treated with an inhibitor may be analysed by using an electrophoretic mobility shift assay (EMSA).
- The inhibitory properties of a molecule can also be analysed by comparing its action to a reference compound. A “reference compound” as referred to herein means a compound, which may be used as a positive control for the determination if a molecule has MEK inhibitor, p38 inhibitor and/or NFκB inhibitor properties. As such also any of the inhibitors listed herein may be used as such a reference compound. A possible test may be one in which cells, which are e.g. stimulated to activate the MEK, p38 and or NFκB pathway are treated with a reference compound and in parallel e.g. in a different well with a compound of interest.
- The inhibitors of the present invention can be used in a method for treating and/or prophylaxis. As such the term “treating” or “treatment” includes administration of a MEK inhibitor, p38 Inhibitor, and/or NFκB inhibitor preferably in the form of a medicament, to a subject suffering from a coinfection comprising a bacterial infection and an influenza virus infection for the purpose of ameliorating or improving symptoms. Similarly included is the administration of a MEK inhibitor, p38 Inhibitor, and/or NFκB inhibitor preferably in the form of a medicament, to a subject suffering from a bacterial infection for the purpose of ameliorating or improving symptoms.
- Furthermore, the terms “prophylaxis” as used herein, refers to any medical or public health procedure whose purpose is to prevent a disease. As used herein, the terms “prevent”, “prevention” and “preventing” refer to the reduction in the risk of acquiring or developing a given condition, namely a coninfection comprising an influenza virus infection and a bacterial infection or a bacterial infection alone. Also meant by “prophylaxis” is the reduction or inhibition of the recurrence of a coninfection comprising an influenza virus infection and a bacterial infection or a bacterial infection alone in a subject.
- The inhibitors of the present invention are effective in treating a coinfection. A “co-infection” as used herein comprises an influenza virus infection and a bacterial infection. Such a coinfection can take place by simultaneous infection of a host e.g. a subject and/or single cell with a bacterium and an influenza virus. It can also be that a host e.g. a subject and/or cell is simultaneously infected with one or more viral particles and one or more bacteria. However, such a coinfection can also take place sequentially. In such a case is firstly infected with one or more viral particles and later in time the same host and/or cell becomes infected with one or more bacteria or vice versa. The time period between the two infections can be a time period of at most 14 days, 13 days, 12 days, 11 days, 10 days, 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days, 2 days, 1 day, 12 hours, 6 hours, 3 hours, 1.5 hours or at minimum 30 minutes.
- Such a situation may also be a superinfection, in which a second infection is superimposed on an earlier one especially by a different microbial agent of exogenous or endogenous origin that is resistant to the treatment used against the first infection.
- Within the co-infection the influenza virus infection can be mediated by influenza A virus or influenza B virus, preferably the influenza A virus is H1N1, H2N2, H3N2, H6N1, H7N7, H7N9, H9N2 H10N7, H10N8 or H5N1. In one embodiment, the influenza A virus is H1N1. In other embodiments, the influenza A virus is H3N2, H5N1 and H7N9. In additional embodiments, the influenza A virus is H3N2, H5N1, H1N1 and H7N9.
- The present invention also relates to a “bacterial infection” which can take place in the setting of a co-infection described above or can occur as the only infection present in a host e.g. a subject and/or cell. The bacterial infection can be mediated by any bacterium, preferably it is mediated by a bacterium selected from the group consisting of Staphylococcaceae, Streptococcaceae, Legionellaceae, Pseudomonadaceae, Chlamydiaceae, Mycoplasmataceae, Enterobacteriaceae, Pseudomonadales and/or Pasteurellaceae.
- In other embodiments the bacterial infection is mediated by a bacterium selected from the group consisting of of Staphylococcus, preferably Staphylococcus aureus, methicillin sensitive and methicillin resistant Staphylococcus aureus, Panton-Valentine leukocidin (PVL)-expressing Staphylococcus aureus and/or Streptococcaceae, preferably Streptococcus mitis, Streptococcus pyogenes or Streptococcus pneumonia, Legionella, preferably Legionella pneumophila, Pseudomonas, preferably Pseudomonas aeruginosa, Chlamydophila, preferably Chlamydophila pneumonia, Mycoplasma, preferably Mycoplasma pneumonia, Klebsiella, preferably Klebsiella pneumonia, Moraxella, preferably Moraxella catarrhalis and/or Haemophilus, preferably Haemophilius influenza. Preferably the bacterium is selected from the group consisting of Staphylococcus aureus, Streptococcus pneumonia or Haemophilius influenza. Most preferably the bacterium is Staphylococcus aureus.
- It is also envisaged by the present invention that the inhibitors can be combined with each other. As such in one embodiment the MEK inhibitor is combined with another MEK inhibitor, the p38 inhibitor and/or the NFκB inhibitor. In further embodiments, the p38 inhibitor is combined with another p38 inhibitor, the MEK inhibitor and/or the NFκB inhibitor. In another embodiment the NFκB inhibitor is combined with another NFκB inhibitor, the p38 inhibitor and/or the MEK inhibitor. With respect to the above, the term “another inhibitor” is used to clarify that e.g. one MEK inhibitor can also be combined with another MEK inhibitor, while these two MEK inhibitors are not the same. E.g. the MEK inhibitor CI-1040 can be combined with the MEK inhibitor GDC-0973. This equally relates to the p38 and NFκB inhibitors.
- In one embodiment, the MEK inhibitor, the p38 inhibitor and/or the NFκB inhibitor is/are administered contemporaneously, previously or subsequently to the one or more additional inhibitors targeting the influenza virus and the bacterium.
- In further embodiments, the MEK inhibitor, p38 inhibitor and/or NFκB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection of the present invention, wherein the MEK inhibitor, the p38 inhibitor and/or the NFκB inhibitor are combined with one or more inhibitors targeting the influenza virus and/or the bacterium. In one embodiment, the MEK inhibitor, the p38 inhibitor and/or the NFκB inhibitor is/are administered contemporaneously, previously or subsequently to the one or more inhibitors targeting the influenza virus and/or the bacterium.
- In general, an inhibitor targeting the influenza virus is any inhibitor or medicament effective in influenza therapy. Different substances are known to be effective in reducing an influenza infection. Among them are for example neuraminidase inhibitors, compounds targeting an ion channel protein (M2) and compounds targeting polymerase or endonuclease activity via interfering with a component of the viral polymerase complex, PB1, PB2, PA or NP. By the invention also pharmaceutically acceptable salts of these inhibitors are envisioned.
- A “neuraminidase inhibitor” is an antiviral drug targeted at influenza virus, which works by blocking the function of the viral neuraminidase protein, thus preventing the virus from binding to a cell it aims to infect and/or preventing the virus from reproducing by budding from the host cell, since the newly produced viruses cannot bud off from the cell in which they have replicated. Also comprised are pharmaceutically acceptable salts of a neuraminidase inhibitor. Preferred neuraminidase inhibitors are oseltamivir, zanamivir, peramivir, or a pharmaceutically acceptable salt of any of these substances, such as oseltamivir phosphate, oseltamivir carboxylate, etc. Most preferred neuraminidase inhibitors are oseltamivir phosphate, zanamivir, oseltamivir or peramivir.
- Compounds targeting an ion channel protein (M2) are for example amantadine and/or rimantadine, while compounds targeting polymerase or endonuclease activity via interfering with a component of the viral polymerase complex, PB1, PB2, PA or NP are for example the NP blocker Nucleozin or the polymerase inhibitor T-705.
- Alternatively or additionally, the MEK inhibitor, p38 inhibitor and/or NFκB inhibitor can be combined with one or more inhibitors targeting the bacterium. An inhibitor targeting the bacterium can be any inhibitor effective in reducing bacterial infection. A preferred inhibitor, well known to the skilled artesian is an antibiotic. Preferred antibiotics can be obtained from table 5 (
FIG. 11 ). Thus, in one embodiment, the antibiotic is selected from the group consisting of the antibiotics as listed in table 5 (FIG. 11 ). In a further embodiment, the antibiotic is selected from the group consisting of the class of antibiotics as listed in table 5 (FIG. 11 ). In another embodiment, the antibiotic is selected from the group consisting of the generic name of the antibiotics as listed in table 5 (FIG. 11 ). More preferred are antibiotics selected from Gentamicin, Rifampicin, Lysosthaphin, Erythromycin, Levofloxacin, Vancomycin, Teicoplanin, Penicillin and Oxacillin. - The “subject”, which may be treated by the inhibitors or combinations of inhibitors of the present invention preferably, is a vertebrate. In the context of the present invention the term “subject” means an individual in need of a treatment of a co-infection or a bacterial infection alone. Preferably, the subject is a patient suffering from a co-infection or a bacterial infection alone or being at a risk thereof. Preferably, the patient is a vertebrate, more preferably a mammal. Mammals include, but are not limited to, farm animals, sport animals, pets, primates, mice and rats. Preferably, a mammal is as a human, dog, cat, cow, pig, mouse, rat etc., particularly preferred, it is a human. In some embodiments, the subject is a human subject, which optionally is more than 1 year old and less than 14 years old; between the ages of 50 and 65, or older than 65 years of age. In other embodiments the the subject is a human subject, which is selected from the group consisting of subjects who are at least 50 years old, subjects who reside in chronic care facilities, subjects who have chronic disorders of the pulmonary or cardiovascular system, subjects who required regular medical follow-up or hospitalization during the preceding year because of chronic metabolic diseases, renal dysfunction, hemoglobinopathies, or immunosuppression, subjects with less than 14 years of age, subjects between 6 months and 18 years of age who are receiving long-term aspirin therapy, and women who will be in the second or third trimester of pregnancy during the influenza season.
- In the method of the invention, the MEK inhibitor, p38 inhibitor or NFκB inhibitor as well as the inhibitor targeting the influenza virus and the inhibitor targeting the bacterium may be administered orally, intravenously, intrapleurally, intramuscularly, topically or via inhalation. Preferably, the MEK inhibitor is administered via nasal inhalation or orally.
- The present invention also envisages different compositions. The present invention relates to a composition comprising a MFK inhibitor, a p38 inhibitor and/or a NFκB inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection. The present invention similarly relates composition comprising a MEK inhibitor, a p38 inhibitor and/or a NFκB inhibitor for use in a method for the prophylaxis and/or treatment of a bacterial infection. Also provided for by the present invention is a composition comprising a MEK inhibitor, a p38 inhibitor and/or a NFκB inhibitor and one or more inhibitors targeting the influenza virus and/or the bacterium for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection. In addition, the present invention relates to a composition comprising a MEK inhibitor, a p38 inhibitor and/or a NFκB inhibitor and one or more inhibitors targeting the the bacterium for use in a method for the prophylaxis and/or treatment of a bacterial infection.
- The composition comprising the MEK inhibitor, the p38 inhibitor and/or the NFκB inhibitor and additionally eventually one or more inhibitors targeting the the bacterium and/or one or more inhibitors targeting the influenza virus may be a pharmaceutical composition. Preferably, such compositions further comprise a carrier, preferably a pharmaceutically acceptable carrier. The composition can be in the form of orally administrable suspensions or tablets; nasal sprays, sterile injectable preparations (intravenously, intrapleurally, intramuscularly), for example, as sterile injectable aqueous or oleaginous suspensions or suppositories. When administered orally as a suspension, these compositions are prepared according to techniques available in the art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners/flavoring agents known in the art. As immediate release tablets, these compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents, and lubricants known in the art. The injectable solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
- The inhibitor or inhibitors are preferably administered in a therapeutically effective amount.
- The pharmaceutical composition for the use of the invention and comprising a MEK inhibitor, a p38 inhibitor and/or a NFκB inhibitor and optionally one or more inhibitors targeting an influenza virus and/or one or more inhibitors targeting a bacterium is administered to a patient which is a mammal or a bird. Examples of suitable mammals include, but are not limited to, a mouse, a rat, a cow, a goat, a sheep, a pig, a dog, a cat, a horse, a guinea pig, a canine, a hamster, a mink, a seal, a whale, a camel, a chimpanzee, a rhesus monkey and a human, with human being preferred. Examples of suitable birds include, but are not limited to, a turkey, a chicken, a goose, a duck, a teal, a mallard, a starling, a Northern pintail, a gull, a swan, a Guinea fowl or water fowl to name a few. Human patients are a particular embodiment of the present invention.
- The “therapeutically effective amount” for each active compound/inhibitor can vary with factors including but not limited to the activity of the compound used, stability of the active compound in the patient's body, the severity of the conditions to be alleviated, the total weight of the patient treated, the route of administration, the ease of absorption, distribution, and excretion of the active compound by the body, the age and sensitivity of the patient to be treated, adverse events, and the like, as will be apparent to a skilled artisan. The amount of administration can be adjusted as the various factors change over time.
- The inhibitors, methods and uses described herein are applicable to both human therapy and veterinary applications. The compounds described herein, in particular, MEK inhibitor, a p38 inhibitor and/or a NFκB inhibitor and optionally one or more inhibitors targeting an influenza virus and/or one or more inhibitors targeting a bacterium having the desired therapeutic activity may be administered in a physiologically acceptable carrier to a subject, as described herein. Depending upon the manner of introduction, the compounds may be formulated in a variety of ways as discussed below. The concentration of therapeutically active compound in the formulation may vary from about 0.1-100 wt %. The agents maybe administered alone or in combination with other treatments.
- The pharmaceutical compounds in the method of present invention can be administered in any suitable unit dosage forms. Suitable oral formulations can be in the form of tablets, capsules, suspension, syrup, chewing gum, wafer, elixir, and the like. Pharmaceutically acceptable carriers such as binders, excipients, lubricants, and sweetening or flavoring agents can be included in the oral pharmaceutical compositions. If desired, conventional agents for modifying tastes, colors, and shapes of the special forms can also be included.
- For injectable formulations, the pharmaceutical compositions can be in lyophilized powder in admixture with suitable excipients in a suitable vial or tube. Before use in the clinic, the drugs may be reconstituted by dissolving the lyophilized powder in a suitable solvent system to form a composition suitable for intravenous or intramuscular injection.
- In accordance with another embodiment of the present invention, a pharmaceutical composition is provided, comprising a therapeutically effective amount of a a MEK inhibitor, a p38 inhibitor and/or a NFκB inhibitor as well as a therapeutically effective amount of a neuraminidase inhibitor chosen from the group of oseltamivir, oseltamivir phosphate, zenamivir and peramivir.
- In one embodiment, the composition can be in an orally administrable form (e.g., tablet or capsule or syrup etc.) with a therapeutically effective amount (e.g., from 0.1 mg to 2000 mg, 0.1 mg to 1000 mg, 0.1 to 500 mg, 0.1 to 200 mg, 30 to 300 mg, 0.1 to 75 mg, 0.1 to 30 mg) of a MEK inhibitor, a p38 inhibitor and/or a NFκB inhibitor and a therapeutically effective amount (e.g., from 0.1 mg to 2000 mg, 0.1 mg to 1000 mg, 0.1 to 500 mg, 0.1 to 200 mg, 30 to 300 mg, 0.1 to 75 mg, 0.1 to 30 mg) of neuraminidase inhibitor as described above.
- In further embodiments, the MEK inhibitor, p38 inhibitor and/or NFκB Inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a co-infection of the present invention, wherein the MEK inhibitor, the p38 inhibitor and/or the NFκB inhibitor reduces both the viral and bacterial infection, when contacting it/them with an in vitro test system, wherein the test system comprises cultured cells infected with
-
- a) an influenza virus and
- b) a bacterium
when compared to the in vitro test system before the contacting. In another embodiment, the MEK inhibitor, p38 inhibitor and/or NFκB inhibitor is/are for use in the methods for the prophylaxis and/or treatment of a bacterial infection of the present invention, wherein the MEK inhibitor, the p38 inhibitor and/or the NFκB inhibitor reduces the bacterial infection, when contacting it/them with an in vitro test system, wherein the test system comprises cultured cells infected with a bacterium, when compared to the in vitro test system before the contacting.
- As such the present invention also relates to an in vitro test system, wherein the test system comprises cultured cells infected with
-
- a) an influenza virus and
- b) a bacterium.
Along this line, the present invention also provides for an in vitro test system, wherein the in vitro test system comprises cultured cells infected with a bacterium.
- In the cases where the in vitro test system includes a viral and bacterial infection, again, these infections can be taking place sequentially or simultaneously.
- A “cultured cell” or “cultured cells” is/are cells, which are not present in their natural environment e.g. within a plant or animal. Rather a cultured cell may be a primary cell culture, which comprises cells isolated from their natural environment, or a cell line. Preferably the cultured cells are human lung epithelial cells. Preferably, the cultured cells are seeded at a density of about 1×105, 2×105, 3×105, 4×105, 5×105, 6×105, 7×105, 8×105, 9×105, 10×105, 11×105 most preferably 8×105 cells in 0.5 ml, 1 ml, 1.5 ml, 2 ml, 2.5 ml, 3 ml, 3.5 ml, 4 ml medium such as DMEM. Most preferred is a density of 8×105 cells per in 2 ml DMEM.
- Such cultured cells are infected with a virus and a bacterium or in other embodiments with a bacterium alone. As already described above, a co-infection can take place in a sequential or simultaneous manner. For example the cultured cells may be infected first with the influenza virus and 30 minutes later with bacterium/bacteria. It is also possible to additionally add an antibiotic to the culture after 3 hours, to remove extracellular bacteria. In such a scenario the antibioticum would then become washed off again. In other embodiments, the cells are only infected with a bacterium.
- The term “contacting” as used herein refers to the bringing of a cell comprising an influenza virus and a bacterium spatially into close proximity to a MEK inhibitor, a p38 inhibitor and/or a NFκB inhibitor.
- This can for example mean that an inhibitor is applied to the medium in which the cultured cells are located via a syringe.
- Upon contacting then, if the inhibitor is active, the viral infection as well as the bacterial infection becomes reduced. In some embodiments, again, the inhibitor of the present invention is used to reduce only a bacterial infection in the absence of an influence virus infection.
- In one embodiment, the reduction of the viral infection is a reduction in plaque forming units (pfu)/ml and the reduction in the bacterial infection is a reduction in colony forming units (CFU)/ml. The “plaque forming units (pfu)/ml” is a measure of the number of particles capable of forming plaques per unit volume, such as virus particles. It is a functional measurement rather than a measurement of the absolute quantity of particles: viral particles that are defective or which fail to infect their target cell will not produce a plaque and thus will not be counted. For example, a solution of influenza virus with a concentration of 1,000 PFU/μl indicates that 1 μl of the solution contains enough virus particles to produce 1000 infectious plaques in a cell monolayer. In the case of the present invention, a cell culture treated with an inhibitor shows a reduced number of plaque forming units in a culture after the treatment, when compared to a culture before the treatment with an inhibitor of the present invention.
- A possible “reduction in plaque forming units (pfu)/ml” is analysed in the following way. First the cultured cells, which are co-infected with an influenza virus and a bacterium are analysed for their ability to generate plaque forming units (pfu)/ml by e.g. sucking of some cells from the petridish and plating them for counting the bacterial plaques that will form. This result is then compared to the number of plaque forming units (pfu)/ml generated by cells of the same culture after the inhibitor was applied. If the number of the plaque forming units (pfu)/ml is reduced after the treatment with an inhibitor compared to the number generated before the application of the inhibitor, there is a reduction in the plaque forming units.
- The “colony forming units (CFU)/ml” estimates the number of viable bacteria in a sample. Different methods exist. For example to generate colony forming units a sample (e.g. cultured cells in a small volume) are spread across the surface of a nutrient agar plate and allowed to dry before incubation for counting. A viable bacterium is defined as the ability to multiply via binary fission under the controlled conditions. The visual appearance of a colony in a cell culture requires significant growth—when counting colonies it is uncertain if the colony arose from one cell or 1,000 cells. Therefore results are reported as CFU/ml (colony-forming units per milliliter) for liquids, and CFU/g (colony-forming units per gram) for solids to reflect this uncertainty (rather than cells/ml or cells/g).
- “Colony forming units (CFU)/ml” can be analysed in the following way. First the cultured cells, which are co-infected with an influenza virus and a bacterium or with a bacterium alone are analysed for their ability to generate colony forming units (CFU)/ml by e.g. sucking of some cells from the petridish and plating them for counting. This result is then compared to the number of colony forming units (CFU)/ml generated by cells of the same culture after the inhibitor was applied. If the number of the colony forming units (CFU)/ml is reduced to the number generated before the application of the inhibitor, there is a reduction.
- In general the person skilled in the art knows these well known techniques of analyzing bacterial and viral infections. How one can measure the plaque forming units (pfu)/ml and the colony forming units (CFU)/ml is further described in the literature (Tuchscherr, L. et al. (2011). Staphylococcus aureus phenotype switching: an effective bacterial strategy to escape host immune response and establish a chronic infection (EMBO
molecular medicine 3, 129-141 and Hrincius, E. R et al. (2010) CRK adaptor protein expression is required for efficient replication of avian influenza A viruses and controls JNK mediated apoptotic responses.Cellular microbiology 12, 831-843). - In addition the present invention relates to the following items:
-
Item 1. The invention also provides for the use of the in vitro test system of of the present invention for the determination of inhibitors effective in reducing a coinfection comprising a bacterial infection and an influenza virus infection. In one embodiment, the reduction of the viral infection is a reduction in plaque forming units (pfu)/ml and the reduction in the bacterial infection is a reduction in colony forming units (CFU)/ml. -
Item 2. In addition the present invention relates to a method for detecting molecules effective in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection comprising contacting the in vitro test system of the present invention with a compound of interest, wherein the compound of interest reduces both the viral and bacterial infection, compared to the in vitro test system before the contacting. In one embodiment, the reduction of the viral infection is a reduction in plaque forming units (pfu)/ml and the reduction in the bacterial infection is a reduction in colony forming units (CFU)/ml. -
Item 3. The present invention, in addition, relates to a use of the in vitro test system of the present invention for the determination of inhibitors effective in reducing a bacterial infection. -
Item 4. Furthermore, the present invention relates to the use of the in vitro test systems of the present invention for the examination of innate host cell responses, which optionally includes examination of the level of signal transduction, resulting cytokine and chemokine expression, induction of apoptosis and necrosis and/or redox hemostasis regulating health and disease. -
Item 5. Also provided for by the present invention is a method for detecting molecules effective in the prophylaxis and/or treatment a bacterial infection comprising contacting the in vitro test system of the present invention with a compound of interest, wherein the compound of interest reduces the bacterial infection, compared to the in vitro test system before the contacting. -
Item 6. The present invention furthermore relates to a cultured cell infected with an influenza virus and a bacterium. -
Item 7. Also provided for is a cultured cell infected with a bacterium. -
Item 8. The present invention also relates to a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection in a subject, comprising administering a therapeutically effective amount of a MEK inhibitor, a p38 inhibitor and/or a NFκB inhibitor of the present invention or a pharmaceutical composition of the present invention to said subject. -
Item 9. Also the present invention provides for a use of a MEK inhibitor, a p38 inhibitor and/or a NFκB inhibitor of the present invention or a composition of the present invention for the preparation of a medicament. -
Item 10. In addition the present invention relates to a use of a MEK inhibitor, a p38 inhibitor and/or a NFκB inhibitor of the present invention or a composition of the present invention for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection. -
Item 11. Similarly, the present invention also provides for a method for the prophylaxis and/or treatment of a bacterial infection in a subject, comprising administering a therapeutically effective amount of a MEK inhibitor, a p38 inhibitor and/or a NFκB inhibitor of the present invention or a pharmaceutical composition of the present invention to said subject. -
Item 12. In addition the present invention relates to a use of a MEK inhibitor, a p38 inhibitor and/or a NFκB inhibitor of the present invention or a composition of the present invention for the prophylaxis and/or treatment of a bacterial infection. - It must be noted that as used herein, the singular forms “a”, “an”, and “the”, include plural references unless the context clearly indicates otherwise. Thus, for example, reference to “a reagent” includes one or more of such different reagents and reference to “the method” includes reference to equivalent steps and methods known to those of ordinary skill in the art that could be modified or substituted for the methods described herein.
- All publications and patents cited in this disclosure are incorporated by reference in their entirety. To the extent the material incorporated by reference contradicts or is inconsistent with this specification, the specification will supersede any such material.
- Unless otherwise indicated, the term “at least” preceding a series of elements is to be understood to refer to every element in the series. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the present invention.
- Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integer or step. When used herein the term “comprising” can be substituted with the term “containing” or sometimes when used herein with the term “having”.
- When used herein “consisting of” excludes any element, step, or ingredient not specified in the claim element. When used herein, “consisting essentially of” does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim.
- In each instance herein any of the terms “comprising”, “consisting essentially of” and “consisting of” may be replaced with either of the other two terms.
- Several documents are cited throughout the text of this specification. Each of the documents cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc.), whether supra or infra, are hereby incorporated by reference in their entirety. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
- The following examples illustrate the invention. These examples should not be construed as to limit the scope of this invention. The examples are included for purposes of illustration and the present invention is limited only by the claims.
- Within the last years the need for additional and alternative therapeutic strategies apart from vaccination or treatment with conventional antivirals against IV (neuraminidase and M2 blockers) and conventional antibiotics against S. aureus steadily increased. In meantime for antiviral intervention several cellular factors have been identified as potential targets. In quite contrast, the knowledge about the rote of cellular factors during bacterial infection and in particular as targets for antibacterial treatment either by reduction of bacterial amount and/or onset of accelerating cytokine expression is less understood, even more in presence of IV co-infection.
- We established an infection protocol that allows determination of (1) progeny virus titers and (2) titers of intracellular bacteria as well as (3) changes in host defense mechanisms in presence or absence of potential antiinfectives upon IV and S. aureus co-infection. In an initial approach we investigated the effect of the MEK inhibitor (U0126=50 μM), the p38 inhibitor (SB202190=10μM) and the NFκB inhibitor (LASAG=5 mM) in comparison to a solvent control against IV and S. aureus infection in a singular or co-infection situation. As a control the viral neuraminidase inhibitor Oseltamivir (Tamiflu) (2 μm) was used in comparison to Hepes. For virus infection we used the human influenza virus A/Puerto Rico/8134 (H1N1) or the avian influenza virus A/FPV/Bratislava/79 (H7N7) and for bacterial infection we used the
S. aureus strain 6850. Procedure of infection (FIG. 1 ): - Human lung epithelial cells were seeded in 6-well plates (8×105 cells/well) in 2 ml DMEM [10% FCS]. 16-20 hrs after seeding, cells were rinsed and incubated with PBS/BA [0.2% bovine serum albumin (BSA), 1 mM MgCl2, 0.9 mM CaCl2, 100 U/mI penicillin, 0.1 mg/ml streptomycin] (500 μl per 6 well) or PBS/BA containing the virus at the indicated multiplicity of infection (MOI) at 37° C. After 30 min incubation, the virus dilution was aspirated, cells were rinsed with PBS and supplemented with invasion medium DMEM/INV [1% human serum albumin, 25 nmol/l HEPES] (2 ml per 6 well) with or without bacteria at the MOI indicated in presence or absence of the test compound. 3 hrs post bacterial infection cells were treated with antibiotics to remove extracellular bacteria. Therefore cells were rinsed with PBS and subsequently incubated with DMEM/INVantibiotics [2 μg/ml lysostaphin (Sigma)] (1 ml per 6 well) for 20 min at 37° C.. After an additional wash with PBS cells were supplemented with DMEM/INV containing the test substance and were incubated for the times indicated at 37° C. Upon A/Puerto Rico/8/34 DMEM/INV was additionally supplemented with 0.333 μg/ml Trypsin (Invitrogen). Determination of IV titers and intracellular bacteria were performed as described in (Hrincius et al., 2010, Tuchscherr et at., 2011).
- IV titers are depicted as plaque forming units (pfu)/ml and S. aureus titers are depicted as colonie forming untits (CFU)/ml. Data represent the means±SD of two to three independent experiments with two biological samples. Statistical significance was evaluated by a two-tailed two sample t-test (*p<0.05; **p<0.01; ***p<0001).
- In a co-infection situation the presence of S. aureus affected IV replication and the presence of IV affected the intracellular amount of S. aureus levels, respectively, due to changes in innate immune responses as well as autophagic and apoptotic mechanisms. Nonetheless, as expected we observed inhibitory effects of U0126 (
FIG. 2, 3 ), SB202190 (FIG. 4 ) and LG-ASA (FIG. 5 ) on IV replication. Interestingly, viral titers were also reduced upon treatment with these inhibitors in presence of S. aureus. Furthermore, we were agreeably surprised when intracellular amounts of S. aureus were reduced in presence of U0126, SB202190 or LG-ASA independent from the absence or presence of IV. Another, amazing observation concerned bacterial replication in presence of U0126 (50μM). When S. aureus was cultivated over night at 37° C. in DMEM/INV without living cells, bacterial titers were already reduced, but to the same degree than during infection of cells, indicating the dependence of bacteria from a cellular factor (FIG. 2E ). - As control we investigated viral titers and intracellular bacterial amounts upon application of the viral neuraminidase inhibitor Oseltamivir (Tamiflu) (
FIG. 6 ). While IV titers were significantly reduced in absence or presence of S. aureus, intracellular bacterial amounts were rather increased. - The results demonstrate the great potential of substances targeting cellular factors as antiinfectives against IV and S. aureus co-infection, rather than substances against the pathogen itself.
- In further experiments the effect of the MEK inhibitor U0126, CI-1040 and Cobimetinib (GDC-0973) in comparison to a solvent control against influenza A virus (IAV) and
S. aureus 6850 infection in a singular or co-infection situation were investigated. - The co-infection procedure is depicted in
FIG. 12 . To examine the viability of human lung epithelial cells in our experimental setting, cell morphology was monitored 18 hrs upon infection by light microscopy (FIG. 13 ), the time at which the pathogen load was determined (FIG. 14 ). - As visible in
FIG. 13 singular infection with S. aureus 6850 (6850), the influenza virus strains A/FPV/Bratislava/79 (H7N7) (FPV) or A/Wisconsin/67/2005 (H3N2), as well as the co-infection resulted in slight but clearly detectable cell damage. In presence of U0126 (50 μM) the cell layer appeared much less damaged. - The effect of the MEK inhibitor U0126 (50 μM) against influenza virus replication A/FPV/Bratislava/79 (H7N7) (FPV) or A/Wisconsin/67/2005 (H3N2) in comparison to a solvent control was determined in human lung epithelial cells in a singular or co-infection situation (
FIG. 14 ). - Inhibition of MEK/ERK signalling resulted in a significant reduction of virus titers upon infection with the IAV subtypes H7N7 and H3N2 in a singular infection situation (
FIG. 14 ). Virus titers were reduced in a co-infection situation in the presence of U0126, too, up to significant levels in H7N7/S. aureus co-infected cells (FIG. 14 ). - Furthermore, the effect of the MEK inhibitor U0126 (50 μM) against internalized
S. aureus 6850 was analysed (FIG. 15A , C). In this experimental setting bacterial titers were only slightly decreased in presence of the inhibitor. - To further investigate the effect of U0126 on bacterial growth in general, a cell-free over-night culture of
S. aureus 6850 was supplemented with different amounts of U0126 (10 μM and 50 μM) or solvent (FIG. 15B , D). Bacterial growth was inhibited in presence of U0126 in a concentration dependent manner, in comparison to the solvent control (FIG. 15B , D). - Since pro-inflammatory cytokine- and chemokine expression contributes to severe inflammation and tissue damage, the mRNA synthesis of respective chemokines, such as CCL3, also known as macrophage inflammatory protein 1α (MIP1α) and CCL5, also known as RANTES were analysed by qRT-PCR in an infection experiment in presence or absence of U0126 (50 μM) (
FIG. 16A , B). The IAV-induced CCL3 mRNA synthesis, which was increased in presence ofS. aureus 6850, was reduced in presence of U0126. Similarly, the IAV-induced CCL5 mRNA synthesis, which was reduced in presence of S. aureus, was further reduced in presence of U0126 (50 μM). - In western-blot analysis the inhibitory effect of U0126 on MEK/ERK signalling was verified by use of a phosphospecific ERK1/2 antibody (
FIG. 16C ). Furthermore, a reduction of viral protein synthesis (PB1) was observed in presence of upon inhibition of MEK/ERK signalling. - To verify the anti-pathogen potential of U0126 in an in vivo mouse model, influenza virus-infected mice were left untreated or treated with U0126 daily and superinfected with S. aureus 6850 (
FIG. 17 ). The administration of U0126 led to a reduction in bacterial titers in vivo independent of viral titers. The fail of reduced virus titers might be explained by the late administration of U0126 at a time point when virus titers are already decreasing in the infection course. Former experiments have indicated that the inhibitor has a higher inhibitory effect, when it is given before influenza virus infection. Nonetheless, the bacterial titers were significantly reduced upon application of U0126. - Within other approaches the effect of the MEK inhibitor CI-1040 (10 μM) against influenza virus replication A/FPV/Bratislava/79 (H7N7) (FPV) or A/Puerto Rico/8/34 (H1N1) in comparison to a solvent control was determined in human lung epithelial cells in a singular or co-infection situation (
FIG. 18 ). - Inhibition of MEK/ERK signalling by CI-1040 resulted in a reduction of virus titers upon infection with the IAV subtypes H7N7 and H1N1 in a singular and co-infection situation (
FIG. 18 ). - To further investigate the effect of CI-1040 on bacteria growth in general, a cell-free over-night culture of
S. aureus 6850 was supplemented with different amounts of CI-1040 (1 μM and 10 μM) or solvent (FIG. 19A , B). Bacterial growth was slightly inhibited in presence of CI-1040 in a concentration dependent manner, in comparison to the solvent control (FIG. 19A , B). - To verify the anti-pathogen potential of another MEK inhibitor, Cobimetinib was tested in an in vivo mouse model, influenza virus-infected mice were left untreated or treated daily with Cobimetinib and were super-infected with S. aureus 6850 (
FIG. 20 ). The administration of Cobimetinib led to a slight but clearly detectable reduction in viral and bacterial titers in vivo. Since it has been shown recently that the maximal tolerated dose of Cobimetinib is 30 mg/kg/day. Thus, the inhibitory effect might be improved by higher dosages than used in the present experiment (10 mg/kg/day), which was far less from the maximal tolerated dosage. - In conclusion, the results show different MEK inhibitors as potential anti-IAV/S. aureus substances.
- In further experiments the effect of the NFκB-inhibitor LG-ASA (LASAG) against influenza A virus (IAV) and
S. aureus 6850 infection in a singular or co-infection situation were investigated. - The co-infection procedure is depicted in
FIG. 21 (upper part). To examine the viability of human lung epithelial cells upon infection in absence and presence of LG-ASA (5 mM) cell morphology was monitored 18 hrs upon infection by light microscopy (FIG. 21 ). While infection with IAV and/or S. aureus in absence of LG-ASA (left panel) results in cell destruction, cell morphology was improved in presence of LG-ASA (right panel). - The effect of the NFκB-inhibitor LG-ASA (5 mM) against influenza virus replication A/Puerto Rico/8/34 (H1N1) was determined in human lung epithelial cells in a singular or co-infection situation (
FIG. 22 /23) 8 h (FIGS. 22 /23 A, B, E, F) and 18 h (FIG. 22 /23 C, D, G, H) post infection. Two different S. aureus strains were used for infection (a) S. aureus SH1000 (FIG. 22 /23 A-D) and (b) S. aureus 6850 (FIG. 22 /23 E-H). - While IAV replication was reduced in presence of LG-
ASA FIG. 22 the results are depicted in a linear scale. To better visualize the pathogen inhibitory effect of LG-ASA, the untreated controls of the three independent experiments were arbitrarily set as 100% and the mean is presented (FIG. 23 ). - Since LG-ASA was added directly during bacterial infection, these results indicate a very early effect on bacterial internalization, which potentiates during ongoing release and new bacterial internalization.
- Very recently it has been shown that NFκB is required for phagocytosis of S. aureus by monocytes (Zhu et al., 2014; Exp. Cell Res. 1; 327(2):256-63). Based on these findings and our own observations we wanted to know if LG-ASA prevents bacterial uptake. We pre-treated human lung
epithelial cells 4 hours before bacterial infection and determined internalized bacteria up to two hours post infection. To ensure that only internalized bacteria were detected, non-internalized bacteria were removed by an antibiotic wash prior to cell lysis. The data indicate a time dependent uptake ofS. aureus 6850, which is blocked in presence of LG-ASA (FIG. 24A , B). A concentration dependent inhibitory effect of LG-ASA could be further demonstrated on the bacterial strain S. aureus USA300 (FIG. 24C , D). To better visualize the pathogen inhibitory effect of LG-ASA, which is visible inFIG. 24A , C the untreated controls of the three independent experiments were arbitrarily set as 100% and the mean is depicted (FIG. 24B , D). - To verify the importance of NFκB-mediated signalling onto S. aureus internalisation, NFκB was induced by TNF-
α stimulation 4 hours prior bacterial infection. The activation of NFκB resulted in the enhanced uptake ofS. aureus 6850 and S. aureus USA300. As a control TNF-α-induced activation was simultaneously blocked by LG-ASA, which resulted in the inhibition of TNF-α-promoted bacterial uptake, as expected (FIG. 25 ). - To verify the anti-pathogen potential of LG-ASA in an in vivo mouse model different co-infection settings in presence and absence of LG-ASA were tested.
- As visible in
FIG. 26 treatment of IAV/S. aureus co-infected mice with LG-ASA results in enhanced survival (FIG. 26A ) and reduced body weight loss (FIG. 26B ). - In conclusion, our results show that NFκB inhibitors such as LG-ASA act as anti-IAV/S. aureus substances in vitro and in vivo.
- Borgeling, Y., Schmolke, M., Viemann, D., Nordhoff, C., Roth, J. and Ludwig, S. (2014). Inhibition of 38 mitogen-activated protein kinase impairs influenza virus-induced primary and secondary host gene responses and protects mice from lethal H5N1 infection. The Journal of biological chemistry 289, 13-27.
- Chertow, D. S. and Memoli, M. J. (2013). Bacterial coinfection in influenza: a ● rand rounds review. JAMA: the Journal of the American Medical Association 309, 275-282.
- Droebner, K., Pleschka, S., Ludwig, S. and Planz, O. (2011). Antiviral activity of the MEK-Inhibitor U0126 against pandemic H1Nlv and highly pathogenic avian influenza virus in vitro and in vivo.
Antiviral research 92, 195-203. - Dudek, S. E., Luig, C, Pauli, E. K., Schubert, U. and Ludwig, S. (2010). The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state. Journal of virology 84, 9439-9451,
- Ehrhardt, C. and Ludwig, S. (2009). A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway.
Cellular microbiology 11, 863-871. - Ehrhardt, C., Marjuki, H., Wolff, T., Nurnberg, B., Planz, O., Pleschka, S. and Ludwig, S. (2006). Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence.
Cellular microbiology 8, 1336-1348. - Ehrhardt, C., Ruckle, A., Hrincius, E. R., Haasbach, E., Anhlan, D., Ahmann, K., et al. (2013). The NF-kappaB inhibitor SC75741 efficiently blocks influenza virus propagation and confers a high barrier for development of viral resistance.
Cellular microbiology 15, 1198-1211. - Ehrhardt C., Wolff, T. and Ludwig, S. (2007a). Activation of phosphatidylinositol 3-kinase signaling by the nonstructural NS1 protein is not conserved among type A and B influenza viruses. Journal of virology 81, 12097-12100.
- Ehrhardt, C., Wolff, T., Pleschka, S., Planz, O., Beermann, W., Bode, J. G., et al. (2007b). Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses. Journal of virology 81, 3058-3067.
- Eierhoff, T., Hrincius, E R., Rescher, Ludwig, S. and Ehrhardt, C. (2010). The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells.
PloS pathogens 6, e1001099. - Gillet, Y., Vanhems, P., Lina, G., Bes, M., Vandenesch, F., Floret, D. and Etienne, J. (2007). Factors predicting mortality in necrotizing community acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 45, 315-321.
- Gong, J., Fang, H., Li, M., Liu, Y., Yang, K., Liu, Y. and Xu, W. (2009). Potential targets and their relevant inhibitors in anti-influenza fields. Current
medicinal chemistry 16, 3716-3739. - Grundmann, H., Aires-de-Sousa, M., Boyce, J. and Tiemersma, E. (2006). Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 368, 874-885.
- Haasbach, E., Reiling, S. J., Ehrhardt, C., Droebner, K., Ruckle, A., Hrincius, E. R., et al. (2013). The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus. Antiviral research 99, 336-344.
- Hayden, F. (2009). Developing new antiviral agents for influenza treatment: what does the future hold? Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 48
Suppl 1, S3-13. - Hayden, F. G. and Hay, A. J. (1992). Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Current topics in microbiology and immunology 176, 119-130.
- Iverson, A. R., Boyd, K. L., McAuley, J. L., Piano, L. R., Hart, M. E. and McCullers, J. A. (2011). Influenza virus primes mice for pneumonia from Staphylococcus aureus. The Journal of infectious diseases 203, 880-888.
- Iwao, Y., Ishii, R., Tomita, Y., Shibuya, Y., Takano, T., Hung, W. C., et al. (2012). The emerging ST8 methicillin-resistant Staphylococcus aureus clone in the community in Japan: associated infections, genetic diversity, and comparative genomics. J Infect
Chemother 18, 228-240. - Lee, L T., Lee, C. W., Tung, W.1-1, Wang, S. W., Lin, C. C., Thu, J. C. and Yang, C. M. (2010). Cooperation of TLR2 with MyD88, PI3K, and Rad in lipoteichoic acid-Induced cPLA2/COX-2-dependent airway inflammatory responses. The American journal of pathology 176, 1671-1684.
- Ludwig, S. (2009). Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. The Journal of antimicrobial chemotherapy 64, 1-4.
- Ludwig, S. (2011). Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections. Biological chemistry 392, 837-847.
- Ludwig, S. and Planz, O. (2008). Influenza viruses and the NF-kappaB signaling pathway—towards a novel concept of antiviral therapy, Biological chemistry 389, 1307-1312.
- Ludwig, S., Planz, O., Pleschka, S. and Wolff, T. (2003) Influenza-virus induced signaling cascades: targets for antiviral therapy? Trends in
molecular medicine 9, 46-52. - Ludwig, S., Wolff, T., Ehrhardt, C., Wurzer, W. J., Reinhardt, J., Planz, O. and Pleschka, S. (2004). MEK inhibition impairs influenza B virus propagation without emergence of resistant variants. FEBS letters 561, 37-43.
- Marjuki, H., Alam, M. I., Ehrhardt, C., Wagner, R., Planz, O., Klenk, H. D., et al. (2006). Membrane accumulation of influenza A virus hemagglutinin triggers nuclear export of the viral genome via protein kinase Calphamediated activation of ERK signaling. The Journal of biological chemistry 281, 16707-16715.
- Mazur, 1., Wurzer, W. J., Ehrhardt, C., Pleschka, S., Puthavathana, P., Silberzahn, T., et al. (2007). Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity.
Cellular microbiology 9, 1683-1694. - Moran, G. J., Krishnadasan, A., Gorwitz, R. J., Fosheim, G. E., McDougal, L. K., Carey, R. B., et al. (2006). Methicillin-resistant S. aureus infections among patients in the emergency department. The New England Journal of medicine 355, 666-674.
- Morens, D. M., Taubenberger, J. K. and Fauci, A. S. (2008). Predominantrote of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. The Journal of infectious diseases 198, 962-970.
- Neumann, G., Noda, T. and Kawaoka, Y. (2009). Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459, 931-939.
- Niemann, S., Ehrhardt, C., Medina, E., Warnking, K., Tuchscherr, L., Heitmann, V., et al. (2012). Combined action of influenza virus and Staphylococcus aureus panton-valentine leukocidin provokes severe lung epithelium damage. The Journal of infectious diseases 206, 1138-1148.
- Olschlager, V., Pleschka, S., Fischer, T., Rziha, H. J., Wurzer, W., Stitz, L., et al. (2004). Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice.
Oncogene 23, 6639-6646. - Oviedo-Boyso, J., Cortes-Vieyra, R., Huante-Mendoza, A., Yu, H. B., Valdez-Alarcon, J. J., Bravo-Patino, A., et al. (2011). The phosphoinositide-3-kinase-Akt signaling pathway is important for Staphylococcus aureus internalization by endothelial cells. Infection and
immunity 79, 4569-4577. - Paddock, C. D., Liu, L., Denison, A. M., Bartlett, J. H., Holman, R. C., Deleon-Carnes, M., et al. (2012). Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal Influenza B Virus infection. The Journal of infectious diseases 205, 895-905.
- Park, B. and Liu, G. Y. (2012)). Targeting the host-pathogen interface for treatment of Staphylococcus aureus infection. Seminars In immunopathology 34, 299-315.
- Parker, D. and Prince, A. (2012). Immunopathogenesis of Staphylococcus aureus pulmonary infection. Seminars in immunopathology 34, 281-297.
- Parry, J. (2013). H7N9 avian flu infects humans for the first time. Bmj 346, f2151.
- Pinto, L. H. and Lamb, R. A. (2006). The M2 proton channels of influenza A and B viruses. The Journal of biological chemistry 281, 8997-9000.
- Pinto, L. H. and Lamb, R. A. (2007). Controlling influenza virus replication by inhibiting its proton channel.
Molecular bioSystems 3, 18-23. - Planz, O. (2013). Development of cellular signaling pathway inhibitors as new antivirals against influenza. Antiviral research 98, 457-468.
- Pleschka, S., Wolff, T., Ehrhardt, C., Hobom, G., Planz, O., Rapp, U. R. and Ludwig, S. (2001). Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade.
Nature cell biology 3, 301-305. - Shilo, N. and Quach, C. (2011). Pulmonary infections and community associated methicillin resistant Staphylococcus aureus: a dangerous mix? Paediatric
respiratory reviews 12, 182-189. - Taubenberger, J. K, and Kash, J. C. (2010). Influenza virus evolution, host adaptation, and pandemic formation. Cell host &
microbe 7, 440-451. - Thorburn, K. and Riordan, A. (2012). Pulmonary bacterial coinfection in infants and children with viral respiratory infection. Expert review of
antiinfective therapy 10, 909-916. - Wurzer, W. J., Ehrhardt, C., Pleschka, S., Berberich-Siebelt, F., Wolff, T., Walczak, H., et al. (2004). NF-kappaB-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagation. The Journal of biological chemistry 279, 30931-30937.
- Zhu F, Yue W, Wang Y. The nuclear factor kappa B (NF-κB) activation is required for phagocytosis of staphylococcus aureus by RAW 264.7 cells. Exp Cell Res. 2014 Oct. 1; 327(2):256-63.
Claims (16)
1. A method of treating a respiratory co-infection comprising a bacterial infection and an influenza virus infection in a human patient comprising administering to the patient an effective amount of a p38 inhibitor, wherein the bacterial infection is by a Staphylococcaceae bacterium or a Streptococcaceae bacterium.
2. The method of claim 1 , wherein the bacterial infection is by a Staphylococcaceae aureus bacterium.
3. The method of claim 1 , wherein the influenza virus infection is by an influenza A virus or an influenza B virus.
4. The method of claim 3 , wherein the influenza A virus is H1N1, H2N2, H3N2, H6N1, H7N7, H7N9, H9N2 H10N7, H10N8 or H5N1.
5. The method of claim 1 , wherein the p38 inhibitor is selected from the group consisting of SB202190, LY2228820, CAY10571, SB 203580, Tie2 Kinase Inhibitor, 2-(4-Chlorophenyl)-4-(fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one, CGH 2466, SB220025, Antibiotic LL Z1640-2, TAK 715, SB202190 hydrochloride, SKF 86002, AMG548, CMPD-1, EO 1428, JX 401, ML 3403, RWJ 67657, SB 202190, SB 203580, SB 203580 hydrochloride, SB 239063, SCIO 469, SX 011, TAK 715, Pamapimod, Losmapimod (GW856553), Dilmapimod (SB681323), VX 702, VX 745, Doramapimod (BIRB 796), BMS-582949, ARRY-797, PH797804 preferably VX-702, SB202190, Pamapimod, Losmapimod (GW856553), Dilmapimod (SB681323), Doramapimod (BIRB 796), BMS-582949, ARRY-797, PH797804 and SCIO-469.
6. The method of claim 1 , wherein the p38 inhibitor is combined with another p38 inhibitor inhibitor, a MEK inhibitor, an NFκB inhibitor, or combinations thereof.
7. The method of claim 1 , wherein the p38 inhibitor is combined with one or more inhibitors targeting the influenza virus, the bacterium, or both the virus and the bacterium.
8. The method of claim 7 , wherein the p38 inhibitor is administered contemporaneously, previously or subsequently to the one or more inhibitors targeting the influenza virus, the bacterium, or both the virus and the bacterium.
9. The method of claim 7 , wherein the one or more inhibitors targeting the influenza virus is a neuraminidase inhibitor.
10. The method of claim 9 , wherein the neuraminidase inhibitor is oseltamivir phosphate, zanamivir, oseltamivir, or peramivir
11. The method of claim 7 , wherein the one or more inhibitors targeting the influenza virus is a compound targeting an ion channel protein (M2).
12. The method of claim 11 , wherein the compound targeting ion channel protein (M2) is amantadine, rimantadine, or both amantadine and rimantadine.
13. The method of claim 7 , wherein the one or more inhibitors targeting the influenza virus is a compound targeting polymerase or endonuclease activity via interfering with a component of the viral polymerase complex, PB1, PB2, PA, or NP.
14. The method of claim 13 , wherein the compound targeting polymerase or endonuclease activity via interfering with a component of the viral polymerase complex, PB1 PB2, PA, or NP is NP blocker Nucleozin or polymerase inhibitor T-705.
15. The method of claim 7 , wherein the one or more inhibitors targeting the bacterium is an antibiotic.
18. The method of claim 15 , wherein the antibiotic is Gentamicin, Rifampicin, Lysosthaphin, Erythromycin, Levofloxacin Vancomycin, Teicoplanin, Penicillin, or Oxacillin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/492,088 US20220096590A1 (en) | 2014-05-16 | 2021-10-01 | Novel-anti-infective strategy against influenza virus and s. aureus coinfections |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LU92455 | 2014-05-16 | ||
LU92455 | 2014-05-16 | ||
PCT/IB2015/053644 WO2015173788A1 (en) | 2014-05-16 | 2015-05-18 | Novel anti-infective strategy against influenza virus and s. aureus coinfections |
US201615310836A | 2016-11-14 | 2016-11-14 | |
US16/571,550 US11135263B2 (en) | 2014-05-16 | 2019-09-16 | Novel-anti-infective strategy against influenza virus and S. aureus coinfections |
US17/492,088 US20220096590A1 (en) | 2014-05-16 | 2021-10-01 | Novel-anti-infective strategy against influenza virus and s. aureus coinfections |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/571,550 Continuation US11135263B2 (en) | 2014-05-16 | 2019-09-16 | Novel-anti-infective strategy against influenza virus and S. aureus coinfections |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220096590A1 true US20220096590A1 (en) | 2022-03-31 |
Family
ID=50980349
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/310,836 Active US10456440B2 (en) | 2014-05-16 | 2015-05-18 | Anti-infective strategy against influenza virus and S. aureus coinfections |
US16/571,550 Active US11135263B2 (en) | 2014-05-16 | 2019-09-16 | Novel-anti-infective strategy against influenza virus and S. aureus coinfections |
US17/492,088 Pending US20220096590A1 (en) | 2014-05-16 | 2021-10-01 | Novel-anti-infective strategy against influenza virus and s. aureus coinfections |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/310,836 Active US10456440B2 (en) | 2014-05-16 | 2015-05-18 | Anti-infective strategy against influenza virus and S. aureus coinfections |
US16/571,550 Active US11135263B2 (en) | 2014-05-16 | 2019-09-16 | Novel-anti-infective strategy against influenza virus and S. aureus coinfections |
Country Status (10)
Country | Link |
---|---|
US (3) | US10456440B2 (en) |
EP (2) | EP3708156A1 (en) |
JP (2) | JP6818676B2 (en) |
KR (1) | KR102405136B1 (en) |
CN (3) | CN113398271A (en) |
AU (3) | AU2015260765B2 (en) |
BR (1) | BR112016026556A8 (en) |
CA (1) | CA2949004A1 (en) |
EA (1) | EA039897B1 (en) |
WO (1) | WO2015173788A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112016026556A8 (en) | 2014-05-16 | 2021-07-06 | Atriva Therapeutics Gmbh | mek, p38 and/or nfkb inhibitors, their uses, composition, in vitro test system, their use, and method for detecting molecules effective in the prophylaxis and/or treatment of a co-infection |
RU2736481C2 (en) * | 2016-03-01 | 2020-11-17 | Эмерджинг Вайрал Терапьютикс (Хк) Лимитед | Compositions and methods for treating influenza virus |
GB201611712D0 (en) | 2016-07-02 | 2016-08-17 | Hvivo Services Ltd | Methods and compounds for the treatment or prevention of severe or persistent influenza |
US11242406B2 (en) | 2016-07-08 | 2022-02-08 | Metastat, Inc. | Methods for the treatment of a cancer or fibrotic disorder associated with MENA or MENA(INV) by administering a map kinase inhibitor |
US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
AU2018351475A1 (en) * | 2017-10-17 | 2020-04-30 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
GB201718285D0 (en) * | 2017-11-03 | 2017-12-20 | Discuva Ltd | Antibacterial Compounds |
GB201721793D0 (en) * | 2017-12-22 | 2018-02-07 | Hvivo Services Ltd | Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza |
CA3118461A1 (en) * | 2018-11-02 | 2020-05-07 | University Of Maryland, Baltimore | Inhibitors of type 3 secretion system and antibiotic therapy |
CN110063954B (en) * | 2019-04-10 | 2021-08-06 | 华中农业大学 | Application of FHIPI (FHIPI) in preparation of medicine for treating feline infectious peritonitis |
LU101183B1 (en) * | 2019-04-16 | 2020-10-16 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
CN110292593A (en) * | 2019-08-05 | 2019-10-01 | 广州呼吸健康研究院 | Application of the Cortex Magnoliae Officinalis in preparation Tamiflu |
WO2021037956A1 (en) | 2019-08-27 | 2021-03-04 | Atriva Therapeutics Gmbh | Combinations of mek inhibitors with cap-dependent endonuclease inhibitors |
US20220378730A1 (en) | 2019-10-08 | 2022-12-01 | Atriva Therapeutics Gmbh | Mek inhibitors for the treatment of hantavirus infections |
CN110859845B (en) * | 2019-12-10 | 2021-02-02 | 南京医科大学 | Application of tanshinone compound |
KR102641463B1 (en) * | 2020-08-18 | 2024-02-27 | 한국생명공학연구원 | Compounds for preventing or treating virus infection disease, composition comprising the same and use thereof |
CN112552189A (en) * | 2020-11-10 | 2021-03-26 | 中国海洋大学 | Pharmaceutical co-crystal of amantadine hydrochloride and resveratrol and preparation method thereof |
WO2023084489A1 (en) * | 2021-11-15 | 2023-05-19 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
WO2023170187A1 (en) * | 2022-03-09 | 2023-09-14 | Technische Universität München | INHIBITION OF INTRACELLULAR PATHOGEN UPTAKE BY INHIBITORS OF THE IKK-α/NIK COMPLEX |
CN116531389B (en) * | 2023-07-04 | 2023-10-20 | 四川大学华西医院 | Application of VS6766 combined with tripterine and pharmaceutical composition |
CN117105810B (en) * | 2023-10-23 | 2024-02-09 | 中国农业大学 | Compound with broad-spectrum antibacterial activity and antibacterial composition thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001522357A (en) | 1997-04-24 | 2001-11-13 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Substituted imidazoles useful for treating inflammatory diseases |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
IL133766A0 (en) | 1997-06-30 | 2001-04-30 | Ortho Mcneil Pharm Inc | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
KR100378937B1 (en) | 1997-10-20 | 2003-05-09 | 에프. 호프만-라 로슈 아게 | Bicyclic kinase inhibitors |
DE69917005T2 (en) | 1998-02-26 | 2005-03-24 | Ortho-Mcneil Pharmaceutical, Inc. | SUBSTITUTED PYRROLOBENZIMIDAZOLE DERIVATIVES FOR INFLAMMATION INHIBITION |
US6448257B1 (en) | 1998-05-22 | 2002-09-10 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
MXPA01002173A (en) | 1998-08-28 | 2003-07-14 | Scios Inc | INHIBITORS OF p38-alpha KINASE. |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
US6509361B1 (en) | 1999-05-12 | 2003-01-21 | Pharmacia Corporation | 1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors |
DE60125980T2 (en) | 2000-11-20 | 2007-10-25 | Scios Inc., Sunnyvale | P38 KINASE INHIBITORS OF THE PIPERIDINE / PIPERAZINE TYPE |
US6649637B2 (en) | 2001-03-16 | 2003-11-18 | Tyler Curiel | Inhibition of intracellular replication by pyridinylimidazoles |
US7345078B2 (en) * | 2002-05-31 | 2008-03-18 | The Board Of Trustees Of Michigan State University | NF-κB inhibitors and uses thereof |
JP2007055983A (en) * | 2005-08-26 | 2007-03-08 | Tokyo Univ Of Science | Prophylactic/ameliorant for disease caused by pathogenic bacterium penetrated into cell |
DE102008004386A1 (en) * | 2008-01-14 | 2009-07-23 | Activaero Gmbh | Use of an acetylsalicylic acid salt for the treatment of viral infections |
KR102174576B1 (en) | 2012-10-08 | 2020-11-06 | 아트리바 테라퓨틱스 게엠베하 | Mek inhibitors in the treatment of virus diseases |
BR112016026556A8 (en) | 2014-05-16 | 2021-07-06 | Atriva Therapeutics Gmbh | mek, p38 and/or nfkb inhibitors, their uses, composition, in vitro test system, their use, and method for detecting molecules effective in the prophylaxis and/or treatment of a co-infection |
-
2015
- 2015-05-18 BR BR112016026556A patent/BR112016026556A8/en not_active Application Discontinuation
- 2015-05-18 CN CN202110506866.XA patent/CN113398271A/en active Pending
- 2015-05-18 CN CN202310240041.7A patent/CN116942832A/en active Pending
- 2015-05-18 EA EA201692303A patent/EA039897B1/en unknown
- 2015-05-18 EP EP20151682.0A patent/EP3708156A1/en active Pending
- 2015-05-18 KR KR1020167035245A patent/KR102405136B1/en active IP Right Grant
- 2015-05-18 AU AU2015260765A patent/AU2015260765B2/en active Active
- 2015-05-18 CA CA2949004A patent/CA2949004A1/en active Pending
- 2015-05-18 CN CN201580038887.6A patent/CN107073123A/en not_active Withdrawn
- 2015-05-18 US US15/310,836 patent/US10456440B2/en active Active
- 2015-05-18 WO PCT/IB2015/053644 patent/WO2015173788A1/en active Application Filing
- 2015-05-18 JP JP2017512462A patent/JP6818676B2/en active Active
- 2015-05-18 EP EP15726345.0A patent/EP3142658B1/en active Active
-
2019
- 2019-09-16 US US16/571,550 patent/US11135263B2/en active Active
-
2020
- 2020-10-13 AU AU2020256326A patent/AU2020256326B2/en active Active
- 2020-12-28 JP JP2020218254A patent/JP2021059592A/en active Pending
-
2021
- 2021-10-01 US US17/492,088 patent/US20220096590A1/en active Pending
-
2022
- 2022-11-10 AU AU2022268364A patent/AU2022268364A1/en active Pending
Non-Patent Citations (3)
Title |
---|
CDC.gov webpage, "Flu Treatment", accessed on 6/2/18. <<https://www.cdc.gov/flu/treatment/index.html>> * |
CDC.gov webpage, "What You Should Know About Flu Antiviral Drugs", accessed on 6/2/18, https://www.cdc.gov/flu/antivirals/whatyoushould.htm * |
Gudiol et al., Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia, Expert opinion on pharmacotherapy, Vol. 18, No. 18, pages 1947-1963. * |
Also Published As
Publication number | Publication date |
---|---|
CA2949004A1 (en) | 2015-11-19 |
EP3142658A1 (en) | 2017-03-22 |
WO2015173788A1 (en) | 2015-11-19 |
JP2017515910A (en) | 2017-06-15 |
JP6818676B2 (en) | 2021-01-20 |
AU2020256326A1 (en) | 2020-11-12 |
AU2015260765A1 (en) | 2016-12-01 |
EA039897B1 (en) | 2022-03-24 |
AU2015260765B2 (en) | 2020-08-13 |
CN107073123A (en) | 2017-08-18 |
JP2021059592A (en) | 2021-04-15 |
AU2020256326B2 (en) | 2022-12-08 |
US11135263B2 (en) | 2021-10-05 |
BR112016026556A2 (en) | 2017-08-15 |
EA201692303A1 (en) | 2017-03-31 |
US10456440B2 (en) | 2019-10-29 |
CN116942832A (en) | 2023-10-27 |
KR20170005110A (en) | 2017-01-11 |
EP3142658B1 (en) | 2020-01-15 |
US20170080045A1 (en) | 2017-03-23 |
EP3708156A1 (en) | 2020-09-16 |
US20200101130A1 (en) | 2020-04-02 |
AU2022268364A1 (en) | 2022-12-15 |
BR112016026556A8 (en) | 2021-07-06 |
CN113398271A (en) | 2021-09-17 |
KR102405136B1 (en) | 2022-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220096590A1 (en) | Novel-anti-infective strategy against influenza virus and s. aureus coinfections | |
US20170209450A1 (en) | Mek inhibitors in the treatment of virus diseases | |
CN111479566B (en) | Novel MEK inhibitors for the treatment of viral and bacterial infections | |
US20220193017A1 (en) | Novel mek-inhibitor for the treatment of viral and bacterial infections | |
US11433080B2 (en) | Antiviral treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ATRIVA THERAPEUTICS GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:EHRHARDT, CHRISTINA;LUDWIG, STEPHAN;REEL/FRAME:057684/0839 Effective date: 20161115 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |